Report on Federal Awards in Accordance with OMB Uniform Guidance June 30, 2022 Employer Identification Number 13-5598093

June 30, 2022 and 2021

	Page(s)
Report of Independent Auditors	1-2
Consolidated Financial Statements	
Statements of Financial Position	3
Statements of Activities	4
Statements of Cash Flows	5
Notes to Financial Statements	6–49
Supplemental Schedules	
Schedule of Expenditures of Federal Awards	50–133
Notes to Schedule of Expenditures of Federal Awards	134-135
Schedule of Financial Responsibility Data	136
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	137-138
Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance	139-140
Summary of Independent Auditors' Results	141
Schedule of Findings and Questioned Costs	142
Summary Schedule of Prior Audit Findings	143



Report of Independent Auditors

To The Trustees of Columbia University in the City of New York

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of The Trustees of Columbia University in the City of New York and its subsidiaries (the "University"), which comprise the consolidated statements of financial position as of June 30, 2022 and 2021, and the related consolidated statements of activities for the year ended June 30, 2022 and of cash flows for the years ended June 30, 2022 and 2021, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the University as of June 30, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Other Matter

We previously audited the consolidated statement of financial position as of June 30, 2021, and the related consolidated statements of activities and of cash flows for the year then ended (the statement of activities is not presented herein), and in our report dated October 20, 2021, we expressed an unmodified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying summarized financial information as of June 30, 2021 and for the year then ended is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material

misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgement made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the University audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2022 and schedule of financial responsibility data as of and for the year ended June 30, 2022 are presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and the Department of Education, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and schedule of financial responsibility data are fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 12, 2022, except with respect to Note 23 to the consolidated financial statements and the opinion on the supplemental schedule of financial responsibility ratios, as to which the date is March 28, 2023, on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2022. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performedin accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

Pricewoterhouse Coopers LAP

New York, New York

October 12, 2022, except for footnote 23 with respect to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is March 28, 2023.

The Trustees of Columbia University in the City of New York Consolidated Statements of Financial Position

At June 30, 2022 and 2021 (in thousands of dollars)

	June 2022	June 2021
Assets		
Cash and cash equivalents	\$714,875	\$754,556
Accounts receivable, net	637,954	587,688
Securities held in trust by others	111	26
Pledges receivable, net	581,246	622,853
Investments, at fair value	14,275,431	15,752,353
Institutional real estate	1,024,420	928,324
Land, buildings, and equipment, net	5,053,175	5,027,166
Right of use, lease assets	280,807	308,244
Other assets	662,986	715,412
Total assets	\$23,231,005	\$24,696,622
Liabilities		
Accounts payable and accrued expenses	\$431,268	\$427,324
Deferred revenue and other prepayments	412,843	400,923
Finance lease obligations	136,087	129,239
Right of use, lease obligations	290,718	316,329
Conditional asset retirement obligations	130,398	126,828
Accrued employee benefit liabilities	451,827	488,839
Federal student loan funds	43,749	54,346
Bonds and notes payable (including bond premium and issuance costs	75,777	34,340
of \$246,980 and \$272,880) (see Note 16)	2,316,548	2,488,870
Other long-term liabilities	584,336	638,014
Total liabilities	4,797,774	5,070,712
70 M. 1110/111100	1,777,771	0,070,712
Net assets		
Without donor restrictions	8,303,326	8,255,479
With donor restrictions	10,129,905	11,370,431
Total net assets	18,433,231	19,625,910
Total liabilities and net assets	\$23,231,005	\$24,696,622

See accompanying notes to the consolidated financial statements.

The Trustees of Columbia University in the City of New York Consolidated Statements of Activities For the Year Ended June 30, 2022, with Summarized Comparative 2021 Totals

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	June 2022	June 2021
Operating activities				
Revenues and support				
Tuition and fees (net of \$524,636 and \$502,986				
in financial aid grants, respectively)	\$1,469,287		\$1,469,287	\$1,138,470
Government grants and contracts:				
Direct	905,073		905,073	814,851
Indirect	307,562		307,562	281,011
Private gifts, grants and contracts:				
Direct	324,971	\$210,431	535,402	542,205
Indirect	37,756		37,756	32,095
Revenue from other educational and	,		ŕ	,
research activities	216,546		216,546	199,602
Patient care revenue	1,511,543		1,511,543	1,480,146
Investment income and gains utilized	407,292	236,485	643,777	607,009
Sales and services of auxiliary enterprises	200,108	250,.05	200,108	99,714
Net assets released from restrictions	648,814	(648,814)	200,100	77,714
rect assets released from restrictions	040,014	(040,014)		
Total operating revenues and support	6,028,952	(201,898)	5,827,054	5,195,103
Expenses				
Instruction and educational administration	2,093,132		2,093,132	1,905,340
Research	812,624		812,624	734,211
				1,246,626
Patient care expense	1,317,600		1,317,600	
Operation and maintenance of plant	322,252		322,252	312,826
Institutional support	360,300		360,300	345,088
Auxiliary enterprises	184,638		184,638	147,938
Depreciation	329,390		329,390	290,839
Interest	58,039		58,039	61,458
Total expenses	5,477,975		5,477,975	5,044,326
Change in net assets from operating activities	550,977	(201,898)	349,079	150,777
Nonoperating activities				
Endowment gifts		171,090	171,090	152,401
Current year realized and unrealized capital		171,000	171,000	132,101
gains (losses)	(295,260)	(756,711)	(1,051,971)	3,435,405
Endowment appreciation utilized	(193,077)	(406,562)	(599,639)	(583,062
Change in net assets held by CPMC Fund, Inc.	(20)	(7,342)	(7,362)	4,084
-	(20)			
Change in funds held by others in perpetuity	1 165	(33,830)	(33,830)	43,696
Present value adjustment to split-interest agreement		(41,383)	(40,218) 16,085	48,634
Net periodic benefit cost other than service cost	16,085		,	7,489
Changes in pension and postretirement obligations	(3,348)	5 2 1 1	(3,348)	77,176
Other	2,124	5,311	7,435	(4,212)
Reclassification	(30,799)	30,799		
Change in net assets from nonoperating activities	(503,130)	(1,038,628)	(1,541,758)	3,181,611
Change in net assets	47,847	(1,240,526)	(1,192,679)	3,332,388
Net assets at beginning of year	8,255,479	11,370,431	19,625,910	16,293,522
Net assets at end of year	\$8,303,326	\$10,129,905	\$18,433,231	\$19,625,910

See accompanying notes to the consolidated financial statements.

The Trustees of Columbia University in the City of New York Consolidated Statements of Cash Flows For the Years Ended June 30, 2022 and 2021 (in thousands of dollars)

	June 2022	June 2021
Cash flows from operating activities		
(Includes adjustments to reconcile change in net assets to net cash provided by operating activities):		
Change in net assets	(\$1,192,679)	\$3,332,388
Depreciation expense	329,390	290,839
Institutional real estate depreciation	31,143	29,981
Change in right of use leases and interest on finance lease obligations and		
conditional asset retirement obligations	17,877	15,248
Realized and unrealized (gains) losses	1,104,588	(3,409,378)
Partnership distributions	809,895	858,552
Contributions restricted for permanent investment,	(246.056)	(220 240)
plant, and split-interest agreements	(246,076)	(220,249)
Contributions other than cash Present value adjustments and	(1,083)	(358)
	40.210	(49.624)
actuarial liability for split-interest agreements Accreted interest on bonds	40,218 408	(48,634) 448
Change in unamortized bond premium and issuance costs	(25,900)	(26,318)
Change in fair value of net assets held by CPMC Fund, Inc. Change in fair value of interest in perpetual trusts held by others	7,362 33,830	(4,084) (43,696)
Change in operating assets and liabilities:	33,630	(43,090)
Accounts receivable, net	(50,266)	(44,522)
Pledges receivable, net	41,607	3,499
Other assets	6,198	(45,708)
	41,259	1,506
Accounts payable and accrued expenses Deferred revenue and other prepayments	11,920	58,578
Accrued employee benefit liabilities	(37,012)	55,136
Conditional asset retirement obligations and other long-term liabilities	(11,651)	24,964
Net cash provided by operating activities	911,028	828,192
· · · ·	911,026	020,132
Cash flows from investing activities		
Proceeds from sales of investments	3,489,217	5,519,175
Purchases of investments	(3,966,980)	(6,280,325)
Collections from student notes	9,715	11,904
Student notes issued	(3,353)	(4,292)
Proceeds from/ (Investment in) cash and securities held in trust by others	(85)	91
Purchases of institutional real estate	(127,239)	(28,089)
Purchases of plant and equipment Net cash used by investing activities	(377,281) (976,006)	(421,563) (1,203,099)
	(- 1,1 - 1,1	(),,
Cash flows from financing activities		
Proceeds from contributions for:		
Investment in endowment	184,585	154,179
Investment in plant	57,159	62,915
Investment in split-interest agreements	4,332	3,155
Investment income on split-interest agreements	3,270	3,413
Payments on split-interest agreements	(6,018)	(5,817)
Payments on finance lease obligations	(16,796)	(16,791)
Repayment of taxable commercial paper		(150,000)
Proceeds from taxable commercial paper issuance	25	125,028
Repayment of bonds and notes payable	(146,855)	(298,774)
Proceeds from bond and note issuance		305,000
Net change in federal student loan funds	(10,597)	(8,054)
Net cash provided by financing activities	69,105	174,254
Net change in cash and cash equivalents	4,127	(200,653)
Cash and cash equivalents at beginning of year	854,305	1,054,958
Cash and cash equivalents at end of year	\$858,432	\$854,305
Constructed the transport of set flowing		
Supplemental disclosures of cash flow information:		
Cash and cash equivalents as shown in the Statements of Financial Position	\$714,875	\$754,556
Cash included in Investments, at fair value (see Note 6)	143,557	99,749
Total cash and cash equivalents as shown on the Consolidated Statements of Cash Flows	\$858,432	\$854,305
Change in accounts payable for land, buildings, and equipment	\$37,315	\$21,362
Equipment and space acquired through finance lease obligations	\$2,537	\$8,924
Right of use, lease assets acquired through new right of use lease obligations	\$1,962	\$13,096
Cash paid during the year for interest Noncash debt extinguishment	\$92,540 (\$15,235)	\$103,456

See accompanying notes to the consolidated financial statements.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

1. Organization

The Trustees of Columbia University in the City of New York (the "University") is a private, nonsectarian, nonprofit institution of higher education whose activities are concentrated at three locations in New York City and extend around the globe. The University provides instruction through seventeen undergraduate, graduate, and professional schools. It operates a variety of research institutes and a library system to support its teaching, learning, and research activities. The University performs research, training, and other services under grants and contracts with agencies of the federal government and other sponsoring organizations. The University enrolls approximately 35,345 full-time and part-time students and employs approximately 18,622 full-time employees, including 7,016 full-time faculty members and research staff. Of these, 1,326 hold positions in the arts and sciences, 4,193 hold health science positions, and the remainder hold positions in the other professional schools.

The University is a New York nonprofit corporation recognized as tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Columbia University Irving Medical Center

Columbia University Irving Medical Center ("CUIMC"), a division of the University, located in the Washington Heights section of northern Manhattan, is one of the largest academic medical centers in the United States. It is composed of four schools: Vagelos College of Physicians and Surgeons, Mailman School of Public Health, College of Dental Medicine, and School of Nursing.

CUIMC has three primary areas of focus: patient care, scientific research, and education. CUIMC offers a wide variety of degrees, certifications, and continuing education in health sciences. Faculty patient care services, sponsored research, tuition, endowment income, patent royalties, and gifts provide the majority of CUIMC's revenues. Approximately 4,582 students are enrolled at CUIMC with a full-time faculty of 2,830 of whom approximately 351 are tenured. Additionally, CUIMC's staff includes 2,597 part-time faculty instructors, 1,323 full-time and 208 part-time researchers, 178 post-doctoral research trainees, and 1,229 post-doctoral clinical trainees. Approximately 64 percent of the full-time faculty and 20 percent of the part-time faculty hold clinical appointments and have admitting privileges at New York-Presbyterian ("NYP")/CUIMC Campus.

Patient care activities include patient visits performed by Columbia faculty through its medical faculty practice plan, as well as clinical, educational and administration services provided to hospitals and other health care institutions through contractual agreements for services.

CUIMC maintains several clinical and education affiliation agreements with other organizations. The most significant affiliation agreements are with NYP, Lawrence Hospital, and Harlem Hospital. Certain faculty physicians also provide patient care and supervision of residents at NYP network hospitals and other affiliates. In addition, through interinstitutional professional service agreements and medical service agreements, CUIMC faculty provide patient care in specialty and subspecialty areas at hospitals in the tristate area and in other parts of the country and the world.

During the year ended June 30, 2022, the clinical faculty handled approximately 2.3 million outpatient and emergency room visits and participated in instruction and supervision of 597 University medical students and 1,031 residents and fellows at NYP. CUIMC physicians generated approximately 59,000 NYP hospital admissions during the year.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Payments for patient care services provided by the full-time faculty in both institutional and private office settings are derived mainly from third-party payers, including commercial insurance and managed care companies (62 percent), Medicare (20 percent), Medicaid (13 percent), and direct patient payment (5 percent).

Other Activities

The University holds a number of limited liability companies, not-for-profit corporations and international organizations, which are established to facilitate various program and research objectives, and the results of which are included in the University's consolidated financial statements, including:

- Columbia Investment Management Company, LLC, a New York limited liability company
 formed by the University to manage the University's investment assets under the
 supervision of a Board appointed by the Trustees of the University and subject to the
 oversight of the Committee on Finance of the Trustees.
- Reid Hall Inc., located in Paris, France, which was donated to the University in 1964. Reid Hall, Inc., a corporation organized under New York membership corporation law as an educational and charitable organization, operates Reid Hall to promote, facilitate, and aid the educational, cultural, and social interests of students studying in France.
- Columbia University Healthcare, Inc., a not-for-profit practice entity in which the University is the sole corporate member.
- Columbia Doctors of New Jersey, P.C, Columbia Doctors of Bergen County, P.C. and Columbia Doctors of Connecticut, which are professional corporations in which the University is the sole corporate member.

The University also provides investment custodial services and manages all of the assets of Columbia Presbyterian Medical Center Fund, Inc. ("CPMC Fund, Inc."), a not-for-profit corporation that was created to hold and receive gifts for the University and NYP. The consolidated financial statements reflect the University's interest in the net assets of CPMC Fund, Inc. as well as the assets and amounts due to NYP.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

2. Summary of Significant Accounting Policies

The significant accounting policies of the University are as follows:

Basis of Consolidation

The consolidated financial statements of the University include the accounts of all academic and administrative departments of the University.

All significant intercompany accounts have been eliminated in consolidation.

Basis of Presentation

The University maintains its accounts in accordance with the principles of fund accounting. Under this method of accounting, resources for various purposes are classified into funds that are consistent with activities or objectives specified by donors. Separate accounts are maintained for each fund.

For reporting purposes, the University prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"), including the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 958 Not-for-Profit Entities that requires resources be classified for reporting purposes based on the existence or absence of donor-imposed restrictions. Accordingly, the University classifies fund balances as without donor restrictions or with donor restrictions.

The consolidated financial statements of the University have, in all material respects, been prepared on an accrual basis.

Revenues and Expenses

Revenues are reported as increases in net assets without donor restrictions unless the use of those assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments are reported as increases or decreases in net assets without donor restrictions, unless their use is restricted by explicit donor stipulation or by law.

Revenue Recognition

Revenue related to exchange transactions is recognized under the provisions of the applicable ASC Topic, which is typically ASC Topic 606, Revenue from Contracts with Customers.

ASC Topic 606, Revenue from Contracts with Customers, requires performance of the following steps as part of the revenue recognition assessment:

- Step 1 Identify the contract(s) with a customer
- Step 2 Identify the performance obligation(s) in the contract
- Step 3 Determine the transaction price
- Step 4 Allocate the transaction price to the performance obligation(s) in the contract
- Step 5 Recognize revenue when the entity satisfies a performance obligation

The University recognizes contributions in accordance with the revenue recognition provisions of ASC Topic 958-605, Not-for-Profit Entities. Revenue is considered a contribution if it is determined not to be an exchange transaction.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Revenue recognition for the University's significant types of revenue is discussed below.

Tuition, Fees, Room and Board, and Financial Aid

Tuition and fees revenue is derived from degree programs and executive and continuing education programs and room and board revenue is derived from the provision of room and board services to students. Tuition and fees are recorded net of scholarships and other discounts and waivers ("Financial aid grants") and displayed in the consolidated statements of activities in "Tuition and fees". Room and board revenues are included as part of "Sales and services of auxiliary enterprises", however the recognition process mirrors that for tuition and fees. Each of these items is supported by separate contracts entered into between the University and the individual student.

Tuition and fees and room and board revenues are recognized as operating revenue in the period in which the University satisfies its performance obligations to its students. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of accounting in ASC Topic 606. The University's performance obligations are to provide education to the student and, in certain instances, other items such as room and board. The University recognizes tuition and fees and room and board on a straight-line basis over each academic session based on gross price, net of explicit price concessions such as financial aid grants which are applied to tuition and fees. The value that is recognized for each performance obligation is set forth in publicly available University price lists and is codified in the individual contracts with each student. Individual contracts for tuition and fees and room and board display the transaction price on a standalone basis for each service to be provided to each specific student. Additionally, the contract will contain the price adjustment in the form of financial aid grants that are being awarded to the student. Given the timing of each year's academic sessions, nearly all performance obligations on behalf of the University are completed within the fiscal year.

The timing(s) of billings, cash collections and revenue recognition results in accounts receivable and deferred revenue and student deposits on the consolidated statements of financial position. Receivables are recognized only to the extent that is it probable that the University will collect substantially all of the consideration to which it is entitled in exchange for goods and services transferred to the student. Receipts received in advance of goods and services performed are recorded as deferred revenue or student deposits.

Contributions and Pledges Receivable

Contributions for University operations and plant, including unconditional promises to give ("pledges"), are recognized as operating revenue in the period earned. Contributions to endowment are recognized as nonoperating revenue in the period earned. Amounts expected to be collected in future years are recorded at the present value of estimated future cash flows, net of an allowance for uncollectable pledges. The discounts on those pledges are computed using an interest rate for the year in which the promise was received and considers market and credit risk as applicable. Subsequent years' accretion of the discount is included in contribution revenue. Conditional promises to give are not recognized as revenue until such time as the conditions are met.

Grant and Contract Income

The University receives sponsored program grant and contract income from governmental and private sources. The funding may represent a nonreciprocal transaction in which the resources provided are for the benefit of the University, the funding organization's mission, or the public at large or it may be a reciprocal transaction in exchange for an equivalent benefit in return.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Revenues from exchange transactions are recognized as performance obligations are satisfied which in most cases mirrors the timing of when related costs are incurred. Revenues from non-exchange transactions may be subject to conditions in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). The University recognizes revenue earned from conditional non-exchange transactions when the barrier is satisfied, typically as related costs are incurred. At June 30, 2022, the University has grants or contracts for which it has not yet met all obligations to recognize revenue, or the right to recognize revenue is dependent on future events. These open commitments total \$3.2 billion and it is expected that revenue will be recognized as the University fulfills its obligations over several years. In addition, the University has elected the simultaneous release option for conditional contributions that are also subject to purpose restrictions. Under this option, net assets without donor restrictions will include the donor-restricted contributions if the purpose restrictions are met in the same reporting year as the revenue is recognized.

Indirect cost recoveries on federally sponsored programs, such as the recovery of facilities and administrative (F&A) costs, are at reimbursement rates negotiated with the University's cognizant agency, the Department of Health and Human Services. The University entered into an agreement with the federal government which defines the rate at which the University can be reimbursed for F&A costs applicable to federal on-campus research effective July 1, 2021. This agreement will remain in place until such time a new agreement is reached.

Patient Care Revenue and Expense

Patient care activities relate to four distinct areas: medical faculty practice plans, affiliation agreements, medical and professional service agreements, and dental clinic.

Patient care expenses include direct expenses associated with providing patient care services, as well as administrative functions within the University's faculty practice organization. Patient care expense does not include rent or utilities in clinical space, as those costs are aggregated with all University space costs within "Operation and maintenance of plant".

The University provides medical care to patients via its ColumbiaDoctors faculty practice, primarily under agreements with third-party payers. The University determines performance obligations based on the nature of the services provided. Generally these performance obligations, regardless of whether the patient is receiving outpatient or inpatient services, are satisfied when the service is provided. The University bills third-party payers and patients after performance obligations are satisfied. For the limited number of patient service performance obligations that will be satisfied over a period of time, it is expected that these obligations will generally be completed soon after the end of the reporting period and the revenue related to the unsatisfied obligation will be deferred into the following fiscal year.

The University determines transaction price based on gross charges for services provided which are established on an annual basis and uniformly applied. The gross charges may be reduced by explicit price concessions, which include contractual adjustments based on agreements with third-party payers or by implicit price concessions provided to uninsured patients, which are reflected as an allowance for doubtful accounts. The University determines its allowance for doubtful accounts based on its historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patients as a collective group rather than individually. The impact of using this practical expedient does not have a material effect on the consolidated financial

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

statements. In addition, the University takes into account current and future conditions that may further impact collectability.

The University maintains several clinical and education affiliation agreements with other organizations, the largest of which is with NYP. Under these affiliation agreements, the University has a performance obligation to provide medical, professional, and supervisory staff as well as other technical assistance and clinical services. Additionally, the University operates clinical departments for specific purposes, including administration, supervision, and teaching of the NYP resident staff as well as clinical programs that the University and NYP would like to see developed or expanded. The transaction price for the provision of these services is the result of an annual negotiation between the University and the other parties to the affiliation agreements that takes the form of a joint budget agreement. All material services are performed by the University, based on the terms of the agreements, within the University's fiscal year and the related revenue is recognized accordingly in the consolidated financial statements. The revenues and expenses from these agreements are accounted for in patient care and education categories of the operating activity in the consolidated statements of activities.

Research and Development

The University engages in numerous research and development projects, which may be partially or fully sponsored by governmental and private funds. These costs are charged to operating expense as incurred. The University periodically funds and develops patents for certain technologies, then licenses the usage of these patents to companies for a specified period of time. The revenue, net of payments due to third parties, is recorded in "Revenue from other educational and research activities" in the consolidated statements of activities. Costs incurred with developing and maintaining these patents are expensed as incurred.

Institutional Support

Institutional support expense includes central administrative functions and expenses that support the management of the University. This category also includes any net operating surplus or deficit of the University's benefit pool, as recoveries from units across the University may be less than or greater than benefits paid in a given year.

Cash and Cash Equivalents

Cash and cash equivalents are recorded at fair value and include several depository accounts, checking accounts, institutional money market funds, and similar temporary investments with maturities of three months or less at the date of purchase. The University has elected to classify cash equivalents that are part of the University's investment portfolio as short-term investments.

Investments

The University's investments, consisting primarily of publicly traded fixed income and equity securities, alternative investments, and cash held for reinvestment, are stated at fair value as of June 30, 2022 and 2021. Alternative investments include investments in absolute return strategy funds, private equity funds, and real asset funds. The management of each respective fund provides the fair value of the investment. The University reflects its share of the partnerships or corporations in the consolidated financial statements.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The University believes

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

that the net asset value of its alternative investments is a reasonable estimate of fair value as of June 30, 2022 and 2021. Because alternative investment funds are not marketable, the estimated value is subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market for the investment existed. Such differences could be material. The amount of gain or loss associated with these investments is reflected in the consolidated financial statements based on the University's proportionate share in the net assets of these investments.

The University's presentation in the consolidated statements of cash flows for limited liability partnerships, limited liability corporations, and other similarly structured investments is consistent with the accounting for equity method investments as it represents the underlying nature of these investments in which the University has a capital account.

The University records purchases and sales of securities on a trade-date basis. Realized gains and losses are determined on the basis of average cost of securities sold and are reflected in the consolidated statements of activities. Dividend income is recorded on the ex-dividend date, and interest income is recorded on an accrual basis.

Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of charitable gift annuities, pooled income funds, and irrevocable charitable remainder trusts for which the University serves as custodian and trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. In the case of irrevocable split-interest agreements whose assets are held in trusts not administered by the University (third-party charitable trusts), the University will recognize its beneficial interest when it receives sufficient reliable information and documentation that establishes the trust's existence, the University's beneficial interest, and the value of that interest.

Contribution revenues for split-interest agreements are recognized at the dates the agreements are established net of the present value of the estimated future payments to be made to the beneficiaries, if applicable, under these agreements. The discounts on those agreements are computed using an interest rate for the year in which the contribution was received and considers market and credit risk as applicable. Assets related to these agreements are recorded in "Investments, at fair value" and the liability for the present value of the estimated future payments to be made to the beneficiaries is recorded in "Other long-term liabilities" in the consolidated statements of financial position. Adjustments to the fair value of these agreements are recorded in the consolidated statements of activities under "Present value adjustment to split-interest agreements".

Institutional Real Estate

Institutional real estate consists primarily of properties proximate to the University's Morningside and Washington Heights campuses, the primary purpose of which is to house faculty, staff, and graduate students. The income earned on this investment is used primarily to finance operating expenditures. The properties are valued at cost and depreciated over useful lives ranging from twelve and one half to fifty years.

Land, Buildings, and Equipment

Land, buildings, and equipment are stated at cost net of accumulated depreciation. Depreciation is calculated on a straight-line basis over useful lives ranging from ten to one hundred years for buildings and building improvements and two to twenty years for equipment, consistent with the

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

method used for government cost reimbursement purposes. Capitalized software costs are amortized over seven years. Upon disposal of assets, the costs and accumulated depreciation are removed from the accounts, and the resulting gain or loss is included in nonoperating activities.

Collections

The University's collections include works of art, literary works, historical treasures and artifacts maintained in the University's libraries and museums. These collections are protected and preserved for public exhibition, education, research, and the furtherance of public service. Proceeds realized from deaccessioning collection items are to be used for the acquisition of new items for the University's collection and/or enhancing the life, usefulness or quality of the existing collection through long-term direct care and preservation, which includes conservation care, cataloging and documenting and proper access and use of the collection. Accordingly, such collections are not capitalized and contributed items are not recognized as revenue for financial statement purposes.

Interest in Perpetual Trusts Held by Others

The University is the beneficiary of certain perpetual trusts administered by others. These trusts are recognized as contributions with donor restrictions when the University receives sufficient reliable information and documentation that establishes the trust's existence, the University's beneficial interest, and the value of that interest. The fair value of the interest in these perpetual trusts is based on the University's proportional share of the fair value of assets reported by the trust, and is recorded in "Other assets" in the consolidated statements of financial position. Adjustments to the fair value of the University's interest are reported as "Change in funds held by others in perpetuity" in nonoperating activity in the consolidated statements of activities.

Leases

The University enters into lease arrangements for space and equipment and, upon entering in an arrangement, determines the appropriate treatment in accordance with ASU 2016-02, Leases (Topic 842). Arrangements in which substantially all of the risks of ownership have been transferred to the University are accounted for as finance leases and extend up to seven years for equipment and up to 50 years for space.

Arrangements which do not qualify for finance lease treatment but still provide the University the right to use the underlying asset are deemed to be operating leases. These leases are recorded on the statement of financial position as "Right of use, lease assets" and "Right of use, lease obligations". The University has elected the short-term lease exemption policy which permits an entity to not capitalize short-term Right of use, lease assets in its statement of financial position. The University uses an incremental borrowing rate for discounting leases, as applicable, and has elected to separate lease and non-lease components in the calculation of the Right of use, lease assets and lease obligations. Right of use leases typically extend up to five years for equipment and up to 20 years for space.

Conditional Asset Retirement Obligations

Conditional asset retirement obligations are recognized for remediation or disposal of asbestos, underground storage tanks, soil, and radioactive sources and equipment as required by law. The fair value of the liability is recognized in the period in which it occurred, provided that it can be reasonably estimated.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Other Long-Term Liabilities

Other long-term liabilities are obligations that extend beyond one year, or operating cycle, whichever is longer. The obligations for medical malpractice liabilities, self-insurance reserves, the fixed payer interest rate swap agreement, split-interest agreement liabilities, and other commitments are categorized in other long-term liabilities.

Use of Estimates

Management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include valuation of investments without readily determinable prices in active markets, useful lives of depreciable assets, actuarially determined costs associated with split-interest agreements, pension, postemployment and postretirement benefits, explicit and implicit price concessions for patient and other receivables, insurance obligations, and conditional asset retirement obligations.

2021 Presentation

Within the consolidated statements of activities, prior year presentation of net asset categorization has been condensed for comparative purposes. Accordingly, such information should be read in conjunction with the University's audited consolidated financial statements for the year ended June 30, 2021. Further, certain prior year information has been reclassified to conform to current year presentation.

New Authoritative Pronouncements

In September 2020, the FASB issued ASU No. 2020-07, Not-for-Profit Entities (Topic 958), Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets. The ASU amends financial reporting requirements in Topic 958, Not-for-Profit Entities by providing new presentation and disclosures requirements about contributed nonfinancial assets for NFP. The University adopted ASU No. 2020-07 for the fiscal year ended June 30, 2022 with no material impact on the consolidated financial statements.

In August of 2018, the FASB issued ASU No. 2018-14, Compensation-Retirement Benefits-Defined Benefit-General (Subtopic 715-20) Disclosure Framework-Changes to the disclosure requirements for defined benefit plans. The ASU removes certain disclosure requirements and adds other new requirements. The University adopted ASU No. 2018-14 for the fiscal year ended June 30, 2022 with no material impact on the consolidated financial statements. See Note 13 for disclosures about pension and other postretirement benefits.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40). The ASU amends financial reporting requirements in ASU No. 2015-05, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. The new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software. The University adopted ASU No. 2018-15 for the fiscal year ended June 30, 2022 with no material impact on the consolidated financial statements.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

3. Net Assets

The University classifies its net assets as without donor restrictions or with donor restrictions. Periodically, donor redesignations may result in reclassifications of net assets. Descriptions of the two net asset categories and the types of transactions affecting each category follow.

Without Donor Restrictions—Net assets that are not subject to explicit donor-imposed restrictions. This category includes funds designated by the Board of Trustees to function as endowment and other undesignated funds such as tuition and other current funds, gifts without restrictions (including gifts whose donor-imposed restrictions were met during the fiscal year), net investment in plant, and student loan funds.

With Donor Restrictions—Net assets that are subject to explicit donor-imposed stipulations. This includes net assets with donor restrictions that will be satisfied by actions of the University, the passage of time, or both. These net assets include gifts for which the donor-imposed restriction(s) have not been met in the year of receipt (including gifts for capital projects not yet placed in service), pledges, split-interest agreements, and net assets from donor-restricted endowments not yet appropriated for spending. Once the restrictions are satisfied, or have been deemed to have been satisfied, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Also included in this category are net assets with donor restrictions that require these to be maintained permanently by the University and invested to provide a perpetual source of income. Net assets with donor restrictions that are permanent include (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment endowment, and (c) realized and unrealized gains and losses to the permanent endowment when stipulated by the donor gift instrument.

The composition of the University's net assets as of June 30 are as follows:

	 2021	
With Donor Restrictions		
Endowment funds	\$ 8,962,550	\$ 9,900,513
Unexpended capital and other (a)	474,197	695,884
Pledges receivable	581,246	622,853
Annuity and life income funds	111,912	 151,181
Total, Net Assets With Donor Restrictions	 10,129,905	 11,370,431
Without Donor Restrictions		
Board designated endowment	4,317,296	4,449,457
Undesignated	 3,986,030	 3,806,022
Total, Net Assets Without Donor Restrictions	8,303,326	8,255,479
Total Net Assets	\$ 18,433,231	\$ 19,625,910

⁽a) Includes capital gifts not yet released from restriction, unspent gift and endowment income balances, and student loan funds.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

4. **Operating Measurement**

The University divides its consolidated statements of activities into operating and nonoperating activities. The operating activities of the University include all income and expenses related to carrying out its mission focused on education, research, and patient care. Operating revenues include investment income and endowment appreciation utilized to fund current operations, the largest portion of which is the distribution of funds budgeted in accordance with the endowment spending rule.

Nonoperating activities include current year realized and unrealized gains and losses on investments, including realized gain distributions from fund investments, less amounts withdrawn from endowment appreciation to fund operations. Nonoperating activities also include new gifts to donor-restricted endowments that the University must hold in perpetuity, changes in net assets held by CPMC Fund, Inc., changes in funds held by others in perpetuity, present value adjustments to split-interest agreements, net periodic benefit cost other than service cost, changes in pension and postretirement obligations, other items, and reclassifications.

5. Patient Care Revenue

The University's affiliation agreements with area hospitals generated \$446.4 million and \$412.6 million of revenue for the years ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and 2021, "Accounts receivable, net" includes \$127.2 million and \$122.8 million, respectively, relating to these agreements.

Medical faculty practice revenue is reported at the estimated net realizable amounts from patients, third-party payers, and others for services rendered. Medical faculty practice revenues are \$926.0 million and \$938.4 million for the years ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and 2021, patient accounts receivable amounts to \$115.2 million and \$115.5 million, respectively. Medical service agreements generated \$41.5 million and \$35.8 million of revenue for the years ended June 30, 2022 and 2021, respectively, and other patient care activities generated \$97.7 million and \$93.3 million of revenue for the years ended June 30, 2022 and 2021, respectively.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

6. Long-Term Investments and Fair Value

The University values its investments at fair value for financial assets and liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value utilize relevant observable inputs and minimize the use of unobservable inputs.

The University follows a fair value hierarchy based on three levels of inputs, described below:

Fair value for Level 1 is based on quoted prices in active markets that the University has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The University does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or inputs other than quoted prices that are observable.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they are not actively traded.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In determining the categorization of the University's investments within the fair value hierarchy, the University has considered market information including observable net asset values and the length of time until the investment will become redeemable. Investments for which fair value is measured using net asset values ("NAV") as a practical expedient are excluded from the hierarchy and have been reported separately within the table below. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of that instrument and does not necessarily correspond to the University's perceived risk of that instrument.

From time to time, the University may hold direct real estate investments. These investments are categorized as Level 3 within the fair value hierarchy. Valuation for material directly held real estate investments is determined from periodic valuations prepared by independent appraisers or broker opinions.

The University holds certain investments for which fair value is determined generally by using the unadjusted NAV per share as provided by the fund management as a practical expedient. Investments categorized as NAV include the University's ownership in funds that invest in alternative assets (i.e. absolute return strategy funds, private equity funds, and real asset funds) and funds that invest in equity and fixed income strategies for which observable net asset values are not available. The value of the University's investments in these funds represents the University's ownership interest in the net asset value of the respective fund. Items classified as NAV do not have a quoted price in an active market place. As a practical expedient, the University estimates the fair value of an investment at the measurement date using the NAV reported by the fund

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

manager without further adjustment, provided the NAV has been calculated in accordance with or in a manner consistent with GAAP, and provided further that the University does not expect to sell the investment at a value other than NAV. The University has various processes and controls in place to ensure investment fair value is reasonable and performs various due diligence procedures over its investments including an assessment of applicable accounting policies, a review of the valuation procedures employed, and consideration of redemption features and price transparency.

The following tables present assets measured at fair value and NAV at June 30, 2022 and June 30, 2021.

			2022		
	Level 1	Level 2	Level 3	NAV	Total
Investments:					
Cash and short-term investments	\$1,018,503	\$ 376,927			\$ 1,395,430
Global equities	802,015	500,136	\$ 658	\$ 2,105,044	3,407,853
Fixed income	311,057	68,949			380,006
Absolute return strategies		4		4,055,448	4,055,452
Private equity	7,075		151,870	3,139,022	3,297,967
Real assets	4,746	1,742	10,241	2,217,772	2,234,501
Subtotal, Investments	2,143,396	947,758	162,769	11,517,286	14,771,209
Receivables for securities sold					15,593
Liabilities for securities purchase	ed				(511,371)
Investments, at fair value					\$ 14,275,431
	Level 1	Level 2	Level 3	NAV	Total
Other assets:					
Interest in perpetual trusts					
held by others			\$ 187,676		\$ 187,676

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

_			2021		
_	Level 1	Level 2	Level 3	NAV	Total
Investments:					
Cash and short-term investments	\$ 1,264,691	\$ 598,646			\$ 1,863,337
Global equities	965,865	36,916	\$ 1,280	\$ 2,366,699	3,370,760
Fixed income	27,849	1,031	17	281,470	310,367
Absolute return strategies		1		4,387,264	4,387,265
Private equity	25,723		208,449	3,415,388	3,649,560
Real assets	9,612	2,241	16,348	2,046,167	2,074,368
Subtotal, Investments	2,293,740	638,835	226,094	12,496,988	15,655,657
Receivables for securities sold					98,856
Liabilities for securities purchased					(2,160)
Investments, at fair value					\$ 15,752,353
_	Level 1	Level 2	Level 3	NAV	Total
Other assets:		'			
Interest in perpetual trusts					
held by others			\$ 221,506		\$ 221,506

Note: The fair value of the NAV investments as of June 30, 2021 is inclusive of \$50 million of receivables for investment subscriptions entered into during the year ended June 30, 2021, with an effective date subsequent to June 30, 2021.

Cash and Short-Term Investments

Cash and short-term investments include government securities and money market instruments and are valued at amortized cost, which approximates fair value.

Global Equities and Fixed Income

Global equities and fixed income consist of investments in publicly traded U.S. and foreign common and preferred equities, funds that invest in equity and fixed income based strategies, and cash held in separate accounts committed to these strategies. The fair value of these investments is based on quoted market prices. Investments that are listed on an exchange are valued, in general, at the last reported sale price (or, if there is no sales price, at the last reported bid price, or, in the absence of reported bid prices, at the mean between the last reported bid and asked prices thereof). Fund investments in equity and fixed income based strategies are valued in accordance with NAV provided by the investment managers of the underlying funds. If the University has valued the investment based on NAV as a practical expedient, the investment has been excluded from the fair value hierarchy and will be categorized as NAV. If the valuation does not meet the practical expedient criteria and the University has the ability to redeem from a fund up to 180 days beyond the measurement date, the investment is categorized as Level 2. If the redemption period extends beyond 180 days, the investment is categorized as Level 3.

Alternative Investments

Alternative investments include absolute return strategies, private equity, and real assets. Holdings in these strategies may be in funds or in separate accounts with direct investments in listed equities and fixed income, as well as cash committed to fund these investments. Private equity funds include large market, leveraged buyout, and venture capital based strategies. The University values

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021 (in thousands of dollars, unless otherwise noted)

these investments in accordance with valuations provided by the investment managers of the underlying funds. Investments in securities that are publicly traded, whether held by a fund or in a separate account, are generally valued based on observable market prices unless a restriction exists. In addition, investments in a private equity fund may be publicly traded and valued based on observable market prices.

As a general rule, alternative investments are valued based upon the best information available for a given circumstance and may incorporate assumptions that are the best estimate after consideration of a variety of internal and external factors. The fair value of investments categorized as Level 1 are based on quoted prices on a public market. If no public market exists for the investments, the fair value is determined by taking into consideration, among other things, the last reported bid price obtained from pricing sources or broker quotes, the cost of the investment, prices of recent significant placements of similar investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. The University's management may consider other factors in assessing the fair value of these investments. If the University has valued these alternative investments based on NAV as a practical expedient, the investment is excluded from the fair value hierarchy and will be categorized as NAV. For investments in absolute return strategies, if the valuation does not meet the practical expedient criteria and the University has the ability to redeem from the investment up to 180 days beyond the measurement date, the investment is categorized as Level 2. If the redemption period extends beyond 180 days, the investment is categorized as Level 3. For private equity funds and real asset funds, if the valuation does not meet the practical expedient criteria, the investments are categorized as Level 3 given that the University does not have discretion for timing of withdrawal.

The fair value of the alternative investment funds in the table above represents the amount the University would expect to receive at June 30, 2022 and 2021, if it had liquidated its investments on these dates. The University has performed due diligence around these investments and believes that the NAV of its alternative investments is a reasonable estimate of fair value as of June 30, 2022 and 2021. Alternative investments may allocate a high percentage of their assets in specific sectors of the market in order to achieve a potentially greater investment return. As a result, the investments may be susceptible to economic, political, and regulatory developments in a particular sector of the market, positive or negative, and may experience increased volatility in net asset values.

Perpetual Trusts

The fair value of interest in perpetual trusts held by others is based on the University's share of the income generated by the trust, ascribed to the fair value of the assets reported by the trust.

Derivatives

Investment fund managers may invest in derivatives, and the value of these positions is reflected in the NAV of the respective funds. Separately, the University employs derivatives primarily to hedge its risks and to rebalance its market exposures. Derivatives used may include futures, swaps, options, and forward contracts and are reflected at fair value following the definition of Level 1 and Level 2 assets as described above. Certain derivative positions held within the endowment portfolio are subject to master netting agreements included within an International Swap and Derivatives Association, Inc. ("ISDA") master agreement with each of the counterparties.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The following positions are reflected on a net basis within "Investments, at fair value" on the consolidated statements of financial position and are summarized below.

	Notional Exposure		Gross				Net	Collate ral		
Derivative Instruments		Long	Short	 Asset Liability		Fa	ir Value	Posted		
June 30, 2022										
Equity	\$	625,646			\$	(5,620)	\$	(5,620)	\$	109,854
Currency*				1,903		(736)		1,167		
June 30, 2021										
Equity	\$	288,118		\$ 24,493			\$	24,493	\$	13,489
Currency*				2,674		(1,316)		1,358		

^{*}The University held currency derivative contracts with an aggregate notional amount of \$52.6 million and \$216.5 million as of June 30, 2022 and 2021, respectively.

Outside of the endowment portfolio, the University entered into a fixed payer interest rate swap as described in Note 16. The estimated fair value of the agreement is reported as a liability of \$45.9 million and \$83.4 million at June 30, 2022 and 2021, respectively, and is considered a Level 2 measurement. The derivatives are reflected as a receivable or payable, as appropriate, on the consolidated statements of financial position. Unrealized gain or loss from derivative investments is a component of the "Current year realized and unrealized capital gains (losses)" in the consolidated statements of activities.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the University believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The following tables roll forward the amounts reported in the consolidated statements of financial position for financial instruments classified by the University within Level 3 of the fair value hierarchy defined above at June 30, 2022 and 2021.

	June 30, 2021	Transfers In/Out	Purchases	Sales	Realized gain/loss	Unrealized gain/loss	June 30, 2022
Global equities	\$ 1,280					\$ (622)	\$ 658
Fixed income	17			(33)		16	
Private equity	208,449	(12,468)	24,230	(9,681)	\$ 5,790	(64,450)	151,870
Real assets	16,348			(2,195)		(3,912)	10,241
Total level 3 investments	\$ 226,094	\$ (12,468)	\$ 24,230	\$ (11,909)	\$ 5,790	\$ (68,968)	\$ 162,769

	June 30, 2021	Transfers In/Out			U	Realized/ nrealized ain/loss, net	June 30, 2022
Interest in perpetual trusts held by others	\$ 221,506		\$	(7,447)	\$	(26,383)	\$ 187,676

	 June 30, 2020	ransfers In/Out	Pı	urchases	Sales	ealized ain/loss	realized in/loss	•	June 30, 2021
Global equities	\$ 1,229				\$ (204)		\$ 255	\$	1,280
Fixed income	16		\$	33	(2)		(30)		17
Private equity	196,634	(6,195)		21,293	(6,546)	\$ (109)	3,372		208,449
Real assets	22,360	(3,127)			(2,197)		(688)		16,348
Total level 3 investments	\$ 220,239	\$ (9,322)	\$	21,326	\$ (8,949)	\$ (109)	\$ 2,909	\$	226,094

	June 30, 2020	Transfers In/Out	Disburse- ments		gain/loss, net		June 30, 2021		
Interest in perpetual trusts held by others	\$ 177,810		\$	(7,184)	\$	50,880	\$	221,506	

All net realized and unrealized gains (losses) in the tables above are reflected in the consolidated statements of activities. Net unrealized gains (losses) relate to those financial instruments held by the University at June 30, 2022 and 2021. The University's policy is to recognize transfers in and transfers out as of the end of the period. Transfers between Level 3 and Level 1, Level 3 and Level 2 as well as between Level 3 and NAV are reported at gross, due to the criteria described above. There were no significant transfers between Level 1 and Level 2 for the years ended June 30, 2022 and 2021. There were no transfers between NAV and Level 2 for the years ended June 30, 2022 and 2021.

Certain investments in global equities and alternative investments may be subject to restrictions that (i) limit the University's ability to withdraw capital after such investment and (ii) limit the amount that may be withdrawn as of a given redemption date. The redemption terms of the University's investments in absolute return strategy funds vary from daily to triennial, with a portion of these investments designated as "illiquid" in "sidepockets" and that portion may not be available for withdrawal until liquidated by the investing fund and redemption notice periods range from 0 days to 180 days. Generally, as noted above, the University has no discretion as to withdrawal of its investment in private equity and real asset funds; distributions are made when sales of assets are

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

made within the funds. In general, the remaining life of these private equity and real asset funds is up to 12 years.

The University is obligated under certain investment fund agreements to advance additional funding up to specified levels over a period of several years. These commitments have fixed expiration dates and other termination clauses. At June 30, 2022, the University had unfunded commitments of approximately \$2.3 billion as follows:

Asset class	Remaining life	_	funded	Timing to draw
(\$ in millions)	of fund	com	mitments	commitments
Global equities	N/A	\$	15	1 to 8 years
Absolute return strategies	N/A		63	1 to 5 years
Private equity	1 to 12 years		1,505	1 to 12 years
Real assets	1 to 12 years		675	1 to 12 years
Total		\$	2,258	

The University's estimate of the lives of the funds could vary significantly depending on the investment decisions of the external fund managers, changes in the University's portfolio, and other circumstances. Furthermore, the University's obligation to fund the commitments noted above may be waived by the fund manager for a variety of reasons including market conditions and/or changes in investment strategy.

The University has various sources of internal liquidity at its disposal, including cash, short-term investments, marketable debt and equity securities, and lines of credit, which are available to fund the committed drawdowns.

Investment Return

Investment income and gains utilized on the consolidated statements of activities contains endowment appreciation utilized to fund the spending rule, institutional real estate revenue net of operating expenses and depreciation, and other investment income. Endowment appreciation utilized was \$599.6 million and \$583.1 million during 2022 and 2021, respectively. "Current year realized and unrealized capital gains (losses)" reported in nonoperating activities reflect investment returns net of external and direct internal investment costs, reduced by endowment appreciation utilized to fund the spending rule.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021 (in thousands of dollars, unless otherwise noted)

7. Endowment Funds

The University's endowment consists of approximately 6,200 separate funds established over many years for a wide variety of purposes, which include support of specific schools or departments of the University, professorships, research, faculty support, scholarships and fellowships, library, building construction, and other purposes. The endowment includes donor-restricted endowments and funds designated by the Board of Trustees to function as endowments. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The University employs a market value unit method of accounting for pooled general investments. Each participating fund enters and withdraws from the pooled investment account based on monthly unit market values. Changes in the market value of investments are distributed proportionately to each fund that participates in the investment pool. Net investment income distributed during the year is allocated on a per unit basis to each participating fund.

Relevant Law

Under New York Prudent Management of Institutional Funds Act ("NYPMIFA"), the University may appropriate so much of a donor-restricted endowment fund as it deems prudent, considering the specific factors set forth in NYPMIFA and subject to the intent of the donor as expressed in the gift instrument. Unless stated otherwise in the gift instrument, the earnings in an endowment fund are considered to have donor restrictions until appropriated.

The University continues to classify as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. Accumulated appreciation on donor-restricted endowment funds is also included as net assets with donor restrictions until those amounts are appropriated for expenditure by the University in a manner consistent with the standard of prudence prescribed by NYPMIFA.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The composition and changes in the University's endowment net assets as of June 30, 2022 and 2021, are as follows:

,				2022	
Changes in University endowment net assets		Without Donor With Donor Restrictions Restrictions			Total
Opening balance - June 30, 2021	\$	4,449,457	\$	9,900,513	\$ 14,349,970
Investment return		(232,424)		(764,852)	(997,276)
New gifts		1,179		210,026	211,205
Appropriation for expenditure		(230,754)		(430,685)	(661,439)
Other changes:					
Transfers		348,730		28,656	377,386
Other / Reclassifications		(18,892)		18,892	
		329,838		47,548	 377,386
Closing balance - June 30, 2022	\$	4,317,296	\$	8,962,550	\$ 13,279,846
University endowment composition					
Donor-restricted endowment funds:					
Restricted in perpetuity			\$	4,062,435	\$ 4,062,435
Appreciation				4,242,064	4,242,064
Board designated endowment:					
Departmental funds		1,879,131		458,860	2,337,991
University funds		1,635,067			1,635,067
Institutional real estate, net		803,098			803,098
CPMC Fund, Inc.				11,515	11,515
Interests in perpetual trusts held by others				187,676	187,676
University's endowment value	\$	4,317,296	\$	8,962,550	\$ 13,279,846

Note: The tables above do not include split-interest agreements, net of 118,223 and pledges receivable, net of 272,420.

Reconciliation to Investments, at fair value		
Investments, at fair value		\$ 14,275,431
Add:		
Interests in perpetual trusts held by others	187,676	
CPMC Fund, Inc.	11,515	
Institutional real estate, net	803,098	
Other receivables and payables	3,599	1,005,888
Subtract:		
Other long-term investments	(1,730,593)	
Split-interest agreements	(180,187)	
Funds held on behalf of others	(90,693)	 (2,001,473)
University's endowment value		\$ 13,279,846

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

	2021								
Changes in University endowment net assets		thout Donor Restrictions		Vith Donor Restrictions		Total			
Opening balance - June 30, 2020	\$	3,565,407	3,565,407	\$	7,691,614	\$	11,257,021		
Investment return		955,012		2,409,708		3,364,720			
New gifts		1,248		186,086		187,334			
Appropriation for expenditure		(210,602)		(427,395)		(637,997)			
Other changes:									
Transfers		131,835		48,780		180,615			
Other / Reclassifications		6,557		(8,280)		(1,723)			
		138,392		40,500		178,892			
Closing balance - June 30, 2021	\$	4,449,457	\$	9,900,513	\$	14,349,970			
University endowment composition									
Donor-restricted endowment funds:									
Restricted in perpetuity			\$	3,842,733	\$	3,842,733			
Appreciation				5,304,917		5,304,917			
Board designated endowment:									
Departmental funds		1,901,660		512,480		2,414,140			
University funds		1,855,140				1,855,140			
Institutional real estate, net		692,657				692,657			
CPMC Fund, Inc.				18,877		18,877			
Interests in perpetual trusts held by others				221,506		221,506			
University's endowment value	\$	4,449,457	\$	9,900,513	\$	14,349,970			

Note: The tables above do not include split-interest agreements, net of \$157,298 and pledges receivable, net of \$285,915.

Reconciliation to Investments, at fair value

University's endowment value		\$ 14,349,970
Funds held on behalf of others	(99,041)	 (2,345,681)
Split-interest agreements	(225,611)	
Other long-term investments	(2,021,029)	
Subtract:		
Other receivables and payables	10,258	943,298
Institutional real estate, net	692,657	
CPMC Fund, Inc.	18,877	
Interests in perpetual trusts held by others	221,506	
Add:		
Investments, at fair value		\$ 15,752,353

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Return Objectives and Risk Parameters

Endowment assets include those assets of donor-restricted funds that the University must hold in perpetuity or for a donor-specified period(s) as well as Board-designated funds. Under the University's investment policies, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce performance which exceeds that of relevant indices for each asset class while assuming a moderate level of investment risk.

Strategies Employed for Achieving Objectives

The University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University targets a diversified asset allocation to achieve its long-term return objectives within prudent risk constraints.

Endowment Spending Rule

The endowment spending rule utilized by the University is designed to be directly responsive to both investment returns and the current level of price inflation. Its long-term objectives are:

- To protect the corpus of the endowment by spending no more than the real investment return;
- To cushion spending against market volatility; and
- To provide specific spending instructions and multiyear spending projections based on explicit future investment return assumptions.

The current endowment spending rule is based on two factors: first, the market value multiplied by a target spending rate of 4.5 percent, which provides a response to investment market conditions; and second, the prior year's spending plus inflation, which ties spending increases to operating needs and cushions spending against market volatility. This allows the University to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return.

As a general policy, each fiscal year's distribution is calculated by adding together the following:

- a. The market value of the endowment at a point twelve months prior to the beginning of the given fiscal year, multiplied by the target spending rate, multiplied by a 40 percent weighting; and
- b. Endowment spending in the year immediately preceding the given fiscal year, grown or reduced by an inflation factor, which is defined as the Higher Education Price Index ("HEPI"), multiplied by a 60 percent weighting.

The Trustees conduct a special review in any year in which either projected endowment distributions are 0.5 percent higher or lower than the target spending rate, or if the increase in endowment distributions over the previous year is more than 3 percentage points higher or lower than HEPI. Additionally, from time to time, management may recommend and the Trustees may approve a temporary override of the spending rule to ensure the University's ability to sustain the permanent nature of the endowment.

In addition to the base spending rate described above, an additional payout component was approved as a temporary measure by the Trustees in 2008, applied as a percentage of the prior year beginning market value for certain endowments in categories key to the University's current

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

development efforts, primarily endowments for purposes core to the University's educational and research mission, including financial aid and faculty support. For both years ended June 30, 2022 and 2021 the additional payout rate was 0.65 percent. The additional payout component is reviewed by the Trustees regularly and has currently been extended through the end of fiscal year 2023.

Underwater Endowment Funds

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the original gift value, which represents the total of the initial and subsequent donor contribution amounts. When this occurs, the deficit is classified as a reduction of donor-restricted net assets. As of June 30, 2022, deficits totaling \$13.6 million existed in funds which combined had an original gift value of \$227.0 million and a current market value of \$213.4 million. As of June 30, 2021, no such deficits existed. The deficits resulted from market fluctuations that occurred after the investment of recent contributions and authorized appropriation from an endowment that was deemed prudent.

8. Accounts Receivable

Accounts receivable, net, consists of the following as of June 30:

	2022	2021
Patient receivables, net of contractual allowances	\$ 175,160	\$ 160,179
Government agencies	131,832	123,937
NewYork-Presbyterian Hospital	140,567	137,363
Patent and licensing	7,649	8,440
Student receivables	88,174	73,067
Investment income receivable	3,951	4,103
Other receivables	174,253	147,762
	721,586	654,851
Less: Allowance for doubtful accounts	(83,632)	(67,163)
Accounts receivable, net	\$ 637,954	\$ 587,688

Patient receivables for medical services are net of an allowance for contractual reserves in the amount of \$345.4 million and \$334.7 million at June 30, 2022 and 2021, respectively.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

9. Student Loans Receivable and Financial Aid

The University participates in various federal loan programs, in addition to administering institutional loan programs. Loans receivable from students are recorded in "Other Assets" and as of June 30 are as follows:

	2022			2021
Government revolving loans	\$	37,046	\$	42,388
Institutional loans		23,340		25,024
Gross student loans		60,386		67,412
Less: Allowance for doubtful collections		(2,444)		(2,462)
Student loans receivable, net	\$	57,942	\$	64,950

Government revolving loans are funded principally with federal advances to the University under the Federal Perkins Loan Program and certain other programs, which are classified as liabilities on the consolidated statements of financial position. The Federal Perkins Loan Program expired on September 30, 2017 and no new disbursements were permitted after June 30, 2018, but there are outstanding balances from loans awarded in previous years. Balances totaled \$32.1 million and \$38.8 million under the Federal Perkins Loan Program, and \$11.7 million and \$15.6 million under the other programs as of June 30, 2022 and 2021, respectively. Interest earned on the revolving and institutional loan programs is reinvested to support additional loans. The repayment and interest rate terms of the institutional loans vary considerably.

Management regularly assesses the adequacy of the allowance for doubtful collections by performing ongoing evaluation of the student loan and student accounts receivable portfolios. Loans receivable under federally guaranteed student loan programs are subject to significant restrictions.

In addition to the loans identified above, the University processes and authorizes loans to students through the William D. Ford Federal Direct Loan Program. The amounts due under this loan program are not recorded in the University's consolidated financial statements since the University does not guarantee any federal loan funds related to this program. Loans issued under this program were \$322.1 million and \$314.5 million for the years ended June 30, 2022 and 2021, respectively.

Undergraduate financial aid represents grants and awards for all or part of a student's tuition and fees, and in certain other instances, items such as room and board. Graduate financial aid represents grants and awards for all or part of a student's tuition and fees.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Financial aid granted to students is summarized as follows for the year ended June 30:

	2022	2021
Undergraduate	\$222,551	\$201,135
Graduate	302,085	_301,851_
Total financial aid grants	\$524,636	\$502,986

Agency activities such as tuition aid grants and Federal Pell Grant Program awards are not included in the University's consolidated financial statements. Both receipts and disbursements for these agency transactions were \$12.5 million and \$12.0 million in years ended June 30, 2022 and 2021, respectively.

10. Pledges Receivable

Unconditional promises to give appear as pledges receivable and revenue of the appropriate net asset category. Pledges are recorded net of an allowance for uncollectible contributions and a discount to reflect the net present value based on projected cash flows. Periodically unconditional promises to give are reviewed for collectability. As a result, the allowance for uncollectible contributions may be adjusted and some contributions may be adjusted or cancelled. Such changes will be reflected in the consolidated financial statements.

Unconditional promises, and their expected collection dates, were as follows at June 30:

	2022	2021
Less than one year	\$ 204,267	\$ 217,914
One to five years	339,810	327,146
More than five years	151,774	184,541
Total unconditional promises	695,851	729,601
Less: Allowance for doubtful contributions	(35,628)	(33,854)
Less: Net present value discount	(78,977)	(72,894)
Net pledges receivable	\$ 581,246	\$ 622,853

New pledges recorded in the years ended June 30, 2022 and 2021, were discounted at an average annual rate of 3.47 percent and 1.08 percent, respectively, using a rate that considers market and credit risk. Credit risk is also considered in the allowance for doubtful contributions.

Pledges receivable were intended for the following purposes as of June 30:

	 2022		2021
Endowment for educational and general purposes	\$ 272,420	\$	285,915
New construction and modernization of plant	136,520		182,176
Support of University operations	172,306		154,762
Net pledges receivable	\$ 581,246	\$	622,853

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The University also has other outstanding pledges of \$61.6 million as of June 30, 2022. These pledges represent either gifts with donor-imposed conditions, containing both a barrier and a right of return/release, or other pledges that have not met the requirements for recognition.

11. Land, Buildings, and Equipment

Investments in land, buildings, and equipment, net, consisted of the following at June 30:

	2022					2021						
	Buildings, and Accumulated Buildings, and Building		Buildings, and Accumulated Bu		otal Land, ildings, and Equipment		ccumulated epreciation	Bu	Net Land, ildings, and quipment			
Land	\$	523,294			\$	523,294	\$	504,793			\$	504,793
Building and building												
improvements		7,853,721		(3,765,403)		4,088,318		6,778,681		(3,493,789)		3,284,892
Construction in progress		213,021				213,021		996,106				996,106
Equipment		745,719		(517,177)		228,542		704,693		(463,318)		241,375
Total	\$	9,335,755	\$	(4,282,580)	\$	5,053,175	\$	8,984,273	\$	(3,957,107)	\$	5,027,166

The University uses componentized depreciation to calculate depreciation expense for buildings and building improvements for research facilities included in operations. The costs of research facilities are separated into the building shell, building service systems, and fixed equipment, and each component is separately depreciated.

Equipment includes physical assets owned by the University as well as software costs and moveable equipment acquired through finance leases.

Building and building improvements include physical assets owned by the University as well as leasehold improvements, financed space leases, and construction in progress. The net book value of financed space leases at June 30, 2022 and 2021, was \$74.6 million and \$65.5 million, respectively.

12. Accrued Employee Benefit Liabilities

Accrued employee benefit liabilities arise from employment at the University. These include liabilities for pension, postretirement benefits, postemployment benefits, unused vacation, and deferred compensation.

Postemployment benefits relating to workers' compensation, short-term disability, and continuation of medical benefits for those on long-term disability are provided to former or inactive employees after employment but before retirement. The University records the costs of such benefits on an accrual basis if the employee has provided the services from which those benefits are derived. As of June 30, 2022 and 2021, the actuarially computed liabilities on the University's consolidated statements of financial position are \$59.3 million and \$59.6 million, respectively.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

13. Pension and Other Postretirement Benefit Costs

Pension Plan Benefits

During 2022 and 2021, the University had four non-contributory pension plans (the "pension plans") for supporting staff employees. All four pension plans are subject to collective bargaining agreements. Two of the pension plans include defined benefits for past and future service. Two of the pension plans were terminated in December 2021; these plans provided defined benefits for service prior to January 1 and July 1, 1976, respectively. For these two terminated pension plans, future benefits were provided by defined contributions.

In addition, the University provides retirement benefits for full-time faculty, officers, certain other employees, and supporting staff under various defined contribution plans. University contributions for the plans reported in operating expenses were \$178.0 million and \$145.5 million for the years ended June 30, 2022 and 2021, respectively.

Postretirement Health Care and Life Insurance Benefits

The University provides postretirement health care and life insurance benefits for certain employees. The University accrues the estimated cost of these benefits over the years that eligible employees render service.

Obligations and Funded Status

The University follows authoritative guidance, which requires recognition on the consolidated statements of financial position of the difference between benefit obligations and any plan assets of the University's defined benefit and other postretirement benefit plans. In addition, the authoritative guidance requires unamortized amounts (e.g., net actuarial gains or losses and prior service cost or credits) to be recognized as changes to net assets without donor restrictions and that those amounts be adjusted as they are subsequently recognized as components of net periodic pension cost.

Amounts recognized in net assets without donor restrictions are as follows:

						Other Post	retir	ement	
		Pension Plan Benefits				Benefits			
	2022 2021			2022		2021			
Net actuarial (gain) / loss	\$	21,109	\$	41,831	\$	(66,802)	\$	(84,082)	
Prior service cost		52		117					
Total amount recognized	\$	21,161	\$	41,948	\$	(66,802)	\$	(84,082)	

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The components of accrued benefit costs for pension benefits and other postretirement benefits are as follows:

	Pension Plan Benefits		Other Postretirement Benefits		
	2022	2021	2022	2021	
Change in benefit obligation:					
Benefit obligation, beginning of year	\$ 277,208	\$ 274,358	\$ 147,211	\$ 151,358	
Service cost	10,840	11,665	7,267	7,596	
Interest cost	8,830	8,849	4,575	4,753	
Plan participants' contributions			6,166	5,974	
Actuarial gain	(65,195)	(4,589)	(35,429)	(11,772)	
Federal subsidy			462	539	
Plan termination	(9,654)				
Net disbursements and transfers	(9,265)	(13,075)	(13,626)	(11,237)	
Benefit obligation, end of year	212,764	277,208	116,626	147,211	
Change in plan assets:					
Fair value of assets, beginning of year	245,598	219,020	260,243	211,725	
Actual return on plan assets	(43,168)	28,368	(31,159)	53,781	
Employer contributions	12,687	11,285			
Plan participants' contributions			6,166	5,974	
Plan termination	(9,654)				
Net disbursements and transfers	(9,265)	(13,075)	(13,626)	(11,237)	
Fair value of assets, end of year	196,198	245,598	221,624	260,243	
Net amount recognized	\$ (16,566)	\$ (31,610)	\$ 104,998	\$ 113,032	

weighted-average assumptions used to determine	2022	2021
end of year benefit obligation		
Discount rate	4.95%	2.25% to 3.10%
Rate of compensation increase	3.00%	3.00%

For pension plans, actuarial gains for the year ended June 30, 2022 were the result of an increase in the discount rate and changes in demographic assumptions, offset by lower asset returns than assumed and two plan terminations. Actuarial gains for the year ended June 30, 2021 resulted from asset returns in excess of planned returns and lower utilization per experience study conducted during the year.

For postretirement plans, actuarial gains for the year ended June 30, 2022 resulted from an increase in the discount rate and plan experience through the mortality table, offset by lower asset returns than assumed and higher claims. Actuarial gains for the year ended June 30, 2021 resulted from asset returns in excess of planned returns and a lower utilization per experience study conducted during the year.

The accumulated benefit obligations for the two underfunded pension plans at June 30, 2022 and 2021, were \$196.4 and \$243.6 million, respectively.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

At June 30, 2022 and 2021, the projected benefit obligation exceeded the pension plan assets for two plans. The projected benefit obligation for the pension plans were as follows:

End of year	2022		2021	
Projected benefit obligation	\$	212,764	\$	267,393
Fair value of plan assets		196,198		233,359

The accumulated postretirement benefit obligation for the other postretirement benefit plan and the fair value of plan assets with plan assets in excess of the accumulated postretirement benefit obligation was as follows:

End of year	2022			2021	
Accumulated postretirement benefit obligation	\$	116,626	\$	147,211	
Fair value of plan assets		221,624		260,243	

A 6.50 percent annual rate of increase in the per capita cost of covered health care benefits for the other postretirement benefit plan was assumed for 2023. The rate was assumed to decrease gradually to 4.75 percent for year ended June 30, 2030 and remain at that level thereafter. Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans.

The asset allocation for the two defined benefit plans for both past and future service at June 30, 2022 and 2021, and the target allocation for 2023, by asset category, follows:

	Targetallocation	Percentage of plan assets at year end		
	2023	2022	2021	
Asset category				
U.S. large cap equity and global equity funds	26%	17%	18%	
International equities (non-U.S.)	14%	21%	21%	
High yield fixed income securities	10%	10%	10%	
U.S. core fixed income	50%	52%	51%	
	100%	100%	100%	

The following presents investments of the pension plans as of June 30, 2022. The Plans' investments in common collective trusts are valued at NAV as a practical expedient and are therefore excluded from the fair value hierarchy and are reported as NAV. Level 3 assets represent fixed income related investment contracts with a major life insurance company.

	Level 1	Level 2	Level 3	NAV	Total
Common collective trust funds					
Global equity				\$ 75,241	\$ 75,241
Fixed income				120,957	120,957
Investments, at fair value				\$ 196,198	\$ 196,198

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The following table is a roll forward of the amounts for investments classified within Level 3 as described above.

	J	June 30, 2021	Purchases (Gross)	Sales Gross)	 stment /(loss)	June 30, 2022
Investment contracts	\$	1,956		\$ (1,969)	\$ 13	
Total level 3 investments	\$	1,956		\$ (1,969)	\$ 13	

The following presents investments of the pension plans as of June 30, 2021:

	Level 1	Level 2	<u>L</u>	evel 3	NAV	Total
Common collective trust funds						
Global equity					\$ 90,873	\$ 90,873
Fixed income					152,769	152,769
Fixed income investment contracts			\$	1,956		1,956
Investments, at fair value			\$	1,956	\$ 243,642	\$ 245,598

The following table is a roll forward of the amounts for investments classified within Level 3 as described above.

	une 30, 2020	Purchases (Gross)	Sales Gross)	stment n/(loss)	une 30, 2021
Investment contracts	\$ 1,991		\$ (161)	\$ 126	\$ 1,956
Total level 3 investments	\$ 1,991		\$ (161)	\$ 126	\$ 1,956

The asset allocation for the other postretirement benefit plan at June 30, 2022 and 2021, and the target allocation for 2023, by asset category, follows:

	Target allocation	,		
	2023 2022		2021	
Asset category				
U.S. large cap equity and global equity funds	52%	38%	38%	
International equities (non-U.S.)	16%	30%	30%	
U.S. fixed income	32%	32%	32%	
	100%	100%	100%	

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

The following presents investments of the other postretirement benefit plan as of June 30, 2022. The Plans' investments in common collective trusts are valued at NAV as a practical expedient and are therefore excluded from the fair value hierarchy and reported as NAV.

	Level 1	Level 2	Level 3	NAV	<u>Total</u>
Common collective trust funds					
Global equity				\$ 149,623	\$ 149,623
Fixed income				72,001	72,001
Investments, at fair value				\$ 221,624	\$ 221,624

The following presents investments of the other postretirement benefit plan as of June 30, 2021:

	Level 1	Level 2	Level 3	NAV NAV	<u>Total</u>
Common collective trust funds					
Global equity				\$ 176,724	\$ 176,724
Fixed income				83,519	83,519
Investments, at fair value				\$ 260,243	\$ 260,243

Net Periodic Benefit Cost

The components of net periodic benefit cost for pension benefits and other postretirement benefits are as follows:

	Pension Plan Benefits			Other Postretiremen Benefits				
		2022		2021		2022		2021
Components of net periodic benefit cost								
Service cost	\$	10,840	\$	11,665	\$	7,267	\$	7,596
Interest cost on projected benefit obligation		8,830		8,849		4,575		4,753
Expected return on assets		(12,160)		(11,351)		(16,098)		(13,063)
Amortization of prior service cost		65		65				
Settlement loss		6,636						
Amortization of unrecognized net losses/(gain)		3,999		4,222		(5,296)		(964)
Net periodic benefit cost		18,210		13,450		(9,552)		(1,678)

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Amounts recognized in the Consolidated Statements of Activities

A summary of changes in plan assets and benefit obligations recognized in the consolidated statements of activities is as follows:

	Pension Plan Benefits			Other Postretirement Benefits				
		2022		2021		2022		2021
Summary of changes in plan assets and benefit obligations recognized in the Consolidated								
Statements of Activities								
Net periodic benefit cost - service cost	\$	10,840	\$	11,665	\$	7,267	\$	7,596
Total recognized in operating		10,840		11,665		7,267		7,596
Net periodic benefit cost other than service cost		7,370		1,785		(16,819)		(9,274)
Current year actuarial (gain)/loss		(9,868)		(21,605)		11,984	((52,248)
Amortization of actuarial gain/(loss)		(3,999)		(4,222)		5,296		964
Settlement cost		(6,636)		,				
Amortization of prior service cost		(65)		(65)				
Total recognized in nonoperating		(13,198)		(24,107)		461	((60,558)
Total recognized in operating								
and nonoperating	\$	(2,358)	\$	(12,442)	\$	7,728	\$ ((52,962)

Weighted-average assumptions used to determine net	2022	2021		
periodic pension cost				
Discount rate	2.25% to 3.10%	2.15% to 3.15%		
Expected return on plan assets	3.75% to 5.50%	3.75% to 5.50%		
Rate of compensation increase	3.00%	3.00%		

To arrive at assumptions for expected long-term rates of return on assets in the pension plans and the postretirement benefit plan, the University considered historical returns and future expectations for returns in each asset class in the asset allocation for the previously described pension and postretirement benefit portfolios.

Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Expected Cash Flows

Information about the expected cash flows for the plans is as follows:

		Pension Plan Benefits		Other Postretirement Benefits		
Expected University contributions	Ф	11.406		_		
2023	\$	11,496				
Expected benefit payments						
2023	\$	8,386	\$	5,473		
2024		8,990		5,639		
2025		9,611		5,786		
2026		10,212		6,310		
2027		10,827		6,583		
2028-2032		64,259		36,169		
Total	\$	112,285	\$	65,960		

Total benefits expected to be paid include both the University's share of the benefit cost net of Medicare subsidies and the participants' share of the cost, which is funded by participant contributions to the other postretirement benefit plan. The University receives a Medicare Part D subsidy from the federal government as reimbursement for certain retiree health benefits paid to plan participants, which was approximately \$0.5 million in fiscal year 2022.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

14. Lease Obligations

The University is the lessee of various equipment and space under noncancelable right of use and finance leases. Finance lease obligations at June 30, 2022 and 2021, were \$136.1 million and \$129.2 million, respectively. Right of use lease obligations at June 30, 2022 and 2021 were \$290.7 million and \$316.3 million, respectively.

Rental expense related to operating leases totaled \$38.5 million and \$40.8 million for fiscal years ended 2022 and 2021, respectively. Future minimum rental payments under right of use and finance leases are as follows:

	Right of use		Finance		
Future minimum rental payments:		_		_	
2023	\$	35,266	\$	11,904	
2024		34,588		9,099	
2025		33,474		8,399	
2026		29,516		7,629	
2027		28,253		6,585	
Thereafter		200,442		216,362	
Total lease payments		361,539		259,978	
Less: Imputed Interest		(70,821)		(123,891)	
Present value of lease obligations at June 30, 2022	\$	290,718	\$	136,087	

Weighted-average remaining lease term and discount rate for right of use and finance leases are as follows:

	2022	2021
Weighted average remaining lease term (in years)		
Right of use leases	7.2	7.2
Finance leases	17.1	17.1
Weighted average discount rate		
Right of use leases	3.54%	3.53%
Finance leases	4.41%	4.42%

Cash paid for amounts included in the measurement of lease obligations is as follows:

	2022	2021
Operating cash flows for right of use leases	\$39,125	\$37,734
Operating cash flows for finance leases	\$9,294	\$5,831
Financing cash flows for finance leases	\$16,796	\$16,791

The University leases properties to customers under agreements that are classified as right of use leases. The University's lessor arrangements are all operating leases and do not include any salestype or direct finance leases. Space and equipment leased to others are included in "Land, buildings, and equipment, net" and "Institutional real estate".

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021 (in thousands of dollars, unless otherwise noted)

15. Conditional Asset Retirement Obligations

Conditional asset retirement obligations are a legal obligation to perform an asset retirement activity in which the timing and/or method of settlement are conditioned on a future event that may or may not be within the control of the University. The University recognizes the fair value of this obligation in the period in which it occurred if a reasonable estimate of fair value can be made. Uncertainty with respect to the timing and/or method of settlement of the asset retirement obligation does not defer recognition of a liability.

Conditional asset retirement obligations related to remediation or disposal of asbestos, underground storage tanks, soil, radioactive sources, equipment, and miscellaneous other items were \$130.4 million and \$126.8 million at June 30, 2022 and 2021, respectively.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

16. Bonds and Notes Payable

Bonds and notes payable outstanding are as follows at June 30:

	2022	2021
Dormitory Authority of the State of New York, tax exempt		
revenue bonds, Columbia University issues:		
Series 2020 A, 2.11%, maturing FY2051	\$ 150,000	\$ 150,000
Series 2018 A, 2.45% to 3.41%, maturing FY2029 to FY2049	150,000	150,000
Series 2018 B, 2.98%, maturing FY2039	175,185	175,185
Series 2017 A, 2.40% to 3.49%, maturing FY2028 to FY2048	150,000	150,000
Series 2017 B, 1.96% to 2.61%, maturing FY2025 to FY2030	40,475	40,475
Series 2016 A-1, 1.67%, maturing FY2027	50,000	50,000
Series 2016 A-2, 1.35% to 2.89%, maturing FY2024 to FY2047	130,000	130,000
Series 2016 B, 1.17% to 2.04%, maturing FY2023 to FY2032	105,885	123,965
Series 2015 A, 1.95% to 3.00%, maturing FY2026 to FY2046	92,535	92,535
Series 2015 B, 1.64% to 1.88%, maturing FY2023 to FY2025	15,525	21,545
Series 2012 A, 1.92%, maturing FY2023	52,005	89,065
Series 2011 A, 3.36%, maturing FY2022		15,000
Series 2009 A, variable rate, 0.82%, maturing FY2039	117,000	117,000
Series 2003 B, variable rate, 0.83%, maturing FY2024 to FY2028	30,000	30,000
Series 2002 C, variable rates, 0.06% to 1.25%, maturing FY2025 to FY2027	23,300	23,300
Taxable Series 2021 A, 2.85%, maturing FY2051	125,000	125,000
Taxable Series 2021 B, 1.52% to 2.59%, maturing FY2031 to FY2050	180,000	180,000
Taxable Series 2020 B, 2.34%, maturing FY2024 to FY2030	75,000	75,000
Taxable Series 2020 C, 2.00%, maturing FY2023 to FY2024	100,000	150,000
Taxable Series 2015, 3.46%, maturing FY2046	75,000	75,000
Taxable Series 2012, 3.83%, maturing FY2043	100,000	100,000
New Jersey Economic Development Corporation, tax exempt		
Series 2002, variable rate, 1.30%, maturing FY2028	3,245	3,730
Medium-Term Notes, Taxable Series C 6.53% to 7.36%,		
maturing FY2022		1,210
Empire State Development Corporation issues:		
9.00%, maturing FY2029	4,360	4,852
Interest-free, due FY2022		8,100
Economic Development Corporation		10.000
Interest-free, due FY2022	125.052	10,000
Taxable Commercial Paper, variable rate, 0.05% to 2.25%	125,053	125,028
Subtotal, principal payments	2,069,568	2,215,990
Unamortized bond premium	250,833	276,896
Unamortized cost of issuance	(3,853)	(4,016)
Subtotal, bond premium and cost of issuance	246,980	272,880
Total bonds and notes payable	\$ 2,316,548	\$ 2,488,870

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

Estimated principal payments on bonds and notes payable and taxable commercial paper are summarized below:

Fiscal Year	<u>Principal</u>
2023	\$ 121,692
2024	101,395
2025	64,988
2026	71,625
2027	84,228
Thereafter (through 2051)	1,500,588_
Subtotal, Bonds and Notes Payable	\$ 1,944,515
Taxable Commercial Paper	125,053_
Total, Principal Payments	\$ 2,069,568

The University issues most of its tax-exempt debt through the Dormitory Authority of the State of New York ("DASNY"). The University has not issued tax-exempt debt since fiscal year 2020.

In July 2020, the University issued \$125 million of Series 2021A taxable bonds. These bonds pay interest at 2.85% and mature in 2050. The proceeds from Series 2021A will be used for general corporate purposes.

In July 2020, the University issued \$180 million of Series 2021B taxable bonds. These bonds pay interest at 1.52%, 2.43% and 2.59% and mature in 2030, 2044, and 2049, respectively. The proceeds from Series 2021B will be used for general corporate purposes.

The University has a \$150 million taxable commercial paper program. In April 2021, the University issued \$125 million under its taxable commercial paper program. As of both June 30, 2022 and 2021 there was \$125 million of commercial paper outstanding under this program.

The University recorded amortization of bond premium and issuance costs, net, of \$26.1 million and \$27.1 million for the years ended June 30, 2022 and 2021, respectively, as a reduction to interest expense.

As of June 30, 2022, the University had the following operating lines of credit: \$150 million expiring in May 2025; \$100 million expiring in November 2023; \$100 million expiring in June 2023; \$200 million expiring in October 2022. Additionally, the University had two \$100 million standby lines of credit supporting self-liquidity for variable rate debt outstanding, expiring in January 2025 and January 2023. The lines are provided by six different lending institutions and, as of June 30, 2022, no balances were outstanding on the lines of credit.

The University has administrative covenants on its tax-exempt debt and lines of credit, with which it was in compliance as of June 30, 2022 and 2021.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021 (in thousands of dollars, unless otherwise noted)

On October 1, 2008, the University entered into a \$200 million notional value fixed payer interest rate swap agreement to protect against the risk of interest rate changes. The estimated fair value of the swap liability was \$45.9 million and \$83.4 million at June 30, 2022 and 2021, respectively. The fair value of the swap is obtained by taking the present value of all future cash flows on the swap implied by the forward curve.

The University has letters of credit with various financial institutions totaling \$70.6 million and \$55.2 million at June 30, 2022 and 2021, respectively, primarily to secure certain self-insured liabilities in accordance with New York State requirements related to workers' compensation. There have been no draws under the letters of credit.

17. Insurance

In connection with managing financial risks through various third-party insurance programs, the University is self-insured in certain areas. Funded self-insurance liabilities primarily cover deductibles on general liability, trustees and officers' liability, and property insurance claims. Self-insurance liabilities are actuarially calculated on an annual basis. The University's core liability coverage is purchased through Pinnacle RRG, a Vermont-based risk retention group with seventeen other universities.

The University obtains medical malpractice insurance through MCIC and MLMIC. MCIC is a group-captive insurance company owned by the University, The Johns Hopkins Hospital, The Johns Hopkins University, University of Rochester Medical Center, Weill Cornell Medical College, Yale New Haven Health, Yale University School of Medicine, and NYP. MLMIC is a mutual company where policyholders are owners with full voting rights to elect the company's Board of Directors, thereby having direct input into vital areas of operation. The governing Board is comprised primarily of practicing physicians, dentists, and hospital administrators. More than 2,000 of the University's faculty physicians and dentists are enrolled in MCIC or MLMIC. The University has recorded self-insurance and medical malpractice liabilities of approximately \$374.7 million and \$356.7 million as of June 30, 2022 and 2021, respectively in "Other long-term liabilities". The medical malpractice liabilities of approximately \$221.8 million and \$216.5 million as of June 30, 2022 and 2021, respectively, are reported gross with an offsetting receivable for anticipated recoveries of \$153.3 million and \$145.2 million, respectively, recorded in "Other assets".

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

18. Affiliations and Related Party Transactions

The University maintains several clinical and education affiliation agreements with other organizations. Revenues and expenses from these agreements are accounted for in the operating activities section of the consolidated statements of activities. The most significant affiliation agreement is with NYP.

The University receives reimbursement from NYP for the provision of medical, professional, and supervisory staff services as well as other technical assistance. NYP provides funding to clinical departments for specific purposes including administration, supervision, and teaching of the NYP resident staff and salary support for faculty and staff providing services to NYP. In addition, NYP provides funding for clinical programs that the University and NYP would like to see developed or expanded. NYP also provides the departments with certain facilities and services (outpatient faculty practice offices, nursing, telecommunications, etc.) for which the University is invoiced on a monthly basis. Finally, the University and NYP collaborate and fund joint projects for which specific agreements are negotiated.

In addition, the University and NYP negotiate a funds flow, which forms the basis for the affiliation agreement. The fiscal year 2022 funds flow was approximately \$416.8 million. The payments to NYP for goods and services were \$106.6 million and \$108.1 million for the years ended Jun 30, 2022 and 2021, respectively. The majority of revenues received pursuant to this agreement are reflected in the consolidated financial statements as a portion of "Patient care revenue" and the majority of the expenses related to this agreement are reflected in "Patient care expense".

The University records both receivables from and payables to NYP on the consolidated statements of financial position. The University has no liability for obligations and debt incurred by NYP. The University and NYP operate a radiological imaging center, ColumbiaDoctors/NewYork-Presbyterian Imaging, Inc. (CDNYPI). CDNYPI is a not-for-profit membership corporation, which was incorporated to operate pursuant to the terms and provisions of Article 28 of the New York Public Health Law, whereby it provides a full range of general radiology and interventional radiology services. In order to provide for efficient delivery of services and to secure a high level of expertise from existing resources, CDNYPI has entered into clinical and administrative agreements with the University and NYP. The revenue generated from these agreements was \$40.6 million and \$34.6 million for the years ended June 30, 2022 and 2021, respectively. In addition, the University recorded an interest in CDNYPI in the amount of \$20.1 million and \$15.1 million as of June 30, 2022 and 2021, respectively.

The University controls a not-for-profit practice entity and three professional corporations and, as such, consolidates these entities into the University's consolidated financial statements.

From time to time endowment funds held for the benefit of the University may be transferred from the CPMC Fund, Inc. to the University pursuant to the consent of the Trustees of the CPMC Fund, Inc. During the year ended June 30, 2022, the CPMC Fund, Inc. transferred one endowment to the University. The value of the endowment at the time of transfer was \$5.3 million, with \$0.7 million being donor-restricted funds that the University must hold in perpetuity. There were no transfers during the year ended June 30, 2021.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

19. Liquidity and Availability of Resources

As part of the University's liquidity management, financial assets are structured to be available as its general expenditures, liabilities, and other obligations come due. In addition, the University may invest cash in excess of daily requirements in short-term and/or liquid investments. To further help manage unanticipated liquidity needs, the University has committed bank lines of credit along with a taxable commercial paper program.

The University's financial assets and liquidity resources available for general expenditures within one year of the date of the consolidated statements of financial position are as follows:

		2022	 2021
Financial Assets:	<u> </u>		
Cash and cash equivalents	\$	714,875	\$ 754,556
Accounts receivable, net		593,353	549,336
Pledges receivable for operations and plant, net		106,031	119,771
Operating investments		1,533,215	1,727,252
Approved endowment payout for subsequent year		629,050	554,972
Other financial assets		17,786	22,107
Total financial assets available within one year		3,594,310	3,727,994
Liquidity resources:			
Taxable commercial paper program		150,000	150,000
Less: Taxable commercial paper issued		(125,053)	(125,000)
Bank lines of credit (undrawn)		750,000	800,000
Total liquidity resources available		774,947	825,000
Total financial assets and liquidity resources			
available within one year	\$	4,369,257	\$ 4,552,994

Additionally, the University has board-designated funds functioning as endowments of \$4.0 billion and \$4.3 billion as of June 30, 2022 and 2021, respectively. Although the University does not intend to spend from these endowments other than amounts appropriated for general expenditure as part of its annual appropriation process, \$3.5 billion and \$3.8 billion, respectively, of these endowments without donor restrictions could be made available if necessary. However, both the funds functioning as endowment and donor-restricted endowments contain investments with lock-up provisions that reduce the total investments that could be made available (see Note 6 for disclosures about investments).

The Trustees of Columbia University in the City of New York **Notes to the Consolidated Financial Statements** For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

20. **Contingencies and Commitments**

From time to time, various claims and suits generally incident to the conduct of normal business are pending or may arise against the University.

In the opinion of counsel and management of the University, after taking into account insurance coverage, losses, if any, from the resolution of pending litigation should not have a material effect on the University's financial position or results of operations.

All funds expended in connection with government grants and contracts are subject to audit by government agencies. While the ultimate liability, if any, from audits of government grants and contracts by government agencies, claims, and suits is presently not determinable, it should not, in the opinion of counsel and management, have a material effect on the University's financial position or results of activities.

The University is subject to laws and regulations concerning environmental remediation and will, from time to time, establish reserves for potential obligations that management considers probable and for which reasonable estimates can be made (see Note 15 for disclosures about conditional asset retirement obligations). These estimates may change depending upon the nature and extent of contamination, appropriate remediation technologies, and regulatory approvals. The University is not aware of any existing conditions that it currently believes are likely to have a material adverse effect on the University's financial position, changes in net assets, or cash flows.

The University's capital improvement program and related commitments include projects that address the major strategic objectives of the University. As part of the capital improvement program, the University has entered into contracts to purchase properties with an aggregate value of \$44.5 million. As of June 30, 2022, approximately \$43.6 million is still outstanding.

The University has made commitments related to its expansion in Manhattanville, certain of which are based upon events in the future which would result in cash and in-kind payments from the University. Those that are estimable have been recorded as liabilities.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

21. Expenses by Functional and Natural Classification

Expenses are reported for the University's primary program activities. The consolidated statements of activities also report certain categories of expenditures that support more than one major program of the University. These expenses include operation and maintenance of plant, depreciation expense, and interest expense.

Expenses by functional and natural classification for the years ended June 30, 2022 and 2021 are as follows:

						2022								
						Natural	Classi	fication post A	llocat	ion				
	Expenses per Statement of Activities		Statement of		Statement of		A	llocation		mpensation nd Benefits		Other		Final Allocated Expenses
Instruction and educational administration	\$	2,093,132	\$	320,443	\$	1,655,687	\$	757,888	\$	2,413,575				
Research		812,624		114,250		489,141		437,733		926,874				
Patient care expense		1,317,600		89,992		1,095,933		311,659		1,407,592				
Operation and maintenance of plant		322,252		(322,252)										
Institutional support		360,300		55,595		254,638		161,257		415,895				
Auxiliary enterprise		184,638		129,401		113,576		200,463		314,039				
Depreciation expense		329,390		(329,390)										
Interest expense		58,039		(58,039)										
Total operating expenses		5,477,975				3,608,975		1,869,000		5,477,975				
Net periodic benefit cost other than service cost		(16,085)				(16,085)				(16,085)				
Total expenses	\$	5,461,890			\$	3,592,890	\$	1,869,000	\$	5,461,890				
						2021								
						Natural	Classi	fication post A	llocati	ion				
	E	xpenses per			-			•		Final				

						ion						
	Expenses per Statement of		• •				Compensation and Benefits		Other		Final Allocated Expenses	
		renvines		<u> </u>		iu Benerits		Other		Ехрепзез		
Instruction and educational administration	\$	1,905,340	\$	300,419	\$	1,557,511	\$	648,248	\$	2,205,759		
Research		734,211		105,443		447,742		391,912		839,654		
Patient care expense		1,246,626		87,219		1,025,328		308,517		1,333,845		
Operation and maintenance of plant		312,826		(312,827)								
Institutional support		345,088		51,824		254,055		142,857		396,912		
Auxiliary enterprise		147,938		120,219		101,430		166,726		268,156		
Depreciation expense		290,839		(290,839)								
Interest expense		61,458		(61,458)								
Total operating expenses		5,044,326				3,386,066		1,658,260		5,044,326		
Net periodic benefit cost other than service cost		(7,489)				(7,489)				(7,489)		
Total expenses	\$	5,036,837			\$	3,378,577	\$	1,658,260	\$	5,036,837		

The allocation of operation and maintenance of plant is based on square footage occupancy. Depreciation expense includes depreciation of buildings, building improvements, and equipment. The allocation of depreciation on buildings and building improvements is based on square footage occupancy. Depreciation on equipment is allocated to the programs for which the equipment was purchased. Interest expense is allocated according to the same methodologies used for building depreciation.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021 (in thousands of dollars, unless otherwise noted)

22. Subsequent Events

The University has performed an evaluation of subsequent events through October 12, 2022, which is the date the consolidated financial statements were issued. In October 2022, the University renewed a \$200 million operating line of credit which now expires in October 2025.

The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2022 and 2021

(in thousands of dollars, unless otherwise noted)

23. Financial Responsibility Standards

The University participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR 668.171. The criteria for private institutions include the annual calculation by ED of a financial responsibility composite score, as further outlined in 34 CFR 668.172, using audited financial statements submitted through ED's eZ-Audit system. The composite score has been and will continue to be based on three ratios: Primary Reserve, Equity, and Net Income. These ratios utilize the following financial data of the Institution, which are not otherwise presented in the financial statements or other notes to the financial statements, as of and for the year ended June 30, 2022:

Required input per standards	Ratio(s) Uses	In	put Amount	amount n	inancial statement ot used as input on nentary schedule
Property, plant and equipment, net - pre-implementation	Primary reserve	\$	4,732,022		
Property, plant and equipment, net - post-implementation	Primary reserve	•	,,.		
with outstanding debt for original purchase	Ž		1,154,765		
Property, plant and equipment, net - post-implementation	Primary reserve		, ,		
with outstanding debt for original purchase	Ž		23,968		
Construction in progress	Primary reserve		166,840		
Total property, plant, and equipment, net	N/A			\$	6,077,595
Institutional real estate				\$	1,024,420
Land, buildings, and equipment, net					5,053,175
Total property, plant, and equipment, net				\$	6,077,595
Long-term debt - for long-term purposes pre-implementation	Primary reserve	\$	1,586,760		
Long-term debt - for long-term purposes post-implementation	Primary reserve		172,158		
Subtotal long-term debt for the purchase of PPE	Primary reserve			\$	1,758,918
Other long-term debt	N/A				693,717
Total long-term debt	N/A			\$	2,452,635
Bonds and notes payable				\$	2,316,548
Capital leases					136,087
Total long-term debt				\$	2,452,635
Net assets with donor restrictions: restricted by purpose or time					
Annuities and life income funds with donor restrictions	Primary reserve	\$	72,694		
Term endowments with donor restrictions	Primary reserve		4,706,345		
Pledges	N/A			\$	308,827
Unexpended capital and other	N/A				474,194
Net assets with donor restrictions: restricted in perpetuity	Primary reserve		4,567,845		
Total net assets with donor restrictions				\$	10,129,905
Unsecured related party receivable	Primary reserve; Equity	\$	9,397		
Inputs directly from the statement of activities					
Total expenses without donor restrictions (operating)	Primary reserve	\$	5,477,975		
Plus: non-operating expenses and other losses	Primary reserve		30,819		
Total expenses and losses without donor restrictions	Primary reserve	\$	5,508,794		
Total operating revenue and other additions	Net income	\$	6,028,952		
Less: investment return appropriated for spending	Net income		(193,077)		
Plus: non-operating revenues and other gains	Net income		19,374		
Total revenue and gains without donor restrictions	Net income	\$	5,855,249		

Supplemental Schedule

				R&D Cluster
Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number Passthrough	<u>Name</u> <u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
93.RD	CDC 200-2012-53665/0005		\$0	\$307,516
93.084	6U01CK000592-02-00		\$0	\$393,412
93.226	1R01HS28454-01A1		\$0	\$2,812
9 93.914	1H1LHA37344-01-00		\$-4,643	\$61,421
			-4,643	765,161
93.RD	BARDA 75A50121C00017		\$829,542	\$2,177,701
93.059	5D88HP37554 -02-00		\$0	\$704,719
93.061	5R01TS000285-02-00		\$0	\$199,012
93.084	5U01CK000592-02-00		\$0	\$495,582
93.103	5R01FD005745-03		\$33,373	\$1,390,972
	93.RD 93.084 93.914 93.059 93.061	93.RD CDC 200-2012-53665/0005 93.084 6U01CK000592-02-00 93.226 1R01HS28454-01A1 93.914 1H1LHA37344-01-00 93.RD BARDA 75A50121C00017 93.059 5D88HP37554 -02-00 93.061 5R01TS000285-02-00	93.RD CDC 200-2012-53665/0005 93.084 6U01CK000592-02-00 93.226 1R01HS28454-01A1 93.914 1H1LHA37344-01-00 93.RD BARDA 75A50121C00017 93.069 5D88HP37554 -02-00 93.061 5R01TS000285-02-00	Sarp

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	R&D Cluster Total Expenditures
1	Listing No.	Identfication No				(Includes Subrecipients
Naternal and Child Health Federal Consolidated Programs	93.110	5 H17MC40192 02 00			\$0	\$56,336
Emergency Medical Services for Children	93.127	5U03MC00007 22 00			\$225,645	\$570,205
njury Prevention and Control Research and State and Community Based Programs	93.136	5R49CE003094-04-00			\$39,802	\$755,472
Community Programs to Improve Minority Health Grant Program	93.137	1CPIMP211308-01-00			\$0	\$215,326
National Research Service Award in Primary Care Medicine	93.186	6T32HP10260 14 02			\$0	\$90,547
National Research Service Awards Health Services Research Training	93.225	5T32HS026121-05			\$0	\$495,372
Research on Healthcare Costs, Quality and Outcomes	93.226	5R01HS025198-05			\$533,936	\$3,228,977
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	5U01DP006436-04-00			\$107,381	\$987,120
CDC Undergraduate Public Health Scholars Program (CUPS): A Public Health Experience to Expose Undergraduates Interested in Minority Health to Public Health and the Public Health Professions	93.456	5NU50MN000003-05-00			\$0	\$761,202
Public Health Training Centers Program	93.516	6UB6HP31686-04-01			\$369,174	\$819,761

For year ended June 30, 2022

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name Sul	<u>orecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Mental and Behavioral Health Education and Training Grants	93.732	5 MC1HP42105 02 00			\$0	\$443,785
Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants	93.924	5H65HA00014 -20 -00			\$140,440	\$312,322
HIV Demonstration, Research, Public and Professional Education Projects	93.941	1U01PS005229-01-00			\$32,679	\$420,411
Primary Care Medicine and Dentistry Clinician Educator Career Development Awards	93.976	5K02HP30811 -04-00			\$0	\$37,811
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	5NU62PS924586-03-00			\$0	\$647,903
				<u>-</u>	2,311,972	14,810,536
Total Direct Award Programs				_	\$2,307,329	\$15,575,697
Pass-through Awards Covid 19 Related Funding:						
Biomedical Advanced Research and Development Authority						
COVID-19-An Al-Based Multi-Functional Hand-Held Lumify Ultrasound for Automatic and Intelligent Quantitative Assessment of Lung Injuries, Diseases and Traumatic Injuries in a Mass-Casualty	93.RD	ORSHUN 1019000 COLUMBIA	75A50120C000097	OREGON HEALTH SCIENCES UNIVERSITY	\$0	\$167,541
COVID-19-Virtual Network to Investigate the Trajectory of COVID-19-Related Severe Outcomes	93.RD	WESTAT 6765-00SA005	75D30120C07986	WESTAT	\$0	\$28,960
COVID-19-Applied Research to Address the Coronavirus (COVID-19) Emerging Public Health Emergency, BAA NOTICE ID 75301-20-R-67897	93.RD	ABTAI 51352	75D30120C08150	ABT ASSOCIATES INC.	\$0	\$251,049
COVID-19-Monitoring Diversity in SARS-CoV-2 Genomes for Tracking Emerging Variants, Measuring Impact of Mitigation Strategies, and Gauging Clinical Outcomes	93.RD	CHOP GRT-00001190	75D30121C11102	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$72,864
Centers for Disease Control and Prevention Investigations and Technical Assistance				<u></u>	\$0	\$520,414
COVID-19-Virtual Network to Investigate the Trajectory of COVID-19-Related Severe Outcomes	93.283	Westat 6765-00-SA010	75D30120C07986	WESTAT	\$0	\$406,686
					\$0	\$406,686
Strengthening Public Health Systems and Services through National Partnerships to Improve	e and Protect the	e Nation's Health				
COVID-19-Modeling and forecast of COVID 19 at state and county scales	93.421	CSTE 7727	5NU38OT000297	COUNCIL OF STATE AND TERRITORIA EPIDEMIOLOGISTS	L \$0	\$47,352
COVID-19-Heterogeneous forecast and nowcast of COVID -19 at county scale	93.421	CSTE 7456	5NU38OT000297-02-00	COUNCIL OF STATE AND TERRITORIA EPIDEMIOLOGISTS	L \$0	\$192,478
COVID-19-COVID-19 Electronic Health Data Initiative	93.421	TFGH CD33-PCOR	NU38OT000316-03-02	TASK FORCE FOR GLOBAL HEALTH INC	\$0	\$83,704

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name	\$0 0	Total Expenditures (Includes Subrecipients) \$323,534 1,250,634
Biomedical Advanced Research and Development Authority						
An Al-Based Multi-Functional Hand-Held Lumify Ultrasound for Automatic and Intelligent Quantitative Assessment of Lung Injuries, Diseases and Traumatic Injuries in a Mass-Casualty Incident	93.RD	ORSHUN 1019000 COLUMBIA	75A50120C000097	OREGON HEALTH SCIENCES UNIVERSITY	\$0	\$45,223
Virtual Network to Investigate the Trajectory of COVID-19-Related Severe Outcomes	93.RD	WESTAT 6765-00SA005	75D30120C07986	WESTAT	\$0	\$5,711
Applied Research to Address the Coronavirus (COVID-19) Emerging Public Health Emergency, BAA NOTICE ID 75301-20-R-67897	93.RD	ABTAI 51352	75D30120C08150	ABT ASSOCIATES INC.	\$0	\$1,329,982
Respiratory Virus Transmission Network	93.RD	VUMC 96462	75D30121C11656	VANDERBILT UNIVERSITY MEDIC. CENTER	AL \$0	\$241,457
Study to Investigate the Combination of Physical Activity and Heart Rate with the Use of Actigraphy as a Novel, Well-defined, Reliable, Sensitive, Easy -to-use and Non-invasive Study	93.RD	UCOL FY21.827.008	75F40119C10090	UNIVERSITY OF COLORADO	\$0	\$37,500
QUANTIFYING PATIENTS BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A	93.RD	DUMC A034238	75F40120C00179	DUKE UNIVERSITY MEDICAL CEN	TER \$0	\$20,833
COLLARORATIVE FEFORT WITH THE RAPID PATHWAYS PATIENT, SCIENCE WORK Pandemic Influenza Study TASK ORDER NO. 50345	93.RD	ABTAI 50345	HHSD20002013M53890B/200 2013-F)-ABT ASSOCIATES INC.	\$0	\$2,587
Biodosimetry After Radiologic and Nuclear Events	93.RD	ASELL PO 20170003	PO 20170003	ASELL LLC.	\$0	\$37,597
Prevention of Disease, Disability, and Death by Infectious Diseases				······································	\$0	\$1,720,890
Northeast Regional Center for Excellence in Vector Borne Diseases	93.084	CU 81477-10822	6U01CK000509-01-11	CORNELL UNIVERSITY	\$0	\$445,838
				<u>-</u>	\$0	\$445,838
Food and Drug Administration Research						
Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Public-Private Partnership	93.103	URMC SUB00000201	1U01FD007474-01	UNIVERSITY OF ROCHESTER MEI CENTER	DICAL \$0	\$32,112
Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership	93.103	URMC 417811G URFAOGR511088	5U01FD005936-05	UNIVERSITY OF ROCHESTER MEI CENTER	DICAL \$0	\$10,243
				· · · · · · · · · · · · · · · · · · ·	\$0	\$42,355
Injury Prevention and Control Research and State and Community Based Programs Michigan Youth Violence Prevention Center (MI-YVPC) Community Engagement and	93.136	UMICHG 3004386942	5U01CE002698-02	UNIVERSITY OF MICHIGAN	\$0	\$-46.559
Revitalization						
Studying the Philadelphia Resilience Project as a Response to Overdose	93.136	UPENN 580641	6R01CE003143-01-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$25,805
Research on Healthcare Costs, Quality and Outcomes				•	\$0	\$-20,754
SNEPT and SPLIT Network Implementation of a QoI measure in pediatric transplant recipients	93.226	UAP 136450-3	1U18HS028380-01	UNIVERSITY OF PITTSBURGH	\$0	\$12,001
Consumer Assessment of Healthcare Providers and Systems CAHPS V	93.226	YU GR112701 (CON-80002977)	5U18HS016978-13	YALE UNIVERSITY	\$0	\$18,596
Preventing Wrong Drug and Wrong Patient Errors with Indication Alerts in CPOE Systems	93.226	NWU SP0037488-PROJ0010282	R01HS024945	NORTHWESTERN UNIVERSITY	\$0	\$25,597

<u> </u>						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name Subre	<u>cipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Homecare-CONCERN: Building risk models for preventable hospitalizations and emergency department visits in homecare	93.226	VNSNY 4629 2020 CUSON	R01HS027742	VISITING NURSE SERVICE OF NEW YORK	\$0	\$25,056
				<u></u>	\$0	\$81,250
Policy Research and Evaluation Grants	00.000	LIMIANA D. ZOOKOOO	4117045000400.04	LININ/EDOLTY OF WICCONON MADICON	* 0	005.750
Supporting the Development of the Poverty Research Center at the University of Wisconsin	93.239	UWIMAD 703K802	1H79AE000103-01	UNIVERSITY OF WISCONSIN MADISON	\$0 	\$35,759
Substance Abuse and Mental Health Services Projects of Regional and National Significan-	ice				\$0	\$35,759
Mental Disorders Prevalence Study	93.243	RTI 2-312-0217186-65729L	1H79FG000030-01	RESEARCH TRIANGLE INSTITUTE	\$0	\$229,901
SAMHSA's Suicide Prevention Resource Center Grant	93.243	CUOHSC RS20201621-01	1H79SM083028-01	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	\$0	\$55,234
Medication Assisted Treatment Program at Project HOME	93.243	PROHOME CU62310-01	1H79TI081611-01	PROJECT H.O.M.E.	\$0	\$36,133
2019 Providers Clinical Support System-Medicated Assisted Treatment	93.243	AAAP PCSSMAT19-15	1H79TI081968-01	AMERICAN ACADEMY OF ADDICTION PSYCHIATRY	\$0	\$112,538
Increasing Community Access to Early Childhood EBT Services at the Family PEACE Trauma Treatment Program	93.243	NYPH CU19-3449	U79SM063220-01	PRESBYTERIAN HOSPITAL IN THE CITY OF NEWYORK	\$0	\$62,367
Advanced Nursing Education Workforce Grant Program					\$0	\$496,173
Advanced Nursing Education Nurse Practitioner Residency Integration Program (ANE-NPRIP)	93.247	CHCNTWK CU20-1905	1T58HP39869-01-00	COMMUNITY HEALTHCARE NETWORK	\$0	\$300,477
HRSA Advanced Nursing Education Nurse Practitioner Residency (ANE-NPR) Program	93.247	BASSETT CU19-0741	HRSA 1T14HP33198-01-00	BASSETT HEALTHCARE NETWORK	\$0	\$31,489
				······	\$0	\$331,966
Occupational Safety and Health Program Prenatal WTC Chemical Exposures, Birth Outcomes and CardiometabolicRisks	93.262	NYU 17-A1-00-006514	U01OH011299	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$75,267
				······································	\$0	\$75,267
Protecting and Improving Health Globally: Building and Strengthening Public Health Impac						
Ethiopia SI GEEKS Data Triangulation	93.318	TFGH CU21-1643	6NU2GGH002090	TASK FORCE FOR GLOBAL HEALTH INC	\$0	\$55,373
Sickle Cell Treatment Demonstration Program					\$0	\$55,373
Northeast Region Sickle Cell Disease Treatment Demonstration Regional Collaborative Program	93.365	JH 2003735144	5U1EMC227864-06-00	JOHNS HOPKINS UNIVERSITY	\$0	\$28,417
				· · · · · · · · · · · · · · · · · · ·	\$0	\$28,417
ACL National Institute on Disability, Independent Living, and Rehabilitation Research						
RERC on TECH. for the Deaf and Hard of Hearing	93.433	GU #25172	90RE5020-02-01	GALLAUDET UNIVERSITY	\$0	\$11,288
Opioid STR					\$0	\$11,288
Opioid Response Network: Collaborating, Advancing, Responding, Educating	93.788	AAAP SOR-CARE-40	1H79 TI083343-01	AMERICAN ACADEMY OF ADDICTION PSYCHIATRY	\$0	\$183,919

Foderal Crenter / Base through Crenter	A		D # 10 : ::: :	D # 1.N	0.1	R&D Cluster
	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
	<u> </u>	<u></u>		•	\$0	\$183,919
Health Careers Opportunity Program						
HCOP Northeast Regional Alliance (NERA) MedPrep Scholars Program	93.822	ISMMS 0253-6647-4609	1D18HP321210100	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$133,149
HIV Emergency Relief Project Grants				······································	\$0	\$133,149
RYAN WHITE PART A CONTRACT 93-EVL-4645 FOR PLANNING AND EVALUATION (BASE)	93.914	93-EVL-4645T-502	6 H89HA00015 31 01	Public Health Solutions	\$0	\$686,242
				······································	\$0	\$686,242
					0	4,307,132
Total Pass-through Programs					\$0	\$5,557,766
Total Department of Health & Human Services (Excluding NIH)					\$2,307,329	\$21,133,463
National Institute of Health						
Direct Awards Covid 19 Related Funding:						
COVID-19-Effects of Prenatal Exposure To Environmental Tobacco Smoke on Brain Function and Academic Skills	93.113	5K23ES026239-05			\$9,634	\$64,351
COVID-19-Neurocognitive & neuropsychiatric impact of chemosensory alterations: Implications of olfactory dysfunction in COVID-19	93.173	5K23DC019678-02			\$26,119	\$283,851
COVID-19-OVID-19 Mother Baby Outcomes (COMBO): brain-behavior functioning	93.242	5R01MH126531-02			\$144,809	\$719,229
COVID-19-Tissue Engineering Resource Center-Treatment of COVID-19 Induced Acute Respiratory Distress by Inhalation of Exosomes	93.286	3P41EB027062-02S1			\$0	\$5,039
COVID-19-Impact of Social Cohesion and Social Capital in PrEP Uptake and Adherence Among Transwomen of Color	93.307	3R01MD013554-05S1			\$0	\$303,760
COVID-19-Optimizing SARS-CoV-2 wastewater based surveillance in urban and university campus settings	93.310	5U01DA053949-02			\$45,662	\$2,831,046

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number Passthro	ugh Nama Subraginianta	R&D Cluster Total Expenditures
- Cucra Grantor / 1 ass anough Grantor	Listing No.	Identfication No	Pass-tillough Contract Number Passuillo	ugh Name Subrecipients	(Includes Subrecipients)
COVID-19-Columbia University Minority/Underserved Site NCI Community Oncology Research Program	93.399	5UG1CA189960-09		\$0	\$2,530
COVID-19-Ubiquitin Regulation of K Channels in Health and Disease	93.837	3R01HL142111-04S1		\$29,822	\$593,940
COVID-19-COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS)	93.838	5R01HL157634-02		\$361,343	\$1,236,423
COVID-19-RECONFIG - REcovery of CONciousness Following Intracerebral hemorrhaGe	93.853	5R01NS106014-04		\$0	\$53,543
COVID-19-Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2	93.855	5R01Al160961-02		\$77,755	\$2,776,30 ⁷
COVID-19-Discovering and Applying Knowledge in Clinical Databases	93.879	2R01LM006910-22		\$0	\$33,859
COVID-19-Health and Psychosocial Need: The Asenze study of risk and protection in adolescence	93.989	5R01TW011228-04		\$0	\$3,932
				695,144	8,909,282
Fogarty International Center/NIH/DHHS	93.RD	FIC CU19-1769		\$98,835	\$11,802,047
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	5R21HL153700-02		\$0	\$161,652
Environmental Health	93.113	5T32ES007322-20		\$2,780,076	\$15,737,246

					R&D Cluster
Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
93.121	5R01DE029068-04			\$698,709	\$5,530,123
93.143	5P42ES010349-18			\$43,398	\$53,309
93.172	5U01HG008680-06			\$590,574	\$7,030,926
93.173	5R01DC018060-04			\$864,504	\$6,213,223
93.213	5DP1AT011979-02			\$4,300	\$1,063,039
93.233	5R01HL141494-05			\$11,469	\$1,779,615
93.242	5P50MH109429-05			\$6,315,651	\$36,690,028
93.273	51R01AA027079-04			\$958,197	\$5,234,667
93.279	5UM1DA049415-04			\$5,120,905	\$26,848,032
93.286	5P41EB027062-04			\$595,979	\$6,843,339
	93.121 93.143 93.172 93.173 93.213 93.233 93.242 93.273	Listing No. Identification No 93.121 5R01DE029068-04 93.143 5P42ES010349-18 93.172 5U01HG008680-06 93.173 5R01DC018060-04 93.213 5DP1AT011979-02 93.233 5R01HL141494-05 93.242 5P50MH109429-05 93.273 51R01AA027079-04 93.279 5UM1DA049415-04	Listing No. Identification No 93.121 5R01DE029068-04 93.143 5P42ES010349-18 93.172 5U01HG008680-06 93.173 5R01DC018060-04 93.213 5DP1AT011979-02 93.233 5R01HL141494-05 93.242 5P50MH109429-05 93.273 51R01AA027079-04 93.279 5UM1DA049415-04	Listing No. Identification No 93.121	Listing No. Identification No 93.121 5R01DE029088-04 \$688,709 93.143 5P42ES010349-18 \$43,398 93.172 5U01HG008680-06 \$590,574 93.173 5R01DC018060-04 \$884,504 93.213 5DP1AT011979-02 \$4,300 93.233 5R01HL141494-05 \$11,469 93.242 5P50MH109429-05 \$6,315,651 93.273 51R01AA027079-04 \$958,197 93.279 5UM1DA049415-04 \$5,120,905

					R&D Cluster
Federal Grantor / Pass-through Grantor Minority Health and Health Disparities Research	Assistance <u>Listing No.</u> 93.307	Award <u>Identfication No</u> 5U01MD011279-05	Pass-through Contract Number Passthrough Name	Subrecipients \$707,595	Total Expenditures (Includes Subrecipients) \$4,419,200
Trans-NIH Research Support	93.310	3OT2OD026556-01S3		\$4,979,791	\$19,249,896
National Center for Advancing Translational Sciences	93.350	5U18TR003211-02		\$348,450	\$4,606,843
Research Infrastructure Programs	93.351	1S10OD028696-01A1		\$0	\$1,337,500
Construction Support	93.352	1C06OD030152-01		\$0	\$340,184
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	5U01CA247573-03		\$0	\$530,521
Nursing Research	93.361	5R01NR017571-05		\$1,241,184	\$5,293,383
Cancer Cause and Prevention Research	93.393	5U01CA164920-10		\$2,968,650	\$18,556,254
Cancer Detection and Diagnosis Research	93.394	5R01CA238433-04		\$503,723	\$2,445,760
Cancer Treatment Research	93.395	5R01CA201788-07		\$236,658	\$5,317,426
Cancer Biology Research	93.396	5P01CA087497-20		\$2,404,146	\$22,077,492

Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number Passthrough Name	Subrecipients	R&D Cluster Total Expenditures (Includes Subrecipients)
Cancer Centers Support Grants	93.397	5P30CA013696-47		\$626,556	\$7,890,965
Cancer Research Manpower	93.398	5T32CA203703-07		\$0	\$3,312,451
Cancer Control	93.399	5UG1CA189960-09		\$45,000	\$850,055
Preventing Heart Attacks and Strokes in High Need Areas	93.816	7R01Al067946-13		\$0	\$73,141
Cardiovascular Diseases Research	93.837	5R01HL139671-04		\$4,256,653	\$37,718,186
Lung Diseases Research	93.838	5R01HL093081-11		\$2,740,066	\$14,822,741
Blood Diseases and Resources Research	93.839	5R01HL148151-04		\$1,374,692	\$6,435,856
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	5R01AR071986-04		\$1,147,631	\$9,039,716
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5U01DK123559-04		\$4,880,231	\$38,679,836
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	5U01NS095869-05		\$12,291,001	\$57,172,771
Allergy and Infectious Diseases Research	93.855	4U54AI138370-06		\$5,607,427	\$45,572,163

Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	er Passthrough Name	Subrecipients	R&D Cluster Total Expenditures (Includes Subrecipients
National Cancer Institute/NIH/DHHS	93.856	5R01CA224428-05			\$183,614	\$1,178,33
Biomedical Research and Research Training	93.859	2T32GM007367-42			\$457,232	\$32,777,23
Child Health and Human Development Extramural Research	93.865	5R01HD104599-03			\$4,564,314	\$15,296,67
iging Research	93.866	5U01AG051412-05			\$14,376,593	\$81,251,06
/ision Research	93.867	5R24EY028758-02			\$914,374	\$13,814,95.
nedical Library Assistance	93.879	5T15LM007079-30			\$573,462	\$3,431,15
nternational Research and Research Training	93.989	5R01TW011228-04			\$338,419	\$871,43
Fotal Direct Award Programs Pass-through Awards Covid 19 Related Funding: National Cancer Institute/NIH/DHHS					85,850,059 \$86,545,203	\$579,350,44 \$588,259,72
COVID-19-Multiplexed in-solution serological test for SARS-COV-2, human coronaviruses and other	r 93.RD	ASU ASUB00000660	75N91019D00024	ARIZONA STATE UNIVERSITY	\$0	\$477,14
espiratory pathogens OVID-19-An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled rial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous	93.RD	LEIDOS 21CTA-DC0021	75N91020F00009	LEIDOS BIOMEDICAL RESEARCH	INC \$0	\$79,33
DOVID-19- In vitro testing and early detection of SARS-CoV-2 variants	93.RD	ISSM 0258-A700-4609	75N93021C00014	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$1,215,38
OVID-19-Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)	93.RD	ACTIV-2/A5401	HHSN272201700078C	PPD DEVELOPMENT	\$0	\$11,76
					\$0	\$1,783,636

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name Su	ıbrecipients	R&D Cluster Total Expenditures
reactal Grantol / Fass through Grantol	Listing No.	Identfication No	Pass-illiough Contract Number	<u>rassiliougirivanie</u> <u>Si</u>	ibrecipients	(Includes Subrecipients)
Research on Healthcare Costs, Quality and Outcomes						
COVID-19-Evaluating and Enhancing Health Information Technology for COVID-19 Emergency Response Workflow in a Specialized COVID-19 Hospital in a Medically Underserved Community	93.226	SUNYRF 100-1165500-90112	1R01HS028220-01	RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK	\$0	\$21,064
Mental Health Research Grants				_	\$0	\$21,064
COVID-19-Web-Based Therapist Training on Complicated Grief Therapy	93.242	CFT 001	1R41MH118126-01A1	CENTER FOR TELEPSYCHOLOGY	\$0	\$17,072
COVID-19-Adapting Coordinated Specialty Care in the Post COVID-19 Era	93.242	RFMH 27327	3R01MH120597-02S1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$1,133
COVID-19-StepWell: Stepped Care Mental Health and Substance Use Telehealth Services for COVID-19 Affected Patients	93.242	SRFMH 154388	3U19MH113203-04S3	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$196,879
Drug Abuse and Addiction Research Programs				<u></u>	\$0	\$215,084
COVID-19-Methadone in the Time of COVID: A natural experiment on the impact of relaxed methadone regulations on treatment outcome	93.279	21-A0-R2-003671	3UG1DA013035-19S3	NEW YORK UNIVERSITY	\$0	\$46,912
Trans-NIH Research Support				<u></u>	\$0	\$46,912
COVID-19-Diagnosing and predicting risk in children with SARS-CoV-2-related illness	93.310	UCSD KR704295	1R61HD105590-01	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$202,469
COVID-19-Antibody library display for precision screening of antibody responses to SARS-CoV-2	93.310	KUCR FY2021-048	3DP5OD023118-05S1	UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC.	DR \$0	\$2,471
COVID-19-Leveraging Social Networks to Increase COVID-19 Testing Uptake: A Comparison of Credible Messenger and Chain Referral Recruitment Approaches	93.310	RFMH 152302	3UG1DA050071-02S1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$173,353
Cardiovascular Diseases Research				<u></u>	\$0	\$378,293
COVID-19-A5332: Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (Study) and the REPRIEVE sub-study A5333s: Effects of Pitavastatin on Coronary Artery Disease and	93.837	BWH CU21-2542	3U01HL123336-06S2	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$3,000
Inflammatory Riomarkers COVID-19-Pediatric Heart Network U24HL135691	93.837	NERI CU17-3862	U24HL135691	NEW ENGLAND RESEARCH INSTITUTES	\$0	\$107,026
Lung Diseases Research				<u></u>	\$0	\$110,026
COVID-19-Collaborative Cohort of Cohorts for COVID-19 Research (C4R)	93.838	RTI 22-312-0217571-66178	1OT2HL156812-01	RESEARCH TRIANGLE INSTITUTE	\$5,680,988	\$7,826,946
COVID-19-NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoVInfection in Pediatric Populations	-2 93.838	NYMC PED-05-21	OT2HL161847-01	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$245,344
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Slee	on Disorders			<u></u>	\$5,680,988	\$8,072,290
COVID-19- ACTIV 4d RAAS	93.840	VUMC 92541	1OT2HL156812-01	VANDERBILT UNIVERSITY MEDICAL CENTER	\$0	\$5,031
Diabetes, Digestive, and Kidney Diseases Extramural Research				<u></u>	\$0	\$5,031
COVID-19- Experimental and natural SARS-CoV-2 infection of the human pancreas	93.847	ISMMS 0255-F641-4609	1R01DK130425-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$26,876
				<u></u>	\$0	\$26,876

For year ended June 30, 2022						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Allergy and Infectious Diseases Research						
COVID-19-Surveillance of COVID-19 at the building scale: SARS-CoV-2 in building dust	93.855	OSU GR126534/SPC-1000006185	1R21Al68817-01	OHIO STATE UNIVERSITY	\$0	\$1,812
COVID-19-Immune Tolerance Network	93.855	BRI FY21ITN440	2UM1AI109565-08	BENAROYA RESEARCH INSTITUTE	≣ \$0	\$51,814
COVID-19-COVID-19 Prevention Network (CoVPN) Site Preparation	93.855	FHCRC 0001033117	3UM1AI068614-14	FRED HUTCHINSON CANCER CEN	ITER \$0	\$2,677
COVID-19-CoVPN 3002 Protocol Funding (PF) - New York-Columbia P&S Clinical Research Site	93.855	FHCRC 0001035530	3UM1Al068614-14S1	FRED HUTCHINSON CANCER CEN	ITER \$0	\$1,545,427
COVID-19-A randomized controlled study to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19	93.855	HCRC 0001064473	3UM1Al068614-15	FRED HUTCHINSON CANCER CEN	ITER \$0	\$-36,108
COVID-19-COVID-19 Prevention Network (CoVPN) Site Preparedness Funding-New York - Bronx Prevention Clinical Research site	93.855	FHCRC 0001081380	3UM1Al068614-15S1	FRED HUTCHINSON CANCER CEN	ITER \$0	\$121,107
COVID-19-CoVPN Vaccine Site Preparation	93.855	PO20002667	3UM1Al06861914S1	FHI DEVELOPMENT 360 LLC	\$0	\$-21,363
COVID-19-ADAPT Out COVID: ACTIV-2/ACTG A5401	93.855	UCLA CRS 30329 CU 30606 A5401	3UM1AI068636-14S2	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$0	\$84,039
COVID-19-Genetic and ecological determinants of coronavirus recombination	93.855	UCD A21-2861-S001-A02	5R01Al149693-03	UNIVERSITY OF CALIFORNIA, DAV	'IS \$0	\$54,536
COVID-19-CoVPN 3003: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Asses the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2- mediated COVID-19 in		FHID P020003035	UM1 Al068619	FHI DEVELOPMENT 360 LLC	\$0	\$192,465
Adults Agart 18 Vagre en COVID-19-CoVPN 5002 Seroprevalence Study	93.855	FHID PO20002908	UM1Al068619	FHI DEVELOPMENT 360 LLC	\$0	\$2,473,427
Biomedical Research and Research Training				······	\$0	\$4,469,833
COVID-19-Efficient Statistical Learning Methods for Personalized Medicine Using Large Scale Biomedical Data.	93.859	UNC 5118007	3R01GM124104-03S1	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL	A AT \$0	\$92,280
Child Health and Human Development Extramural Research					\$0	\$92,280
COVID-19-Fragile Families and the Transition to Adulthood	93.865	PU SUB0000462	5R01HD036916-18	PRINCETON UNIVERSITY	\$0	\$7,062
COVID-19-1 ragner annines and the Transition to Additiood	95.005	F 0 30B0000402		·····		φ1,002
					\$0	\$7,062
					5,680,988	15,228,387
National Institutes of Health/DHHS						
Direct activators of protein phosphatase 2A (PP2A) as novel Alzheimer s Disease (AD) therapeutics	93.RD	ATUX CU20-1222	1R43AG071040-01	ATUX ISKAY LLC	\$0	\$57,682
Strong Heart Study (SHS) - AZ Field Center Core Field Studies, TO 75N2019F0001	93.RD	MERI 5002263976	75N2019D00023	Medstar Research Institute	\$0	\$45,928
Strong Heart Study Arizona Field Center	93.RD	MERI 5001681646	75N2019D00023/TO-75N2019 F0001	9 Medstar Research Institute	\$0	\$28,886
Integrated imaging and molecular analysis of glioblastoma using SCOPE-Seq on the AIR FLOW System	93.RD	CMICRO 021820	75N91019C00029	CELL MICROSYSTEMS	\$0	\$159,908
Leidos RFP S18-144QF2	93.RD	LEIDOS S18-144QF2	75N91019D00024	LEIDOS BIOMEDICAL RESEARCH I	NC \$0	\$157,781

Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) 93.RD MB CU20-4666 75N91020C00016 Deep Learning Clinical Trial Matching System MASSIVE BIO INC \$0 \$20,002 LUNA 33483.02ADARC CNT-Vectored Delivery of mRNA for HIV-Vaccines 93.RD 75N93019C00034 LUNA LABS USA LLC \$0 \$173,669 3441-ARM-2S 3 Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute 93.RD LEIDOS 17X152 HHSN261200800001E LEIDOS BIOMEDICAL RESEARCH INC \$58,697 PumpKIN Trial NERI CU18-1664 HHSN2682012000001 NEW ENGLAND RESEARCH \$11,000 93 RD \$0 **INSTITUTES** Pharmacokinetics and Safety Profile of Digoxin in Infants with Single Ventricle Congenital Heart 93.RD **DUKEU 243797** HHSN-275201800003I **DUKE UNIVERSITY** \$0 \$7.960 \$0 \$721,513 National Institutes of Health/DHHS 93.RD Kaiser Foundation Research Institute-\$0 Improving Blood Pressure Screening and Treatment Strategies in Young Adults KFDNI RNG211455-Columbia 1R01HL158790-01 \$85,934 -Division of Research 93.RD BRIGHAM AND WOMEN'S HOSPITAL \$321,251 Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance BWH 125535 1R01HL159012-01 \$0 UNIVERSITY OF CALIFORNIA, DAVIS The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population 93.RD CUD CU22-0748 1U19NS120384 \$0 \$37,783 with Cognitive Complaints (INDEED) National Alzheimer's Coordinating Center (NACC)- Competitive Renewal 93.RD UWSC12960 1U24AG072122-01 UNIVERSITY OF \$0 \$23,118 WASHINGTONSEATTLE WASHINGTON ACTG Protocol Funding - Core Funding 93.RD UCLA CRS 30329 CU 30606 2UM1AI068636-15 UNIVERSITY OF CALIFORNIA, LOS \$0 \$-25,137 ANGELES National Alzheimer s Coordinating Center 93.RD UWASH CU21-1939 3U24AG072122-01S1 UNIVERSITY OF \$0 \$82,740 WASHINGTONSEATTLE WASHINGTON **CDUKE A03-5266** DUKE CLINICAL RESEARCH INSTITUTE \$52.185 93.RD DUKE School vs. Home Environmental Exposure and Respiratory Outcomes (SHEERO) \$0 Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing HHSN261201200034I UNIVERSITY OF TEXAS M.D. \$40.272 93.RD UTMDA \$0 Salpingo-Oophorectomy 3001109242/3001109711 ANDERSON CANCERCENTER HVTN Research & Mentorship Program (RAMP) FRED HUTCHINSON CANCER CENTER 93.RD FHCC CU22-1487 NIH \$0 \$11,000 Investigating neuroanatomical underpinnings of apathy in ADRD through neuroimaging and 93.RD BCMH CU20-3451 R01MH127200 BAYLOR COLLEGE OF MEDICINE --\$168,774 \$0 electrical manipulation HOUSTON \$0 \$797,920 Family Smoking Prevention and Tobacco Control Act Regulatory Research Examining the Effects of Advertising, Packaging, and Labeling, and Perceptions, Use, and 93.077 RUTGER PO 25098129 1U54CA229973-01 RUTGERS, THE STATE UNIVERSITY OF \$0 \$122,784 Exposure of Combustible Tobacco Products NEW JERDEPARTMENT OF PADIOI OCV \$0 \$122,784 **Environmental Health** 1R01ES027747-01 HARVARD UNIVERSITY \$0 Air Particulate, Metals, and Cognitive Performance in an Aging Cohort- Roles of Circulating 93.113 HARVARD 112557-5108340 \$439,615 Extracellular Vesicles and Non-coding RNAs The Effects of Environmental Exposures on Semen Quality and the Sperm Epigenome. BRIGHAM AND WOMEN'S HOSPITAL 93.113 BWH 118582 1R01ES028712-01 \$0 \$91.416 **DUKEU A03-3136** 1R01ES029945-01A1 DUKE UNIVERSITY \$31.179 Impact of preconception and onward exposure to air pollution on growth trajectories of infants and 93.113 \$0 A national birth cohort study of prenatal factors and neurodevelopmental psychiatric disorders 93.113 RFMH 147870 1R01ES030966-01A1 RESEARCH FOUNDATION FOR \$51,818 MENTAL HYGIENEINC

Assistance

Listing No.

Award

Identfication No

For year ended June 30, 2022

Federal Grantor / Pass-through Grantor

										R	2 8	S.	C)	•	2	ı	uster
						(1			o	ta	al	E	Ξ	κŗ)(er	ıc	ditures ecipients) \$31,132
												-						\$226,673
			-	-		-	•		-	-			-		-	-	-	\$57,132
-	-	-		-	-		-	-		-	-	-	-	-	-	-	-	\$30,248
	-	÷	-	-	÷	-	-	÷	-	-	÷	-	-	÷	-	-	-	\$29,639
-	-	•	-	-	•	-	-	•	-	-	•	-	-	•	-	-	-	\$19,822
	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-		\$34,725
	-	-			-			-			-			-				\$20,000
				-						-			-		-	-		\$103,896
																	-	\$26,126
	-	-		-	-			-		-	-		-	-		-		\$12,476
	-	-		-	-		-	-		-	-		-	-	-	-	-	\$224,286
																	_	

Subrecipients

	LISTING INO.	identification (40			<u>U</u>	Holdaca Capicolpicitia
Urban air pollution and neurobehavioral trajectories in the ABCD study	93.113	USC 139981076	1R01ES031074-01A1	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$31,132
Developmental Exposure to Arsenic: Pneumonia, Immunity, and Microbiome (DEAPIM)	93.113	UNMEX 3RKW2	1R01ES031743-01A1	UNIVERSITY OF NEW MEXICO	\$40,987	\$226,673
Building Capacity to study mixed metal-induced neurotoxicity in Bangladeshi children-A1	93.113	TEXASSU 22200C	1R01ES032149-01A1	TEXAS STATE UNIVERSITY	\$0	\$57,132
The Role of Air Pollution in Emotional Neurodevelopment and Risk for Psychiatric Disorders	93.113	USC 138935395	1R01ES032295-01	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$30,248
The Impact of Drought on Arsenic Exposure and Cardiometabolic Outcomes in a Rural Aging Population	93.113	FY22.659.003	1R01ES032612-01A1	UNIVERSITY OF COLORADO	\$0	\$29,639
Ambient Air Pollution, Weather, and Placental Abruption (APWA)	93.113	RUTGERS 2100	1R01ES033190-01	RUTGERS, THE STATE UNIVERSITY OF NEW JERDEPARTMENT OF	\$0	\$19,822
Extreme weather, air pollution, and stroke among an aging female population	93.113	BRICHCC 63427.2010840.669304	1R01ES033413-01	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE CANCER CENTER	\$0	\$34,725
Xenobiotic Receptors in the Crossroad of Xenobiotic Metabolism and Endobiotic Metabolism	93.113	UPITT AWD00000936 (133648-2)	1R35ES030429-01	UNIVERSITY OF PITTSBURGH	\$0	\$20,000
Human Health Exposure Analysis Resource (HHEAR) Data Center	93.113	0255-C751-4609	2U2CES026555-02	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$103,896
Stress-Chemical Interactions and Neurobehavior in School Age Children	93.113	ISMMS 0255-5545-4609	5R01ES013744-13	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$26,126
Participatory Interventions to Reduce Arsenic Exposure in American Indian Communities	93.113	JHU 2003073212	5R01ES025135-02	JOHNS HOPKINS UNIVERSITY	\$0	\$12,476
Prenatal endocrine-disrupting chemicals and social/cognitive risk inmothers and infants: Potential biologic pathways	93.113	RFMH 26840	5R01ES027424	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$224,286
Prenatal metal mixtures and neurodevelopment: Role of placental extracellular microRNAs	93.113	ISMMS 0255-B981-4609	5R01ES030302-02	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$149,845
Air Particulate Pollution and Stress: Effects and Mechanisms for Long-term Maternal Obesity Risks	93.113	ISMMS 0255-E141-4609	5R01ES032242-02	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$129,138
The Programming Research in Obesity, Growth, Environmental and Social Stress (PROGRESS) Cohort	93.113	ISMM 0255-4921-4609	5R24ES028622-02	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$30,506
Manganese-related Neurotoxicity in Asymptomatic Welders	93.113	PSU COLES019672	R01ES019672	PENNSYLVANIA STATE UNIVERSITY	\$0	\$11,571
Arsenic and Immune Response to Influenza Vaccination in Pregnant Women and Newborns	93.113	JHU 2003603451	R01ES026973	JOHNS HOPKINS UNIVERSITY	\$0	\$15,392
				······· <u>····</u>	\$40,987	\$1,766,635
Oral Diseases and Disorders Research	00.404	MAIT 01140 0070	DO AD FORMAT	WALT COURTIFICATION	20	*
Development of Minimally Invasive Drug Delivery System for TMJ Regeneration	93.121	WNT CU19-2978	R24DE028215	WNT SCIENTIFIC LLC	\$0	\$302,050
Injury Prevention and Control Research and State and Community Based Programs					\$0	\$302,050
Association of maternal inflammation with preterm delivery and maternal disease progression	93.136	Westat 6579-S61	HHSN275201800001I	WESTAT	\$0	\$12,053
				·····	\$0	\$12,053
Human Genome Research	93.172	NYU F1228-01	1R21HG010420-01A1	NEW YORK UNIVERSITY	\$0	#40.000
Developing Clinical Translational Tools to Communicate Genetic Risk to Individuals who are at Clinical High Risk for Psychosis	93.172	INTU F 1220-U'I	IRZ INGU1U4ZU-U1A1	INEW TORK UNIVERSITY	⊅ U	\$19,899

Pass-through Contract Number Passthrough Name

Listing AND Deciding Supporting with Concentrated Capability to Sequence Multiple Date 1.00	Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name S	ubrecipients	R&D Cluster Total Expenditures
Modification at Siligit—saws Resource	rederal Grantol / 1 ass-unough Grantor			Fass-tillough Contract Number	<u>rasstillougii Naille</u>	ubrecipients	(Includes Subrecipients
The Dake FUNCTION Corner Percenting the comprehensive identification of combinatorial 03.172 U.O.A.034104 18M1 HG011123-01A1 DUKE LINIVERSITY MEDICAL CENTER 80 88-81 increased accounts of discases of the line Resource and Analysis 10.172 SU 02.172 SU 02.		93.172	NYIT 1R56HG011099-01C1	1R56HG011099-01	New York Institute of Technology	\$0	\$1,602
Section Sect	Center for Integrated Cellular Analysis	93.172	NYGC 2019-0014-CU-01	1RM1HG011014-01	NEW YORK GENOME CENTER	\$0	\$284,769
Secure Populations in Calorande & Desgon 13.172 KAISER 2005000229-2-clumba 2001HG007292-06 Caloran Foundation Research institute. 50 31.174 17.175 17.17		93.172	DU A034194	1RM1-HG011123-01A1	DUKE UNIVERSITY MEDICAL CENTE	ER \$0	\$68,197
Considerating Constituting and Evaluating Polygenic Scores Sal 172 Mail-Cit Substituting and Evaluating Polygenic Scores Sal 172 Mail-Cit Substituting and Evaluating Polygenic Scores Sal 172 Substituting Polygenic Scores Sal 172 Substituting and Evaluating and Evaluating Polygenic Scores Sal 172 Substituting Polygenic Scores	ELSI.hub: National Center for ELSI Resources and Analysis	93.172	SU 62196601-139696	1U24HG010733-01	STANFORD UNIVERSITY	\$14,490	\$640,472
New Methods for Constructing and Evaluating Polygenic Scores 93.172 SU 82472179-198855 SR01HG011432-02 STANFORD UNIVERSITY \$ 3132.83 Research Related to Desfiness and Communication Disorders Remodificated Controlled Trial of Valgancedoor for Asymptomatic Cytomegalovirus Infected Hearing 93.173 UUMC 10041913-010 1U01DC014706-0141 UnivERSITY OF UTAH MEDICAL 30 \$- separated Infatric (Valgancedoor for Asymptomatic Cytomegalovirus Infected Hearing Prosthedos 93.173 MEA 530973 SR01DC016874-02 MASSACHUSETTS EYE AND EAR 30 \$32.08 Chearacterizing the temporal processing of sound in human auditory cortex 93.173 NYU 20-A1-00-1003976 SR01DC016874-02 NEW YORK UNIVERSITY 90 \$75.00 Chearacterizing the temporal processing of sound in human auditory cortex 93.173 NYU 20-A1-00-1003976 SR01DC016806-02 NEW YORK UNIVERSITY 90 \$75.00 Research and Trailing in Complementary and Integrative Health White in the Tital bit Assesse Chelation Therapy 2 (TACT2) 92.21 MSMCM R01 AT008273 1R01AT008273-01 MOUNT SINAI MEDICAL CENTER MIXMIN 50 \$72.00 Comprehensive CBT via reSET for a Hub and Spoke MAT System of Case 93.213 PSU COLATO1018 1R21AT01018-01 PENNSYLVANIA STATE UNIVERSITY 90 \$36.60 Mental Health Research Grants Neural dynamics underlying rule based decision-making and Traination to Outpatient Psychiatric Care 93.242 RFMH 2653 1R01MH10828-014 RESEARCH FOLINGATION FOR 50 \$36.00 Mental Health Research Grants Neural dynamics underlying rule based decision-making and Traination to Outpatient Psychiatric Care 93.242 RFMH 2653 1R01MH10828-014 RESEARCH FOLINGATION FOR 50 \$36.00 Mental Health Research Grants Scorendary of Conversion Risk and Treatment Response in Early-Stage Schizophronia 93.242 RFMH 2639 1R01MH10828-014 RESEARCH FOLINGATION FOR 50 \$35.00 Scorendary of Conversion Risk and Treatment Response in Early-Stage Schizophronia 93.242 RFMH 2639 1R01MH10828-014 (MSN 1600C) (FMEDICIN) 1 100 \$36.25 Scorendary of Conversion Risk and Treatment Response in Early-Stage Schizophronia 93.242 RFMH 2679 1R01MH10828-014 (MSN 1600C) (F	Exome sequencing in Diverse Populations in Colorado & Oregon	93.172		2U01HG007292-06		\$0	\$17,94
Research Related to Desfiness and Communication Disorders Remodurated Controlled Trial of Valgemedictory for Approprimatic Cylomegatovirus Infected Hearing Post Park Research Related to Desfiness and Communication Disorders Research Related to Desfiness and Communication Disorders 83.173	Tensor Array Methods for RNA-Seq Analysis	93.172	UMICHG SUBK00014336	5R01HG010731-03	UNIVERSITY OF MICHIGAN	\$0	\$-25,599
Research Related to Deafness and Communication Disorders	New Methods for Constructing and Evaluating Polygenic Scores	93.172	SU 62472179-159655	5R01HG011432-02	STANFORD UNIVERSITY	\$0	\$132,836
Rendering Countering Titled Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing 93.173 UMC 10041913-010 1U01DC014706-01A1 UNIVERSITY OF UTAH MEDICAL \$0 \$5. \$25.08					<u>.</u>	\$14,490	\$1,140,119
Impaired Infants (VIBEAR Trial)	Research Related to Deafness and Communication Disorders						
Characterizing the temporal processing of sound in human auditory cortex 93.173 NYU 20-A1-00-1003975 SR01DC018805-02 NEW YORK UNIVERSITY 50 \$75.00 \$100.981		93.173	UUMC 10041913-010	1U01DC014706-01A1		\$0	\$-1
Research and Training in Complementary and Integrative Health Metals in the Trial to Assess Chelation Therapy 2 (TACT2) 93.213 MSMCM R01 AT009273 1R01AT009273-01 MOUNT SINAI MEDICAL CENTER-MIAMI \$0 \$206,64 Defining disease mechanisms in SLC35A2 epilepsy 93.213 UNCCH 5118022 1R01NS11507-01A1 UNIVERSITY OF NORTH CARCLINA AT \$0 \$72.30 Comprehensive CBT via reSET for a Hub and Spoke MAT System of Care 93.213 PSU COLATOIO118 1R21AT010118-01 PENNSYLVANIA STATE UNIVERSITY \$0 \$67.66 Mental Health Research Grants Neural dynamics underlying rule based decision-making 93.242 SRFMH 145453 1K06MH120434-01 RESEARCH FOUNDATION FOR \$0 \$86.10 Hospital Discharge Planning and Transition to Outpatient Psychiatric Care 93.242 RFMH 26439 1R01MH106559-01A1 RESEARCH FOUNDATION FOR \$0 \$34.03 2/2 Familial Early-Onset Suicide Attempt Biomarkers 93.242 RFMH 26230 1R01MH108032-01 RESEARCH FOUNDATION FOR \$0 \$22.95 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CMC 213052-1 R01MH108032-01 RESEARCH FOUNDATION FOR \$0 \$83.25 Improving Cognition via Exercise in Schizophrenia 93.242 MSSM 0255-3351-4609 RO1MH110250-01A1 WELL LOOM AND SANFORD 1) \$0 \$88.75 Mental Health Research Ground And Danker Profiles 93.242 RFMH 26719 R01MH113250-01A RESEARCH FOUNDATION FOR \$0 \$88.75 MENTAL HYGIENERINC \$0 \$88.75 MCDIT SINAI HYGIENERINC \$0 \$88.75 MCDIT SIN	Implantable Microphones for Fully Implantable Hearing Prosthetics	93.173	MEA 530673	5R01DC016874-02	MASSACHUSETTS EYE AND EAR	\$0	\$25,98
Research and Training in Complementary and Integrative Health	Characterizing the temporal processing of sound in human auditory cortex	93.173	NYU 20-A1-00-1003975	5R01DC018805-02	NEW YORK UNIVERSITY	\$0	\$75,009
Metals in the Trial to Assess Chelation Therapy 2 (TACT2) 93.213 MSMCM R01 AT009273 1R01AT009273-01 MOUNT SINAI MEDICAL CENTER-MIAMI \$0 \$206.64 Defining disease mechanisms in SLC35A2 epilepsy 93.213 UNCCH 5118022 1R01NS11507-01A1 UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL \$0 \$72.30 Comprehensive CBT via reSET for a Hub and Spoke MAT System of Care 93.213 PSU COLAT010118 1R21AT010118-01 PENNSYLVANIA STATE UNIVERSITY \$0 \$67.66 Mental Health Research Grants \$0 \$346.62 \$0 \$346.62 Mental Health Research Grants \$0 \$86.10 \$0 \$86.10 Hospital Discharge Planning and Transition to Outpatient Psychiatric Care 93.242 RFMH 26439 1R01MH106558-0141 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC \$0 \$34.03 2/2 Familial Early-Onset Suicide Altempt Biomarkers 93.242 RFMH 26230 1R01MH106032-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC \$0 \$22.95 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CUMC 213052-1 1R01MH10270-0141 WEILL LICAN AND SANFORD L) MEDICINE AT MULL PLAN SCHOOL OF MEDICINE AT MOUNT SINAI MOUNT SINAI	Possarch and Training in Complementary and Integrative Health				<u>.</u>	\$0	\$100,989
CHAPEL HILL Comprehensive CBT via reSET for a Hub and Spoke MAT System of Care 93.213 PSU COLAT010118 1R21AT010118-01 PENNSYLVANIA STATE UNIVERSITY \$0 \$67.66 Mental Health Research Grants Neural dynamics underlying rule based decision-making 93.242 SRFMH 145453 1K08MH120434-01 RESEARCH FOUNDATION FOR \$0 \$86.10 MENTAL HYGIENEINC Hospital Discharge Planning and Transition to Outpatient Psychiatric Care 93.242 RFMH 26439 1R01MH106558-01A1 RESEARCH FOUNDATION FOR \$0 \$34.03 MENTAL HYGIENEINC 2/2 Familial Early-Onset Suicide Attempt Biomarkers 93.242 RFMH 26230 1R01MH108032-01 RESEARCH FOUNDATION FOR \$0 \$22.95 MENTAL HYGIENEINC Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CUMC 213052-1 1R01MH110270-01A1 WEILL (JOAN AND SANFORD I) MEDICAL COLLEGE OF CORNELL INDICEDITY IND		93.213	MSMCM R01 AT009273	1R01AT009273-01	MOUNT SINAI MEDICAL CENTER-MI	AMI \$0	\$206,647
Mental Health Research Grants \$0 \$346,621	Defining disease mechanisms in SLC35A2 epilepsy	93.213	UNCCH 5118022	1R01NS11507-01A1		AT \$0	\$72,309
Mental Health Research Grants Neural dynamics underlying rule based decision-making 93.242 SRFMH 145453 1K08MH120434-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC Hospital Discharge Planning and Transition to Outpatient Psychiatric Care 93.242 RFMH 26439 1R01MH106558-0141 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC 2/2 Familial Early-Onset Suicide Attempt Biomarkers 93.242 RFMH 26230 1R01MH108032-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CUMC 213052-1 1R01MH110270-01A1 WEILL (JOAN AND SANFORD I.) Improving Cognition via Exercise in Schizophrenia 93.242 MSSM 0255-3351-4609 1R01MH110623-01A1 CAHN SCHOOL OF MEDICINE AT MOUNT SINAL Identifying Reproducible Brain Signatures of Obsessive Compulsive Profiles 93.242 RFMH 26719 1R01MH113250-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC 90 \$34.03 854.03 854.03 855.45 856.10 80 \$34.03 856.10 80 \$34.03 856.10 80 \$34.03 856.10 80 \$34.03 80 \$36.10 80 \$36.10 80 \$36.10 80 \$36.25 8	Comprehensive CBT via reSET for a Hub and Spoke MAT System of Care	93.213	PSU COLAT010118	1R21AT010118-01	PENNSYLVANIA STATE UNIVERSITY	ý \$0	\$67,664
Neural dynamics underlying rule based decision-making 93.242 SRFMH 145453 1K08MH120434-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC \$0 \$86,10 MENTAL HYGIENEINC \$0 \$84,03 MENTAL HYGIENEINC \$0 \$34,03 MENTAL HYGIENEINC \$0 \$32,95 MENTAL HYGIENEINC \$0 \$32,95 MENTAL HYGIENEINC \$0 \$32,95 MENTAL HYGIENEINC \$0 \$33,25					<u>-</u>	\$0	\$346,620
Hospital Discharge Planning and Transition to Outpatient Psychiatric Care 93.242 RFMH 26439 1R01MH108558-01A1 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC 2/2 Familial Early-Onset Suicide Attempt Biomarkers 93.242 RFMH 26230 1R01MH108032-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CUMC 213052-1 1R01MH110270-01A1 WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL INNIVERSITY Improving Cognition via Exercise in Schizophrenia 93.242 MSSM 0255-3351-4609 1R01MH110623-01A1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Identifying Reproducible Brain Signatures of Obsessive Compulsive Profiles 93.242 RFMH 26719 1R01MH113250-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC 80 \$34,03 \$40 \$22,95 MENTAL HYGIENEINC							
MENTAL HYGIENEINC 2/2 Familial Early-Onset Suicide Attempt Biomarkers 93.242 RFMH 26230 1R01MH108032-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CUMC 213052-1 1R01MH110270-01A1 WEILL (JOAN AND SANFORD I.) \$0 \$63,25 MEDICAL COLLEGE OF CORNELL INMIX/ERCHTY Improving Cognition via Exercise in Schizophrenia 93.242 MSSM 0255-3351-4609 1R01MH110623-01A1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAL MOUNT SINAL MOUNT SINAL MEDICAL COLLEGE OF CORNELL INMIX/ERCHTY Identifying Reproducible Brain Signatures of Obsessive Compulsive Profiles 93.242 RFMH 26719 1R01MH113250-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	Neural dynamics underlying rule based decision-making	93.242	SRFMH 145453	1K08MH120434-01		\$0	\$86,106
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia 93.242 CUMC 213052-1 1R01MH110270-01A1 WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL ILINIM/AEPCRITY ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Identifying Reproducible Brain Signatures of Obsessive Compulsive Profiles 93.242 RFMH 26719 1R01MH113250-01 RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	Hospital Discharge Planning and Transition to Outpatient Psychiatric Care	93.242	RFMH 26439	1R01MH106558-01A1		\$0	\$34,034
MEDICÂL COLLEGE OF CORNÉLL ININIVERSITY IMProving Cognition via Exercise in Schizophrenia 93.242 MSSM 0255-3351-4609 1R01MH110623-01A1 ICAHN SCHOOL OF MEDICINE AT \$0 \$89,73 MOUNT SINAI Identifying Reproducible Brain Signatures of Obsessive Compulsive Profiles 93.242 RFMH 26719 1R01MH113250-01 RESEARCH FOUNDATION FOR \$0 \$76,82 MENTAL HYGIENEINC	2/2 Familial Early-Onset Suicide Attempt Biomarkers	93.242	RFMH 26230	1R01MH108032-01		\$0	\$22,95
Improving Cognition via Exercise in Schizophrenia 93.242 MSSM 0255-3351-4609 1R01MH110623-01A1 ICAHN SCHOOL OF MEDICINE AT \$0 \$89,73 MOUNT SINAI Identifying Reproducible Brain Signatures of Obsessive Compulsive Profiles 93.242 RFMH 26719 1R01MH113250-01 RESEARCH FOUNDATION FOR \$0 \$76,82 MENTAL HYGIENEINC	Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia	93.242	CUMC 213052-1	1R01MH110270-01A1	MEDICAL COLLEGE OF CORNELL	\$0	\$63,25
MENTAL HYGIENEINC	Improving Cognition via Exercise in Schizophrenia	93.242	MSSM 0255-3351-4609	1R01MH110623-01A1	ICAHN SCHOOL OF MEDICINE AT	\$0	\$89,732
An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression 93.242 UMINN N006073701 1R01MH113748-01 UNIVERSITY OF MINNESOTA \$0 \$40,22	ldentifying Reproducible Brain Signatures of Obsessive Compulsive Profiles	93.242	RFMH 26719	1R01MH113250-01		\$0	\$76,825
	An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression	93.242	UMINN N006073701	1R01MH113748-01	UNIVERSITY OF MINNESOTA	\$0	\$40,227

Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) 93.242 RFMH 26737 The Neurobiology of Violence in a Psychosis-Risk Cohort 1R01MH113861-01 RESEARCH FOUNDATION FOR \$0 \$244.876 MENTAL HYGIENEINC 2/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in 93.242 RFMH 26754 1R01MH114980-01 RESEARCH FOUNDATION FOR \$0 \$1.073 patients with treatment resistant late-life depression. MENTAL HYGIENEINC Deconstructing the cellular control of hippocampal functions related to mental health: a role for 93.242 RFMH 27114 1R01MH115215-01 RESEARCH FOUNDATION FOR \$156,334 MENTAL HYGIENEINC BCM 7000000715 1R01MH115793-01A1 BAYLOR COLLEGE OF MEDICINE--\$45.833 VITAL Start (Video-intervention to Inspire Treatment Adherence for Life): Brief facility based video 93 242 \$0 intervention to improve retention and adherence to ART among pregnant and breastfeeding HOUSTON Targeting cotransmission for circuit-specific pharmacotherapy 93.242 RFMH 27032 1R01MH117128-01 RESEARCH FOUNDATION FOR \$0 \$98,294 MENTAL HYGIENEINC RESEARCH FOUNDATION FOR Individualized Risk Prediction in Persons at Clinical High Risk for Psychosis Using 93.242 RFMH 27054 1R01MH117323-01 \$0 \$63,347 MENTAL HYGIENEINC Uncovering the Risk Architecture of Suicidal Behaviors: a Representative Sample at High Risk 93.242 RFMH 27322 1R01MH117360-01 RESEARCH FOUNDATION FOR \$117,660 \$0 MENTAL HYGIENEINC Inflammatory Biomarkers and Kynurenine Metabolites Tracking Suicidal Ideation and Behavior 93.242 VAI V3362-R1-2 1R01MH118211-01A1 VAN ANDEL INSTITUTE \$0 \$67,152 RFMH 141316 1R01MH118247-01 RESEARCH FOUNDATION FOR \$49,689 Maternal exposure to antidepressants and psychiatric outcomes among offspring in a national birth 93.242 \$0 MENTAL HYGIENEINC RESEARCH FOUNDATION FOR 1/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial 93.242 RFMH 27890 1R01MH120317-01 \$0 \$187,954 MENTAL HYGIENEINC OnTrackNY s Learning Healthcare System 93.242 **RFMH 27327** 1R01MH120597-01 RESEARCH FOUNDATION FOR \$0 \$95,037 MENTAL HYGIENEINC RESEARCH FOUNDATION FOR \$58,331 Maternal adversity, inflammation, and neurodevelopment: How intergenerational processes 93.242 RFMH 27494 1R01MH121070-01 \$0 perpetuate disadvantage in a low-resource setting MENTAL HYGIENEINC TEACHERS COLLEGE COLUMBIA Origins and developmental sequelae of neurophysiological variability in infants at high risk for 93.242 TC 512160-01 1R01MH121605-01 \$0 \$3,558 UNIVERSITY RESEARCH FOUNDATION FOR Behavioral and Neural Correlates of Deficits in Naturalistic Visual and Auditory Social Cognition in 93.242 RFMH 27622 1R01MH121790-01 \$0 \$104,817 Individuals at Clinical High-Risk for Schizophrenia MENTAL HYGIENEINC 1/4 Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and RFMH 27354 1R01MH121921-01 \$79.337 93.242 RESEARCH FOUNDATION FOR \$0 outcomes analysis in psychiatric disorders MENTAL HYGIENEINC Testing the effectiveness of an evidence-based transdiagnostic cognitive behavioral therapy 93 242 BU 4500003536 1R01MH121998-01 **BOSTON UNIVERSITY** \$13,902 approach for improving HIV treatment outcomes among violence-affected and virally 1R01MH122851-01 Validation of Pragmatic Implementation Measure for Task Sharing in Mental Health Services 93.242 NYU F1415-01 NEW YORK UNIVERSITY \$18,666 Glutamatergic Mechanisms of Psychosis and Target Engagement **RFMH 27637** 1R01MH123142-01 RESEARCH FOUNDATION FOR 93.242 \$0 \$112,347 MENTAL HYGIENEINC Adolescence, Motivation and the Maturation of the Prefrontal Cortex 93 242 RFMH 27501 1R01MH123153-01 RESEARCH FOUNDATION FOR \$110.557 \$0 MENTAL HYGIENEINC Synthesizing Best Practice to Accelerate Access to Emerging HIV Prevention Modalities 93.242 RFCUNY CM00004822-02 1R01MH123262-01 RESEARCH FOUNDATION OF CITY \$0 \$201,892 UNIVERSITY OF NEW YORK 93 242 RFMH 27570 1R01MH123639-01 RESEARCH FOUNDATION FOR \$58,384 Neural substrates of deficits in naturalistic social cognition in schizophrenia \$0 MENTAL HYGIENEINC 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) 93.242 RFMH 27618 1R01MH123660-01 RESEARCH FOUNDATION FOR \$25,826 MENTAL HYGIENEINC 93.242 RFMH 27617 1R01MH124106-01 RESEARCH FOUNDATION FOR \$74,893 A Data Science Framework for Empirically Evaluating and Deriving Reproducible and \$0 Transferrable RDoC Constructs in Youth MENTAL HYGIENEINC Co-Regulation of Striatal Dopamine and Acetylcholine During Flexible Learning 93.242 RFMH 27918 1R01MH124858-01 RESEARCH FOUNDATION FOR \$0 \$74,498 MENTAL HYGIENEINC

Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) 93.242 RFMH 27860 VTA-NAc GABAergic communication underlying stress-induced reward deficits 1R01MH124998-01A1 RESEARCH FOUNDATION FOR \$0 \$12.699 MENTAL HYGIENEINC Application of Advanced Quantitative Methods to Schizophrenia Research 93.242 **RFMH 27727** 1R01MH125030-01 RESEARCH FOUNDATION FOR \$0 \$85.792 MENTAL HYGIENEINC IM ketamine for rapid reduction of suicidal thoughts in high-risk ED patients: a 93.242 RFMH 27640 1R01MH125155-01 RESEARCH FOUNDATION FOR \$111,733 midazolam-controlled trial MENTAL HYGIENEINC RFMH 27815 1R01MH126181-01 RESEARCH FOUNDATION FOR \$107.519 Testing a Diathesis-Stress Model of Adolescent Suicide: Dopaminergic, Social, and Inhibitory 93 242 \$0 MENTAL HYGIENEINC Development and clinical interpretation of machine learning emergency department suicide 93.242 **UPENN 583167** 1R01MH126895-01 UNIVERSITY OF PENNSYLVANIA \$0 \$11,590 prediction algorithms using electronic health records and claims data Longitudinal trajectories in treated and untreated schizophrenia 93.242 NYU F1967-01 1R01MH127631-01 **NEW YORK UNIVERSITY** \$0 \$26,299 CRCNS Research Proposal Collaborative Research: Multiple Time Scale Memory Consolidation in 93.242 NYU F1940-01 1R01MH129031-01 **NEW YORK UNIVERSITY** \$0 \$54,806 Neural Networks 93.242 500667-78050 1R21MH120534-01 NORTHEASTERN UNIVERSITY \$0 \$31,048 Nonparametric depth-based methods for analyzing high dimensional data. Applications to An adolescent sensitive period for thalamo-prefrontal circuit maturation 93.242 RFMH 27400 1R21MH121334-01 RESEARCH FOUNDATION FOR \$-1,088 \$0 MENTAL HYGIENEINC RESEARCH FOUNDATION FOR \$26,940 Identifying Positive Valence System Neural Deficits in Adolescent Depression 93.242 RFMH 27856 1R21MH125044-01A1 \$0 MENTAL HYGIENEINC Development of dopamine D2 receptor-targeted DARTs 93.242 RFMH 27807 1R21MH126499-01 RESEARCH FOUNDATION FOR \$0 \$38,526 MENTAL HYGIENEINC RESEARCH FOUNDATION FOR \$4,366 Research Education in Child Psychiatry Residency 93.242 RFMH 27834 1R25MH125775-01 \$0 MENTAL HYGIENEINC UMICHG SUBK00016843 UNIVERSITY OF MICHIGAN Neurally targeted group intervention to reduce early childhood anxiety 93.242 1R33MH121641-01A1 \$0 \$16,417 Optimizing Relapse Prevention and Changing Habits (REACH+) in Anorexia Nervosa RESEARCH FOUNDATION FOR 93.242 RFMH 27905 1R34M127180-01 \$0 \$60,835 MENTAL HYGIENEINC RFMH 27104 1R34MH118318-01 \$88.095 93.242 RESEARCH FOUNDATION FOR \$0 Does the Addition of Cognitive Remediation to Coordinated Specialty Care Services Improve MENTAL HYGIENEINC Engaging Black Youth in Depression and Suicide Prevention Treatment with Urban Schools: A 93 242 NYU F1106-01 1R34MH119290-01 NEW YORK UNIVERSITY \$23,462 Preliminary Study 93.242 CCNY 00003796-00 1R34MH121295-01 City College of New York \$0 \$-4 Optimizing Study Design to Test a Community-level Intervention to Reduce Intersectional Stigma and Increase HIV Testing and Prevention among African-American/Black MSM 1R41MH118126-01A1 CENTER FOR TELEPSYCHOLOGY Web-Based Therapist Training on Complicated Grief Therapy 93.242 CFT 001 \$100 \$43,103 Sensitrak: Automated assessment of forelimb sensation 93 242 R41NS120748-P1SUB1 1R41NS120748-01A1 **VULINTUS INC** \$146.356 \$0 NNCI Synapse: Development of a mobile application to disseminate neuroscience training to 93.242 CFSI CU17-1085 1R44MH11546-01 The Center for Social Innovation \$0 \$16,392 medical professionals Virtual Neuro-navigation System for Personalized, Community-Based TMS 93 242 SOTERIX SMICU0901 1R44MH126833-01A1 SOTERIX MEDICAL INC \$0 \$56,144 Imaging the Neurodevelopmental Trajectory of Depression and Anxiety with HCP Protocols 93.242 MGH 235921 1R56MH121426-01 MASSACHUSETTS GENERAL \$0 \$359 HOSPITAL D-serine augmentation of neuroplasticity-based auditory learning in schizophrenia 93.242 RFMH 27132 1R60MH116093 RESEARCH FOUNDATION FOR \$15,755 \$0 MENTAL HYGIENEINC Use of Advanced Analytics to Understand Brain-Behavior Screen Media Activity Relationship in 93.242 YU CON-80003352 1RF1MH128614-01 YALE UNIVERSITY \$57,288 ARCD Da (RF1MH128614-0

						Rab cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia	93.242	YU GR110672(CON 80002564)	1U01MH121766-01	YALE UNIVERSITY	\$0	\$41,728
HIV Center for Clinical and Behavioral Studies	93.242	SRFMH 151533	2P30MH043520-30	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$258,998
Antecedents of Suicidal Behavior Related Neurobiology	93.242	RFMH 27823	2P50MH090964-05	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$601,556
Early Cortical Processing in Schizophrenia	93.242	RFMH 27066	2R01MH049334-27A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$112,411
Structure and Function of Dopamine Receptors	93.242	RFMH 27888	2R01MH054137-23A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$147,132
Pathways to successful aging among perinatally HIV-infected and exposed young adults. Risk resilience, and the role of HIV (CASAH4)	93.242	RFMH 142647	2R01MH069133-16	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$88,569
Biotyping Placebo and Treatment-Specific Responses for Precision Medicine	93.242	17-A0-00-007642-01	2R01MH099003-06	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$78,094
Optimizing and Personalizing Interventions for Schizophrenia Across the Lifespan (OPAL)	93.242	RFMH 27097	3P50MH115843-02S2	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$16,227
EEG/MRI Controlled TMS Real-Time Neural Feedback in Anti-Depressive Treatment	93.242	MUSC A00-1979-S001	4R33MH106775-04	MEDICAL UNIVERSITY OF SOUTH CAROLINA	\$0	\$72,374
Targeting Dopaminergic Mechanisms of Slowing to ImproveLate Life Depression (R33 Phase)	93.242	SRFMH 27103	4R33MH110029-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$26,089
Gaze-contingent music reward therapy for social anxiety	93.242	RFMH 27820	4R33MH116089-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$20,902
D-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia	93.242	RFMH 27974	4R33MH116093-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$56,478
Neural mechanisms for the genesis of conceptual information	93.242	SRFMH 144711	5K08MH115365-02	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$9,130
Neural and Behavioral Mechanisms of Abstraction in Humans	93.242	SRFMH 146785	5K08MH121775-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$50,044
HIV Center for Clinical and Behavioral Studies	93.242	RFMH 28034	5P30MH043520-31	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$75,216
Antecedents of Suicidal Behavior Related Neurobiology	93.242	RFMH 153426	5P50MH090964-09	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$119,395
Optimizing and Personalizing Interventions for Schizophrenia Across the Lifespan (OPAL)	93.242	RFMH 27699	5P50MH115843-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$284,918
Intervening Early with Neglected Children: Key Behavioral and Neurobiological Outcomes in Adolescence	93.242	UDELAWARE 55078	5R01MH074374-12	UNIVERSITY OF DELAWARE	\$0	\$34,493
Functionally selective D2R s, striatal circuit function and motivation	93.242	RFMH 26444	5R01MH093672-08	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$136,322
Improving the Emergency Department Management of Deliberate Self-Harm	93.242	UPENN 568947/10052478/19439	5R01MH107452-05	UNIVERSITY OF PENNSYLVANIA	\$0	\$36,069
Longitudinal Assessment of Neural Circuits in Adolescents with Anorexia Nervosa	93.242	RFMH 26643	5R01MH110445-04	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$68,593
Cognitive ans Neural Mechanisms of the Accelerated Aging Phenotype in PTSD	93.242	RFMH 26738	5R01MH111596-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$92,954
Functional Brain Networks Mediating Individuals Differences in Valence Bias	93.242	UNL 24-1219-0001-002	5R01MH111640-03	UNIVERSITY OF NEBRASKA- LINCO	OLN \$0	\$12,937
Hippocampal memory circuits in delusions	93.242	NYU 17-A1-00-006880-01	5R01MH112733-05	NEW YORK UNIVERSITY	\$0	\$175,211

Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) 93.242 RFMH 27033 Deficient Belief Updating as a Convergent Computational Mechanism of Psychosis 5R01MH114965-02 RESEARCH FOUNDATION FOR \$0 \$70.314 MENTAL HYGIENEINC Evaluating Implementation Strategies to Scale-up Transdiagnostic Evidence-based Mental Health 93.242 CIDRZ M101S14F04 5R01MH115495-03 Centre for Infectious Diseases Researchin \$0 \$15.854 Care in Zambia (Mental Health- CBT) Effect of GABAergic Inhibition of Dendritic Spines on Synaptic Pruning in mPFC During 93.242 SUNYRF 100-1151016-83329 5R01MH115900-04 RESEARCH FOUNDATION OF THE \$323,683 STATE UNIVERSITY OF NEW YORK BIOPSYCHOSOCIAL MECHANISMS UNDERLYING INTERNALIZING PSYCHOPATHOLOGY IN CON-80002951 (GR112516) 5R01MH118245-03 YALE UNIVERSITY \$24.808 93 242 \$0 A PROSPECTIVE, POPULATION-BASED COHORT OF SEXUAL MINORITY YOUNG ADULTS Social Processing Deficits in Remitted Adolescent Depression 93.242 RFMH 27394 5R01MH119771-02 RESEARCH FOUNDATION FOR \$0 \$21,081 MENTAL HYGIENEINC NEW YORK UNIVERSITY Interactive development of reinforcement learning and adaptive memory 93.242 NYU F1758-01 5R01MH126183-02 \$0 \$8,538 OnTrackChile for First Episode Psychosis 93.242 UOH CU17-1224 5R01MH15502-02 UNIVERSIDAD DE O'HIGGINS \$0 \$288,397 Clearscope 93.242 MBF SUBR44MH116827-04 5R44MH116827-04 MBF BIOSCIENCE \$0 \$181,965 93.242 BNLS CU17-2671 5R44MH117430-03 **Boulder Nonlinear Systems** \$0 \$335,779 Large-Aperture Electrically Tunable Lenses with 40 Microsecond Hysteresis-Free Response for Remote Focusing UNIVERSITY OF CALIFORNIA, UCB 00010181 5RF1MH120680-02 High-throughput Physiological Micro-connectivity Mapping in Vivo 93.242 \$0 \$113,628 **BERKELEY** Genetic neuroscience: How human genes and alleles shape neuronal phenotypes 93.242 BRINST 5U01MH115727-04 **BROAD INSTITUTE** \$0 \$12,683 5100482-5500001084 OREGON 281450B UNIVERSITY OF OREGON \$33,246 Mobile Assessment for the Prediction of Suicide (MAPS) 93.242 5U01MH1163923-02 \$0 RESEARCH FOUNDATION FOR PRIDE SSA - Partnerships in Research to Implement and Disseminate Sustainable and Scalable 93.242 **RFMH 27757** 5U19MH113203-02 \$0 \$20,405 Evidence Based Practices in sub-Saharan Africa MENTAL HYGIENEINC 7R01MH108385-03 **NEW YORK UNIVERSITY** Characterizing Cognition Acrioss the Lifespan in Untreated Psychosis in China 93.242 NYU F8752-04 \$0 93.242 RFMH 26985 7R01MH109289-04 \$35.112 Temporal Dynamics of Neurophysiological Patterns as Treatment Targets in SZ RESEARCH FOUNDATION FOR \$0 MENTAL HYGIENEINC HARVARD 136051-5117272 Structural Stigma and HIV Prevention Outcomes 93 242 7R01MH112384-05 HARVARD UNIVERSITY \$21,288 Investigating quantitative signatures of autism in toddlers QCCUNY CM00007612-00 93.242 7R01MH121605-03 RESEARCH FOUNDATION OF CITY \$0 \$36,407 UNIVERSITY OF NEW YORK WAHU WU-21-182 7RF1MH120034-02 WASHINGTON UNIVERSITY Generating a formal set of collaborative standards for sharing behavioral data and task designs to 93.242 \$0 \$87,599 enable reproducibility in neuroscience 1/2 Task control circuit targets for obsessive compulsive behaviors in children 93.242 RFMH 27047 R01MH115024 RESEARCH FOUNDATION FOR \$0 \$61,754 MENTAL HYGIENEINC \$100 \$7,820,203 **Alcohol Research Programs** Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA) 93.273 000530477-SP002-SC001 1P01AA029540-01 UNIVERSITY OF ALABAMA AT \$0 \$8,040 **BIRMINGHAM** A Randomized Trial of Abandoned Housing Remediation, Substance Abuse and Violence UPENN 569453 1R01AA024941-01 UNIVERSITY OF PENNSYLVANIA \$197,523 93.273 \$0 Dose and Pattern of Adverse Effects in the Diagnosis of Fetal Alcohol Spectrum Disorders: A 1R01AA025905-01 WAYNE STATE UNIVERSITY 93.273 WSU18044 \$0 \$18,677 Secondary Analysis of Data from Five Cohorts Community I-STAR Mozambique : Community Implementation of SBIRT using Technology for 1R01AA025947-01 RESEARCH FOUNDATION FOR 93.273 RFMH 27048 \$0 \$3,797 Alcohol use Reduction in Mozambique MENTAL HYGIENEINC

R&D Cluster

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

						K&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	Subrecipients	Total Expenditures (Includes Subrecipients)
Could long-acting medications facilitate $$ ending AIDS by 2030 $$ in southern Africa? An allocative efficiency analysis $$	93.273	NYUMC 19-A1-00-1001516	1R01AA027481-01A1	NEW YORK UNIVERSITY MEDICAL CENTER	\$ 0	\$61,955
Intersectional Approaches to Population-Level Health Research: Role of HIV Risk, Chronic Conditions, and Mental Health Disparities in Diverse Sexual Minority Youth	93.273	60059892 CU	1R01AA029044-01A1	NORTHWESTERN UNIVERSITY	\$0	\$29,229
Cortical Subcortical Reorganization and Risk Behaviors of Early Alcohol Use Initiation	93.273	CON-800003347 (GR114511)	1R01AA029611-01	YALE UNIVERSITY	\$0	\$95,225
Impact of supportive policies on minority stress, drinking and health among women	93.273	UIL 16343	2R01AA013328-10A1	UNIVERSITY OF ILLINOIS, BOARD TRUSTEES	OF \$0	\$323,839
Role of Alcohol Disparities in HIV Risk among Sexual Minority Youth	93.273	NWU 60057464 CU	3R01AA024409-05S1	NORTHWESTERN UNIVERSITY	\$0	\$43,901
				· · · · · · · · · · · · · · · · · · ·	\$0	\$782,186
Drug Abuse and Addiction Research Programs						
Health and justice: a continuum of care for HIV and SU for justice involved youth	93.279	RFMH 130318	1 R01 DA043122-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$82,744
Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin	93.279	RFMH 26741	1R01DA041543-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$165,503
Micro- to Nanoscale Neurotransmitter Sensors	93.279	UCLA 2000GVG295	1R01DA045550-01	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$ \$0	\$211,541
Examining the synergistic effects of cannabis and prescription opioid policies on chronic pain, opioid prescribing, and opioid poisoning	93.279	19-A0-00-1002539	1R01DA045872-01A1	NEW YORK UNIVERSITY	\$0	\$344,161
Sex-dependent effects of cannabis: Assessing abuse-related and pharmacokinetic differences between men and women	93.279	UCLA 2000 G XK823	1R01DA047296-01A1	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$ \$0	\$26,025
Opioid Overdoses Among Medicaid Beneficiaries: Predictors, Outcomes and State Policy Effect	93.279	RUTGER 1284	1R01DA047347-01	RUTGERS, THE STATE UNIVERSIT	TY OF \$0	\$10,142
Neurocognitive mechanisms underlying smartphone-assisted prevention of relapse in opioid use disorder	93.279	UARK 55623	1R01DA048022-01A1	UNIVERSITY OF ARKANSAS	\$0	\$16,031
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024	93.279	1015580/3/27298	1R01DA048860-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$148,091
Leveraging Social Media to Develop The Cannabis Exposure Index (CEI), A standardized Measure of Cannabis Use	93.279	DARTC R1483	1R01DA050032-01A1	DARTMOUTH COLLEGE	\$0	\$56,874
SOAR: Smartphones for Opioid Addiction Recovery	93.279	21-A0-00-1005963	1R01DA054220-01	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$25,374
Social-environmental drivers of stimulant use and its impact on HIV prevention and treatment in Black men who have sex with men	93.279	RFMH 155214	1R21DA053156-01A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$17,654
Peer-based HIV Self-testing among High Risk Women Who Inject or Use Drugs in Kazakhstan, Central Asia	93.279	RFCUNY CM00005426-01	1R34DA049664-01A1	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	Y \$0	\$176,821
On Demand Electrostimulation	93.279	CORIDEA CORCOL-001	1R43DA055401-01	CORIDEA LLC	\$0	\$19,306
Development of Opioid Use Disorder Severity Scale	93.279	YU CON-80002907 (GR115931)	1U01DA051639-01	YALE UNIVERSITY	\$0	\$1,351
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder	93.279	RFMH 27585	1U01DA146430-01A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$78,211
METHODOLOGY AND ADVANCED ANALYTICS RESOURCE CENTER (MAARC)	93.279	UofC AWD100228	1U2CDA050098-01	UNIVERSITY OF CHICAGO	\$0	\$30,714
Facilitating Opioid Care Connections: System level strategies to improve use of MAT and movement through the opioid care cascade for defendants in a new Opioid Court system	93.279	RFMH 27305	1UG1DA050071-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$137,264
Vaccines for Fentanyl and Its Derivatives: A Strategy to Reduce Illicit Use and Overdose	93.279	UMINN N007622802	1UG3DA048386-01	UNIVERSITY OF MINNESOTA	\$0	\$55,094

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	R&D Cluster Total Expenditures
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?	Listing No. 93.279	Identfication No UPENN 578203	1UG3DA049694-01	UNIVERSITY OF PENNSYLVANIA	\$0	(Includes Subrecipients \$1,804
Monitoring the Future: Drug Use and Lifestyles of American Youth	93.279	UMICHG 3004489406	2R01DA001411-43	UNIVERSITY OF MICHIGAN	\$0	\$76,259
Translational Research Training on Addictions for Racial/Ethnic Minorities	93.279	RFCUNY CM0004811-00	2R25DA035161-06	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$13,550
NIDA Clilincal Trials Network: Greater New York Node	93.279	NYU 20-00-00-003671	2UG1DA013035-19	NEW YORK UNIVERSITY	\$0	\$110,239
Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network	93.279	UMIAMI OS00000236	2UG1DA013720-21	UNIVERSITY OF MIAMI	\$0	\$289,367
The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes	93.279	AMH R34DA050288-A	3R34DA050288-01S1	AVERA MCKENNAN HOSP & UNIV HEALTH CTR	\$0	\$81,71
NIDA Clinical Trials Network: New York Node (CTN-0100)	93.279	NYU 22-A0-S3-003671 /117236	3UG1DA013035-20S2	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$39,304
Clinical Trials Network: Greater New York Node CTN-0094: Data	93.279	NYU 21-A0-S3-003671/117434	3UG1DA013035-20S4	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$311,610
CTN-0121: Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders among Hospitalized Patients	93.279	UMIAMI OS00000846	3UG1DA013720-22S3	UNIVERSITY OF MIAMI	\$0	\$116,982
Clinical Trials Network: New England Node: CTN0099 ED-INNOVATION	93.279	YU GR109716	3UG1DA015831-19S1	YALE UNIVERSITY	\$0	\$249,426
Pharmacological Probes Based on Mitragynine Pseudoindoxyl	93.279	SLCP 807-1-01	4R33DA045884-03	UNIVERSITY OF HEALTH SCIENCE AND PHARMACY IN ST. LOUIS	S \$0	\$117,004
Evaluation of Safety and Pharmacokinetics of Naltrexone Implant	93.279	RFMH CU20-4657	4UH3DA047720-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$83,950
Ending HIV/AIDS Among People Who Use Drugs: Overcoming Challenges	93.279	NYU F1658-S018	5P30DA011041-24	NEW YORK UNIVERSITY	\$0	\$35,39
Cannabis Relapse: Influence of Tobacco Cessation	93.279	RFMH 27059	5R01DA031005-07	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$71,142
HIV/Drug Abuse Prevention Research Ethics Training Institute	93.279	FORDUN FORD0048	5R25DA031608-09	FORDHAM UNIVERSITY	\$0	\$812
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine	93.279	RFMH 27040	5UG3DA047711-02	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$282,440
Missing Data Matters: Substance Use Disorder Clinical Trials	93.279	UUTAH 10058454-01	7R01DA046534-04	UNIVERSITY OF UTAH	\$0	\$2,63
Evaluation of safety and pharmacokinetics of naltrexone implant	93.279	RFMH 27797	UH3DA047720-03	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$132,516
Discours and Applied December for Technological Inscriptions to Insuran Health				<u>-</u>	\$0	\$3,619,051
Discovery and Applied Research for Technological Innovations to Improve Human Health Noninvasive Quantification of Brain Glucose Metabolism Using a Portable Positron Emission Tomography Camera.	93.286	RFMH 27000	1R01EB026481-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$75,992
Causal Inference for Neuroimaging	93.286	JH 2003851642	5R01EB016061-08	JOHNS HOPKINS UNIVERSITY	\$0	\$68,673
Tools for modeling state-dependent sensory encoding by neural populations across spatial and temporal scales	93.286	ORHSUN 1014876 COLUMBIA	5R01EB028155-02	OREGON HEALTH SCIENCES UNIVERSITY	\$0	\$144,748
FEBio Software Suite	93.286	UUTAH 10052732-COL	5U24EB029007-03	UNIVERSITY OF UTAH	\$0	\$33,498
Imaging Human brain Function with Minimal Mobility Restrictions	93.286	UMINN N006264801	U01EB025153	UNIVERSITY OF MINNESOTA	\$0	\$377,692

ECHO Coordinating Center

Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	Total Expenditures (Includes Subrecipients
				_	\$0	\$700,603
Minority Health and Health Disparities Research						
Peer-Administered Asthma Self-Management Intervention in Urban Middle Schools	93.307	RIH 710-7137328	1R01MD012225-01	RHODE ISLAND HOSPITAL	\$0	\$28,844
Maternal trauma, circulating microRNA in extracellular vesicles, and programming of childhood respiratory outcomes	93.307	ISMMS 0255-B281-4609	1R01MD013310-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$68,300
Social Stress Epigenetics and Cardio-Metabolic Health Among Latinos	93.307	EMORYU A193700	1R01MD013320-01A1	EMORY UNIVERSITY	\$0	\$125,970
Identifying and exploring solutions to the ethical challenges of Apol1 testing of donors with recent African ancestry through mixed methods research with stakeholders	93.307	WU-20-108-MOD-2	1R01MD014161-01	WASHINGTON UNIVERSITY	\$0	\$44,920
Social Stress, Epigenetics and Cardiometabolic Health Among Youth	93.307	EMORYU A556942	1R01MD015204-01A1	EMORY UNIVERSITY	\$0	\$17,519
Racial Disparity in Diagnostic Evaluation of Uterine Cancer	93.307	YU CON-80003273 (GR113900)	1R01MD016386-01	YALE UNIVERSITY	\$0	\$128,994
Support via Online Social Networks to promote Safe Infant Care practices Toward Reducing Racial Disparities in Infant Mortality (SUPER SONIC)	93.307	UV GB10972.169699	5R01MD007702-07	UNIVERSITY OF VIRGINIA	\$0	\$34,666
Data Driven Methods for Missing Data Imputation in Surgical Disparities Research	93.307	GWU 19-M111	5R01MD013901-03	GEORGE WASHINGTON UNIVERSIT	Y \$0	\$10,83
Trans-NIH Research Support				<u>.</u>	\$0	\$460,053
A randomized controlled trial of concentrated investment in Black neighborhoods to address structural racism as a fundamental cause of poor health	93.310	UPenn 583513	1U01OD033246-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$48,326
CHEAR Center for Data Science	93.310	0255-0225-4609	1U2CES026555-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$-
Environmental Influences on Child Health Outcomes (ECHO) Coordinating Center	93.310	DUKEU A03-5218	1U2COD023375-01	DUKE UNIVERSITY	\$0	\$28,924
Data and Research Support Center	93.310	VUMC59350	1U2COD23196-01	VANDERBILT UNIVERSITY MEDICAL CENTER	\$0	\$2,076,900
Children s Respiratory Research and Environment Workgroup (CREW)	93.310	UWM 800K450	1UG3OD023282-01	UNIVERSITY OF WISCONSIN MADIS	ON \$0	\$18,69
Exposome Contributors to Child Health Originating from National Fetal Growth Study (ECCHO-NFGS)	93.310	A00-2818-S001	1UG3OD023316-01	MEDICAL UNIVERSITY OF SOUTH CAROLINA	\$0	\$191,983
Breaking The Cycle Of Intergenerational Disadvantage: Neurodevelopment Among Puerto Rican Children	93.310	RFMH 150349	1UG3OD023328-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$232,084
ECHO Consortium on Perinatal Programming of Neurodevelopment	93.310	ISMMS 0255-2299-4609	1UG3OD023337-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$126,114
An integrated and diverse genomic medicine program for undiagnoseddiseases	93.310	DUKEU A033653	2U01HG007672-05	DUKE UNIVERSITY MEDICAL CENT	ER \$0	\$177,37
Quasi-mechanistic modeling of cell line drug response using neural networks as time evolution operators	93.310	1090580-437271	3OT2OD026675-01S3	CARNEGIE MELLON UNIVERSITY	\$0	\$12,41
Environmental Influences on Child Health Outcomes in the Northern Plains Safe Passage Study Cohort	93.310	AMH 5UH3OD023279-B4	4UH3OD023279	AVERA MCKENNAN HOSP & UNIV HEALTH CTR	\$0	\$443,666
Environmental Influences on Child Health Outcomes in the Northern Plains Safe Passage Study Cohort	93.310	AVERA 5UH3OD023279-A3	4UH3OD023279-04	AVERA MCKENNAN HOSP & UNIV HEALTH CTR	\$0	\$385,399
Mega-Scale Identification Tools for Xenobiotic Metabolism	93.310	EMORYU A522325	5U2CES030163-02	EMORY UNIVERSITY	\$0	\$29,502

The accompanying footnotes are an integral part of the Schedule of Expenditures of Federal Awards

DUKEU 2037934

5U2COD023375-04

DUKE UNIVERSITY

93.310

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name Sub	recipients	Total Expenditures
Children s Respiratory Research and Environment Workgroup (CREW)	<u>Listing No.</u> 93.310	Identfication No UWM 000001626	5UH3OD023282-04	UNIVERSITY OF WISCONSIN MADISON	\$0	(Includes Subrecipients \$668,090
National Center for Advancing Translational Sciences					\$0	\$4,499,291
Gut Microbiota in the Modulation of Outcomes after Liver Transplant	93.350	VCU FP00011749 SA001	1R21TR003095-01A1	VIRGINIA COMMONWEALTH UNIVERSITY	\$0	\$46,73
Open Health Natural Language Processing Collaboratory	93.350	MAORO COL-231278/65497608	1U01TR002062-01	Mayo Clinic Rochester	\$0	\$241,514
Coordinated medical treatment of opioid use disorder and infectious disease	93.350	YU GR109957 (CON-80002430)	1U01TR002763-01	YALE UNIVERSITY	\$0	\$46,30
Improving Clinical Trial Enrollment and Recruitment Education at CTSA hubs (I-CERCH)	93.350	VUMC 59243	1U24TR001579-01	VANDERBILT UNIVERSITY MEDICAL CENTER	\$0	\$19,466
Safety and Efficacy of Itacitinib in treatment of JAK/STAT gain of function disorders	93.350	BCMH 7000001566	1UG3TR003908-01	BAYLOR COLLEGE OF MEDICINE HOUSTON	\$0	\$34,719
CD2H - National COVID Cohort Collaborative (N3C) Supplement	93.350	JHU 1011902-001	3U24TR002306-04S1	JOHNS HOPKINS UNIVERSITY	\$0	\$15,218
University of Pittsburgh Clinical and Translational Science Institute ACT Supplement	93.350	AWD000000243 (134445-1)	3UL1TR001857-01S1	UNIVERSITY OF PITTSBURGH	\$0	\$2,192
Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease	93.350	DUKEU A03-3576	5UH3TR002142-05	DUKE UNIVERSITY	\$0	\$184,157
A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease (UH3 Phase II)	93.350	000518169-SC009	5UH3TR002450-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$79,20
21st Century Cures Act - Beau Biden Cancer Moonshot				<u></u>	\$0	\$669,512
Advancing the Quality of Cancer Care through Behavioral Economics and Implementation Science	93.353	UPENN 580281	1-P50-CA-244690-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$34,039
Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis-Functional Unit 3	93.353	MSKCC C21844671	5U2CCA233284-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$65,110
Nursing Research				<u></u>	\$0	\$99,149
Neighborhoods, networks, and the HIV care continuum among HIV infected MSM in NYC	93.361	NYBC IDP-NIH620	1R01MH118960-01A1	NEW YORK BLOOD CENTER	\$0	\$51,935
Gender Affirmation, Quality of Life, and Access to Care: A Mixed-Method Longitudinal Investigation	93.361	VNSNY 4633 2021 CUSON	1R01NR019315-01A1	VISITING NURSE SERVICE OF NEW YORK	\$0	\$99,580
Improving Ethical Care for Patients who are Incapacitated with No Evident Advance Directives or Surrogates (INEADS)	93.361	ISMMS 0255-E151-4609	1R21NR019319-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$61,982
The role of host-microbial interactions in altering preterm birth risk among black women	93.361	UPENN 579470	2R01NR014784-06	UNIVERSITY OF PENNSYLVANIA	\$0	\$30,65
Cancer Cause and Prevention Research				<u></u>	\$0	\$244,148
Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome	93.393	UTMD 3001244409	1R01CA219896-01A1	UNIVERSITY OF TEXAS M.D. ANDERSON CANCERCENTER	\$0	\$48,515
Improving Delivery of Genetic Services to High Risk Childhood Cancer Survivors: A Randomized Study of Remote Genetic Services Versus Usual Care	93.393	UCHICA AWD101267 (SUB00000376)	1R01CA237369-01A1	UNIVERSITY OF CHICAGO	\$0	\$7,68
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry	93.393	RPCI 394-01	1R01CA247281-01A1	ROSWELL PARK CANCER INSTITUTE	\$0	\$-11

Fordered Country / David Marriagh Country						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name Sub	<u>brecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients
Longitudinal investigation of sociocultural and behavioral influences on symptom management, biological response, and functioning between Chinese and White breast cancer survivors	93.393	GU 7774559	1R01CA248413-01A1	GEORGETOWN UNIVERSITY	\$0	\$20,09
Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention	93.393	FHCRC 0001115022	1R01CA248656-01	FRED HUTCHINSON CANCER CENTER	₹ \$0	\$42,94
The ASPIRES Study: Activating Cancer Survivors and their Primary Care Providers to Increase Colorect	93.393	UofC AWD101813	1R01CA255269-01	UNIVERSITY OF CHICAGO	\$0	\$15,85
Leveraging tumor registries and pathology specimens to facilitate genetic testing and traceback for ovarian cancer	93.393	KFDNI OOS030500-COLU-03	1U01CA244323-01	Kaiser Foundation Research Institute- -Division of Research	\$0	\$89,48
A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors	93.393	DFCI 1315802	1U01CA246648-01A1	DANA-FARBER CANCER INSTITUTE	\$0	\$179,92
Structural Cell Biology of DNA Repair Machines	93.393	LBNL 7341650	2P01CA092584-16	LAWRENCE BERKELEY NATIONAL LABORATORY	\$0	\$22,090
Role of Histone and Histone-like Mutations in the Oncogenesis of Human Cancers	93.393	RFU SUB00000166	2P01CA196539-06	ROCKEFELLER UNIVERSITY	\$0	\$350,090
EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer	93.393	DUKE A033139	5R01CA134722-08	DUKE UNIVERSITY MEDICAL CENTER	\$0	\$14,835
Adoption, Diffusion, And Implementation of Tobacco 21 Policies To Address Health Disparities	93.393	RUTGER 1160319	5R01CA231139-02	RUTGERS, THE STATE UNIVERSITY O NEW JERDEPARTMENT OF	DF \$0	\$46,847
Cell lineage determinants of p53-driven fate outcomes in vivo	93.393	ISMMS 0255-E071-4609	5R01CA257548-02	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$160,090
(PC#9) Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer	93.393	UTMD 3001762327	7R01CA206025-06	UNIVERSITY OF TEXAS M.D. ANDERSON CANCERCENTER	\$0	\$103,404
19-M116 Mechanisms and Genomics of Esophageal Carcinogenes	93.393	19-M116	7R01CA208711-05	GEORGE WASHINGTON UNIVERSITY	\$0	\$5,54
Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial	93.393	HSC 6610100234	R01CA251112-01	HOSPITAL FOR SICK CHILDREN	\$0	\$25,018
MULTI-ANCESTRY MAPPING OF PANCREATIC CANCER SUSCEPTIBILITY LOCI	93.393	JHU CU 21-1997	U01CA247283	JOHNS HOPKINS UNIVERSITY	\$0	\$25,19
Advanced Development and Dissemination of EMERSE for Cancer Phenotyping from Medical Records	93.393	UMICHG 3004700011	U24CA204863	UNIVERSITY OF MICHIGAN	\$0	\$47,66
Cancer Detection and Diagnosis Research				<u></u>	\$0	\$1,205,264
Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response	93.394	100-116346-91776	1R01CA24966701A1	STATE UNIVERSITY OF NEW YORK, DOWNSTATEMEDICAL CENTER	\$0	\$15,522
Genomic biomarkers of splenic lymphoma	93.394	UPENN 581239	1R01CA255655-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$32,769
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection	93.394	DFCI 1283205	1U01CA210171-01	DANA-FARBER CANCER INSTITUTE	\$0	\$60,162
Using Markers to Improve Pancreatic Cancer Screening and surveillance	93.394	JHU 2004290640	5U01CA210170-03	JOHNS HOPKINS UNIVERSITY	\$0	\$950
Computational modeling of tumor burden by CT to advance cancer therapeutics	93.394	INOVA FP-152539-A	R01CA194783	INOVA HEALTH SYSTEM	\$0	\$204,169
Quantitative imaging tools to derive DW-MRI oncological biomarkers	93.394	MSKCC BD522043A	U01CA211205	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$166,536
				<u></u>	\$0	\$480,108
Cancer Treatment Research Using Arginine Metabolic Therapies for Sarcoma	93.395	WUSOM WU-20-149	1R01CA227115-01A1	Washington University School of	\$0	\$10,624
				Medicinein St. Louis		

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
ECOG-ACRIN Integrated Leukemia Translational Research Center	<u>Listing No.</u> 93.395	Identfication No MSKCC BD525251B	1UG1CA233332-01	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	(includes Subrecipients) \$11,558
NIH COG Pediatric Early Phase Clinical Trial Network Grant	93.395	CHOP 9500120719-04C	1UM1CA228823-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$149,500
Discovery of Anticancer Agents from Diverse Natural Origin	93.395	UNCG 20190268.1	2P01CA125066-11A1	UNIVERSITY OF NORTH CAROLI GREENSBORO	NA \$0	\$33,000
A Phase II, Open Label, Multi-Center Study in Adults with Recurrent High Grade Glioma	93.395	ONCI CU19-1093	2R44CA192427-04	ONCOCEUTICS IN	\$0	\$8,160
SWOG Network Group Operations Center of the NCTN	93.395	OHSU 1013080	2U10CA180888-06	OREGON HEALTH SCIENCES UNIVERSITY	\$0	\$156,068
Administrative Supplement for VICKtOrY Early Clinical Trials Consortium	93.395	GR109625 (CON-80002374)	2UM1CA186689-06	YALE UNIVERSITY	\$0	\$40,975
The Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance	93.395	CLEVELCL 1496-SUB	5R35CA232097-03	CLEVELAND CLINIC	\$0	\$-13,658
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma	93.395	WFUHS 441111 CORE 3	P01CA207206	WAKE FOREST UNIVERSITY	\$0	\$366,113
Support, NIH COG Phase 1 Grant	93.395	CHOP CU15-2115	UM1CA097452	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$20,000
					\$0	\$782,340
Cancer Biology Research Targeting metabolic stress to induce pancreatic tumor cell death	93.396	UMICHG SUBK00012257	1R01CA244931-01A1	UNIVERSITY OF MICHIGAN	\$0	\$33,146
Lentiviral-Induced Swine Model of Spinal Cord Glioma	93.396	EMORYU A539786	1R01CA2511393-01A1	EMORY UNIVERSITY	\$0	\$86,668
Image-based models of tumor-immune dynamics in glioblastoma	93.396	MAYO AZ COL-281375/PO #6794679	1U01CA250481-01A1	MAYO CLINICARIZONA	\$0	\$143,483
HIF-1alpha and FBP2 in sarcoma metabolism, progression, and metastasis	93.396	571047	5R01CA158301-10	UNIVERSITY OF PENNSYLVANIA	\$0	\$52,114
Patient-Derived Models of Prostate Cancer for Personalized Medicine	93.396	UTMDA 30001831256	5U01CA224044-03	UNIVERSITY OF TEXAS M.D. ANDERSON CANCERCENTER	\$0	\$82,892
Nuclear Dysfunction in Cancer: The Role of Mechanical Stresses Transmitted by the LINC Complex	93.396	TAMU M2101419	U01CA225566	TEXAS A&M UNIVERSITY	\$0	\$328,808
Cancer Centers Support Grants					\$0	\$727,111
MSK SPORE in Lymphoma-(Project 4: Targeting Acetyltransferase Gene Inactivation in Diffuse Large B Cell Lymphoma)	93.397	MSKCC BD520439D	1P50CA192937-01A1	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$67,472
Towards Understanding Prostate Cancer Heterogeneity - Weill Cornell Medicine (WCM) SPORE in Prostate Cancer (Project 4)	93.397	WCMC 213827	1P50CA211024-01A1	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNEL	\$0 L	\$134,979
MSK SPORE in Genomic Instability in Breast Cancer (DRP PP: Characterizing Oncogenic Pl3K Variant Function and Inhibition Across Cancer)	93.397	BD528257	1P50CA247749-01	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$49,998
Center for Systems-level Study of Metastasis	93.397	RFU SUB00000255	1U54CA261701-01	ROCKEFELLER UNIVERSITY	\$0	\$1,836
Characterizing and overcoming resistance to ERBB2 directed therapy in metastatic gastric and esophageal adenocarcinoma	93.397	DFCI 1220313	5P50CA127003-13	DANA-FARBER CANCER INSTITU	JTE \$0	\$136,799
Single-cell transcriptomic analysis of childhood Burkitt lymphoma	93.397	MSKCC BD527979	5P50CA192937-05	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$21,704
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL	93.397	MSKCC BD528141	5R01CA220568-03	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$10,236

						K&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Systems Pharmacology of Therapeutic and Adverse Responses to Immune Checkpoint and Small Molecule Drugs	93.397	HMS 152308.5115347.0511	5U54CA225088-02	HARVARD MEDICAL SCHOOL	\$0	\$142,715
Cancer Control				······································	\$0	\$565,739
NRG Oncology NCORP Research Base	93.399	NCORP-Kachnic-GY6	2UG1CA189867-06	NRG ONCOLOGY	\$0	\$98,904
NRG Oncology NCORP Research Base	93.399	NCORP-CHIN-GY8	2UG1CA189867-08	NRG ONCOLOGY	\$0	\$18,619
Committee Leadership: COG NCORP Research Base	93.399	CHOP FP00028127 SUB13 01	2UG1CA189955-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$-3
SWOG NCORP Research Base	93.399	ORHSUN 1014562 COLUMBIA	2UG1CA189974-06	OREGON HEALTH SCIENCES UNIVERSITY	\$0	\$357,137
Children s Oncology Group NCORP Research Base - Beauchemin Agreement	93.399	CHOP PO# 20147689	5UG1CA189955-07	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$15,508
Children s Oncology Group NCI Community Oncology Research Program (NCORP)Research Base grant	93.399	PHI AR04853	7UG1CA189955-08	Public Health Institute	\$0	\$17,794
ACL National Institute on Disability, Independent Living, and Rehabilitation Research				_	\$0	\$507,959
Home Evaluation System with a Triangulating Intervention Approach:HESTIA-NextGen	93.433	UWIS 213405490	90DPGE0016-01-00	UNIVERSITY OF WISCONSIN	\$0	\$76,095
				············ <u>·</u>	<u>*************************************</u>	\$76,095
Cardiovascular Diseases Research						
RAGE/DIAPH1 and Myocardial Infarction (Project 1)	93.837	NYUMC 18-A0-00-1001609	1P01HL146367-01	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$10,390
Ambulatory blood pressure and falls in older treated patients with hypertension	93.837	KFDNI#OOS030382-CU	1R01HL136445-01A1	Kaiser Foundation Research Institute- -Division of Research	\$0	\$67,184
Cardiac MR imaging of hemorrhagic reperfusion injury after myocardial infarction	93.837	UPENN 574412	1R01HL137984-01A1	UNIVERSITY OF PENNSYLVANIA	\$0	\$80,000
Evaluating novel approaches forestimating awake and sleep blood pressure	93.837	UAB 000518835-SC001	1R01HL139716-01A1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$288,177
Biomechanical Indicators of Bicuspid Aortic Valve Dysfunction	93.837	UTEXAUS CU17-2783	1R01HL142504-01	UNIVERSITY OF TEXAS AT AUSTIN	\$0	\$86,886
Oxidation-mediated structural degeneration of Bioprosthetic Heart Valves	93.837	CHPHI 3201170622	1R01HL143008-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$316,359
Whole-genome sequencing analysis of coronary atherosclerosis and related traits	93.837	UTEXHOUS SA0000631	1R01HL146860-01A1	UNIVERSITY OF TEXAS HOUSTON HEALTH SCIENCE CENTER	\$0	\$9,673
Deep probabilistic predictive models for stroke and coronary heart disease	93.837	NYU F1182-01	1R01HL148248-01	NEW YORK UNIVERSITY	\$0	\$483,742
Nutritional Omics of Pulmonary Function Decline	93.837	RTI 4-312-0217030-65776L	1R01HL149352-01	RESEARCH TRIANGLE INSTITUTE	\$0	\$25,396
Cardiovascular Health After Placental Abruption (CHAP)	93.837	RTSU 1646	1R01HL150065-01A1	RUTGERS, THE STATE UNIVERSITY NEW JERDEPARTMENT OF	Y OF \$0	\$13,899
A stress-induced promoter pause release program in cardiomyocytes protecting against myocardial infarction	93.837	UCSD 131709481 KR Invoice/PO 7	1R01HL150521	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$49,331
Impact of minority stress on cardiovascular disease risk and resilience	93.837	RFMH 153479	1R01HL151559-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$122,793

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name Su	<u>brecipients</u>	Total Expenditures (Includes Subrecipients
Childhood Mass Trauma Exposure, Inflammatory Programming, and Psychopathology in Young Adulthood	93.837	RFMH 27522	1R01HL152385-01A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$67,97
Influencing Basic Behavioral Mechanisms of Action while targeting Daily Walking in Those at Risk for Cardiovascular Disease: Science of Behavior Change Factorial Experiment of Behavioral	93.837	AWD00001348	1R01HL153810-01A1	FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH	\$0	\$69,59
Generalizable prediction of medication adherence in heart failure	93.837	NYU 20-A0-00-1004676	1R01HL155149-01	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$47,88
Unbiased discovery of dynamic NAV1.5 interact	93.837	WCMC 212305	1R01HL160089-01	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL	\$0	\$183,29
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults	93.837	YU CON-8000354 (GR115524)	1R01HL160822-01	YALE UNIVERSITY	\$0	\$12,87
Eating, Activity, and Weight-Related Problems Across the Life Course in Diverse Populations	93.837	UMINN P006297201	1R35HL139853-01	UNIVERSITY OF MINNESOTA	\$0	\$33,47
Blood Pressure as a Modifiable Risk Factor for Cardiovascular Events in Liver Transplant Recipients	93.837	60060152 COL	1R56HL155093-01	NORTHWESTERN UNIVERSITY	\$0	\$47,91
REPRIEVE A5332 and A5333S	93.837	BWH CU15-0282	1U01HL123336-01	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$58,77
Continuation of the nuMoM2b Heart Health Study	93.837	RTI 2-312-0217457-65971L	1U01HL145358-01A1	RESEARCH TRIANGLE INSTITUTE	\$50,432	\$152,24
Atlanta MACS/WIHS Combined Cohort Study Clinical Research Site	93.837	EMORYU A322408	1U01HL46241-01	EMORY UNIVERSITY	\$0	\$60,00
Milrinone in congenital diaphragmatic hernia trial	93.837	5-312-0216392-66524L	1U24HD095254-01	RESEARCH TRIANGLE INSTITUTE	\$0	\$2,55
Pathways of Tissue Lipid Uptake	93.837	NYUMC 20-A1-00-003442	2R01HL045095-29A1	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$10,04
Structure and function of voltage-gated calcium channels	93.837	UCSF 12002sc	2R01HL080050-14A1	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$166,02
Quantitative Prediction of Disease and Outcomes from Next Generation SPECT and CT	93.837	CSMCLA CU 0001703992	2R01HL089765-10	CEDARS-SINAI MEDICAL CENTER	\$0	\$95,5
Incorporation of a Hypertension Working Group into the Jackson Heart Study	93.837	UAB 000528903-SC003	2R01HL117323-08	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$131,11
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration	93.837	GRT 00001011	2R01HL131872-05	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$383,77
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG	93.837	ISMMS 0255-A344-4605	2U01HL088942-12	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$5,59
Administrative Coordinating Center: Bench to Bassinet Program	93.837	CHMCO 313945	2U01HL131003-06	CHILDREN'S HOSPITAL MEDICAL CENTER - OHIO	\$0	\$20,15
SVRIII: Brain Connectome and Neurodevelopment Outcomes	93.837	UPITT CU19-3219	5R01HL128818-05	UNIVERSITY OF PITTSBURGH	\$0	\$21,82
Deep phenotyping of human knockouts and population studies of the APOC3 Pathway	93.837	UPENN 571188	5R01HL133339-04	UNIVERSITY OF PENNSYLVANIA	\$0	\$81,95
Optically Guided Catheter Ablation of Atrial Fibrillation	93.837	CWRU RES514542	5R01HL149369-03	CASE WESTERN RESERVE UNIVERSITY	\$0	\$170,99
UCSF Research in Implementation Sciences for Equity (RISE 2) - Applying Theory-informed, Mixed Methods to Identify Multi-level Determinants of Cardiac Rehabilitation	93.837	UCSF 13071sc	5R25HL126146-07	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$8,42
Chronic Hypertension and Pregnancy-CHAP Clinical Coordinating Center	93.837	UAB 00503570-002	5U01HL120338-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$30
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events andDecompensated heart failure (INVESTED)	93.837	BWH PHC #114117	5U01HL130163-02	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$23,61

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name Sul	<u>brecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Multicenter Interventional lymphangioleiomyomatosis Early Disease Trial	93.837	UCINCI 010575-008	5U01HL131755-03	UNIVERSITY OF CINCINNATI, COLLEG	SE \$0	\$15,076
RLDC molecular pathway-driven diagnostic and therapeutics for rare lung diseases	93.837	LAMF CU16-0725	5U54HL127672-02	LAM FOUNDATION	\$0	\$12,747
TRANSFORM-HF Study	93.837	YU GR104830	7U01HL125511-02	YALE UNIVERSITY	\$0	\$3,320
Notch in Angiogenesis and Vascular Biology	93.837	UIL 16880-00	R01HL112626	UNIVERSITY OF ILLINOIS, BOARD OF TRUSTEES	\$0	\$19
Population Effects of Motivation Interviewing on Pediatric Obesity inPrimary Care	93.837	AAP 101905-Columbia	R01HL128231-01A1	AMERICAN ACADEMY OF PEDIATRICS	S \$0	\$11,962
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches	93.837	NYU CU13-1776	U01HL105907	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$3,181
Study Chair and Data Core for the COmparison of Methods of Pulmonary blood flow Augmentation in neonates: Shunt versus Stent (The COMPASS Trial)	93.837	NERI CU21-2083	U24HL135691	NEW ENGLAND RESEARCH INSTITUTES	\$0	\$118,965
1/2 A randomized controlled trial of pravastatin to prevent preeclampsia in high-risk women	93.837	OSU 60076777	UH3HL140131	OHIO STATE UNIVERSITY	\$0	\$18,541
				············ <u>···</u>	\$50,432	\$3,593,553
Lung Diseases Research						
Secondhand smoke and asthma: Mechanistic outcomes of DNA methylation in T cells	93.838	SU 60519233-107979	1R01HL118612-01	STANFORD UNIVERSITY	\$0	\$2,790
Frailty and patient centered outcomes in candidates for lung transplantation	93.838	UCSF 10296sc	1R01HL134851-01A1	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$46,201
Sleep and Well-being in High Risk Youth	93.838	RFMH 26555	1R01HL134856-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$26,060
The CAPTURE Study: Validating a Unique COPD Screening Tool inPrimary Care	93.838	WCMC 213441-6	1R01HL136682-01	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL JUNIA/ERSITY	\$0	\$26,496
The Road to Destination Therapy: Optimizing Long-Term Mechanical Cardiopulmonary Support for Pulmonary Hypertension	93.838	VUMC 67475	1R01HL140231-01A1	VANDERBILT UNIVERSITY MEDICAL CENTER	\$0	\$13,310
Understanding the Origins of Early COPD	93.838	WCMC 192243-1	1R01HL144718-01A1	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL	\$0	\$7,875
Impact of Prenatal Vitamin A Deficiency on Cell Fate Alterations in Adult Airway Hyper Responsiveness	93.838	AECM 311707	1R01HL145302-01A1	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$287,365
Detecting pleiotropic effects through integration of omics data	93.838	YALE GR105810 (CON-80001760)	1R01HL145660-01A1	YALE UNIVERSITY	\$0	\$261,797
BEdside Exclusion of Pulmonary Emboli in Children without Exposure to Radiation-BEEPER	93.838	IUSM 8486-CU	1R01HL148247-01A1	INDIANA UNIVERSITY	\$0	\$22,823
ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development)	93.838	UMICHG SUBK00014478	1R01HL153519-01	UNIVERSITY OF MICHIGAN	\$0	\$1,800
Balancing Airway Progenitor versus Progeny: a Pathway from Mitochondria	93.838	UCS KR704693	1R01HL160019-01	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$19,530
Evaluation of the Asthma Management Program to Promote Activity for Students In Schools (AsthmaPASS)	93.838	AECM 311874	1R61HL147908-01A1	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$24,689
ORal Bacterial EXtracts (ORBEX): Primary Prevention of Asthma and Wheezing in Children	93.838	UA 330411	1U01HL130045-01	UNIVERSITY OF ARIZONA	\$0	\$33,101
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progression	93.838	UCSF CU17-3435	1U01HL137880-01	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$225,423
Long Term Follow-up of the Lung Transplant Outcomes Group (LTOG) Cohort	93.838	UPENN 582270	1U01HL145435-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$90,753

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name Subre	ecipients	Total Expenditures
SPIROMICS GIC Support	<u>Listing No.</u> 93.838	Identfication No UNC-CH 5111451	1U24HL141762-01	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	\$0	(Includes Subrecipients) \$4,140
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma	93.838	BWH 118345	1UG1HL139124-01	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$13,007
AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)	93.838	UA 585141	1UG3HL147016-01A1	UNIVERSITY OF ARIZONA	\$0	\$48,577
1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension	93.838	JH 2005385029	1UG3HL151458-01A1	JOHNS HOPKINS UNIVERSITY	\$0	\$59,971
1 of 2) Genetic Epidemiology of COPD	93.838	NJMRCCS 20073011	2U01HL089897	National Jewish Health	\$0	\$172,795
Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating Center	93.838	CLEVELCL 1426-SUB	4U01HL125177-06	CLEVELAND CLINIC	\$0	\$1,696
CT-Based Modeling of Bone Micro Architecture and Fracture-Risk in COPD	93.838	UIO S00925-01	5R01HL142042-02	UNIVERSITY OF IOWA	\$0	\$177,386
Pulmonary Vascular Disease Phenomic Program (PVDOMICS)Data Coordinating	93.838	CLEVELCL 743-SUB	5U01HL125177-03	CLEVELAND CLINIC	\$0	\$280
Data, Modeling, and Coordination Center for PrecISE Network	93.838	UNC-CH 5122707-H3COLUMBIA	5U24HL138998-03	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	\$0	\$16,327
Genetic and developmental mechanisms of congenital diaphragmatic hernia	93.838	UCSD KR 704654	7R01HL146859-03	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$31,136
Bedside Exclusion of Pulmonary Emboli in Children without Exposure to Radiation (BEEPER) Grant Transfer	93.838	WSHU WSU22085	7R01HL148247-03	WAYNE STATE UNIVERSITY	\$0	\$32,165
A Post-Acute Sequelae of SARS CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core	93.838	UCOL FY22.1126.041	OT2HL161847-01	UNIVERSITY OF COLORADO	\$0	\$82,653
RESEARCHING COVID TO ENHANCE RECOVERY (RECOVER) INITIATIVE	93.838	WCMC 220367-1	OTSHL161847-01	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL	\$0	\$209,127
Azheimer s Disease Genetics Consortium	93.838	UPENN 579279	U01AG032984	UNIVERSITY OF PENNSYLVANIA	\$0	\$90,243
Blood Diseases and Resources Research					\$0	\$2,029,516
Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome	93.839	CHOP 3201710624	1R01HL148054-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$5,490
Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic	93.839	CIBMTR CU19-2653	5U24HL138660-03	CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND	\$0	\$486
Transplantation mmunobiology of Transfusion	93.839	UVA GB10756. PO#2218568	7P01HL132819-03	UNIVERSITY OF VIRGINIA	\$0	\$45,056
DISPLACE: Dissemination and Implementation of Stroke Prevention looking at the Care Environment	93.839	UAB 000524452-010	7R01HL133896-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$33,569
FET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis	93.839	UTHSCSA 166754/165804	7R01HL146664-02	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	\$0	\$243,000
Translation and Implementation Science Research for Heart Lung Blood Diseases and Stee	an Disordore			······································	\$0	\$327,601
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Slee Actions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Black	93.840	NYU 20-A1-00-1003342	UG3HL151310	NEW YORK UNIVERSITY	\$0	\$22,991
(<u></u>	<u>*************************************</u>	

Arthritis, Musculoskeletal and Skin Diseases Research

Federal Grantor / Pass-through Grantor	A : - t	A	Dana thannah Cantanat Namahan	Danatharanah Nama		R&D Cluster
rederal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name Sub	recipients	<u>Total Expenditures</u> (Includes Subrecipients)
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis	93.846	RUTGERS 0252	1K23AR070286-02	RUTGERS, THE STATE UNIVERSITY OF NEW JERDEPARTMENT OF	\$0	\$2,297
Multiscale models of fibrous interface mechanics	93.846	WU-21-59	1R01AR077793-01	WASHINGTON UNIVERSITY	\$0	\$123,168
Development and Validation of a Novel and HIV-Relevant Prediction Model for Fracture	93.846	CON-80003104	1R01AR078715-01A1	YALE UNIVERSITY	\$0	\$9,998
Small Molecules to Promote Tendon Regeneration by Specific Targeting of Endogenous Stem Cells	93.846	WNT CU20-3470	1R41AR079360-01	WNT SCIENTIFIC LLC	\$0	\$113,679
Treatments Against RA and Effect on FDG PET/Ct: The Target Trial	93.846	BWH 113296	1U01AR068043-01	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$151,161
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain	93.846	JHU 2004879865	4UH3AR077360-02	JOHNS HOPKINS UNIVERSITY	\$0	\$1,627
Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus	93.846	DUKEU A031921	5R01AR073935-04	DUKE UNIVERSITY	\$0	\$217,083
Diabetes, Digestive, and Kidney Diseases Extramural Research				· · · · · · · · · · · · · · · · · · ·	\$0	\$619,013
Study of coding variants in human obesity and their functional characterization using human iPSC-derived cellular models	93.847	ISMMS 0255-2211-4609	1R01DK110113-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$2,276
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease	93.847	IUSM IN46887773CU	1R01DK110871-01	INDIANA UNIVERSITY SCHOOL OF MEDICINE	\$0	\$-41,722
Mechanisms mediating podocyte-parietal epithelial cell crosstalk in proliferative glomerulopathies	93.847	RFSUNY 89194/2/1163728	1R01DK12184601A1	RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK	\$0	\$18,029
Identification of unique nitric oxide-expressing hematopoietic stem cells and their special vascular niche	93.847	BIDMC 01063258	1R01DK121889-01A	BETH ISRAEL DEACONESS MEDICAL CENTER	\$0	\$31
Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications	93.847	NYUMC 20-A1-00-1002209	1R01DK122456-01A1	NEW YORK UNIVERSITY MEDICAL CENTER	\$0	\$2,277
Resilience to obesity in carriers of monogenic obesity mutations a study on the underlying mechanisms	93.847	ISMMS 0255-D641-4609	1R01DK124097-01A1	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$138,303
Role of the gut microbiome in the bone loss induced by hyperparathyroidism in mice	93.847	EMORYU A495330	1R01DK124821-01A1	EMORY UNIVERSITY	\$0	\$103,378
The Impact of Diabetes on Patients with Glomerular Disease: CureGN-Diabetes	93.847	UNC-CH 5120530	1R01DK126959-01	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	\$0	\$102,989
Elucidating Genetic and Environmental Second Hits in Racial and Ethnic Minorities with APOL1 High-Risk Genotypes	93.847	0255-E521-4609	1R01DK127139-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$107,858
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment	93.847	UOHSC RS20210075-01	1R01DK128848-01	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	\$0	\$262,752
Biomechanical drivers of cystogenesis	93.847	ISMMS 0255-F751-4609	1R01DK131047-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$16,697
QSM to Guide Iron Chelating Therapy in Transfusional Iron Overload	93.847	CUMC 221107	1R01K116126-01A1	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL	\$0	\$124,834
The organization of neural representations for flexible behavior in the human brain	93.847	BROWNU 0001873	1R01MH125497-01A1	BROWN UNIVERSITY	\$0	\$10,289
Dissecting the Pathogenesis and Outcomes of PSC Using Mutiomics by Studying the Exposome and Genome	93.847	COL-245818-04/PO#6816965	1RC2DK118619-01	Mayo Clinic Rochester	\$0	\$41,979
Integrating large scale genomics and functional studies to accelerate FSGS/NS discovery	93.847	BIDMC 01062791	1RC2DK122397-01A1	BETH ISRAEL DEACONESS MEDICAL CENTER	\$0	\$433,321
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT)	93.847	UPENN 584696	1U01DK126654-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$204,231

Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) 93.847 WCMC 212169 Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis 1U01DK130221-01 WEILL (JOAN AND SANFORD I.) \$0 \$126,434 MEDICÀL COLLEGE OF CORNÉLL JJNIJ/FRSITV Center for Identification and Study of Individuals with Atypical Diabetes Melllitus 93.847 FP068366-01 H 1U54DK118612-01 UNIVERSITY OF CHICAGO \$0 \$148,226 The Insulin-Only Bionic Pancreas Pivotal Trial: Testing the iLet in Adults and Children with Type 1 93.847 JCHR CU20-0743 1UC4DK108612-01 Jaeb Center for Health Research \$124,492 Long-term Consequences of HIV in the Kidney BCMH 7000000385 2P01DK056492-01 BAYLOR COLLEGE OF MEDICINE--\$158,485 93 847 \$0 HOUSTON Probing the Biochemical Mechanisms of Amyloid Disease 93.847 SCRIPPS 5-53806 2R01DK046335-25A1 Scripps Research Institute \$0 \$1.514 Modulating pathogenic T cells in Type 1 diabetes 93.847 YU GR106198 2R01DK057846-15 YALE UNIVERSITY \$0 \$32,684 APOL1 associated kidney disease 93.847 582940 2R01DK105821-06 UNIVERSITY OF PENNSYLVANIA \$0 \$28,401 Role of RTN1A in the Progression of Diabetic Nephropathy 93.847 ISMMS 0255-1032-4609 2R01DK109683-05 ICAHN SCHOOL OF MEDICINE AT \$0 \$39,852 MOUNT SINAI Treatment Options For Type 2 Diabetes In Adolescents and Youth (Today) Trial T2P2 93.847 GWU 16-D06 2U01DK061230-12 GEORGE WASHINGTON UNIVERSITY \$26,193 \$0 GW S-GRD1718-LL7 GEORGE WASHINGTON UNIVERSITY Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study 93.847 2U01DK098246-06 \$0 \$116,198 Data Coordinating Center for Type 1 Diabetes TrialNet 93.847 USF 6163-1082-00-B 2U01DK106993-02 UNIVERSITY OF SOUTH FLORIDA \$0 \$320,820 JOHNS HOPKINS UNIVERSITY \$14,331 Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Data 93.847 JHU 2005108234 2U24DK061730-18 \$0 Coordinating Center CASE WESTERN RESERVE Epidemiology of Diabetes Interventions and Complications 93.847 **CWRU RES516002** 3U01DK094157-06S1 \$0 \$9,213 UNIVERSITY Glycemic Profile of Pregnancy Consortium Biostatistics Research Center NORTHWESTERN UNIVERSITY 93.847 NWU 60057524 CU 3U01DK123759-02S1 \$0 \$16,486 Methylomics of Prenatal GDM: Natural History & Lifestyle Intervention in Children LSU 50363-S3 5R01DK100790-02 \$4.780 93.847 LOUISIANA STATE UNIVERSITY(BOARD \$0 OF SUPERVISORS OF LSU & A&M) Emotional Distress in a Comparative Effectiveness Trial of Diabetes Treatments 93 847 GWU CU14-1924 5R01DK104845-05 GEORGE WASHINGTON UNIVERSITY \$0 \$2,905 REPRIEVE A5332 Kidney Function Sub Study / Effect of Pitavastatin on Kidney Function in 5R01DK108438-04 93.847 UCLA 1560 B XA412 UNIVERSITY OF CALIFORNIA, LOS \$0 \$-5.030 ANGELES NCIRE SCH2284-11 5R01DK125646-02 NORTHERN CALIFORNIA INSTITUTE \$13,842 Skeletal Health in Type 1 Diabetes and the Role of Diabetic Kidney Disease 93.847 \$0 FORRESEARCH AND EDUCATION Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 93.847 GWU S-DPP2021-JC23 5U01DK048489-27 GEORGE WASHINGTON UNIVERSITY \$19,168 \$0 Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT 93.847 ISMMS 0255-A943-4609 5U01DK119200-02 ICAHN SCHOOL OF MEDICINE AT \$0 \$21,286 MOUNT SINAI The Subgingival Microbiome and Impaired Glucose Regulation 93 847 UM P006923603 7R01DK102932-04 UNIVERSITY OF MINNESOTA \$0 \$40,686 Trialnet Type 1 Diabetes Natural History Study 93.847 UFLRDA 260937 NIDDK UNIVERSITY OF SOUTH FLORIDA \$60,556 JH 2003854718 U01DK061730 JOHNS HOPKINS UNIVERSITY \$-2,845 Losartan for the Treatment of Pediatirc NAFLD: A Phase 2 Randomized, Placebo-ControlledTrial 93.847 \$0 (STOP-NAFLD). \$0 \$2,846,199

R&D Cluster

Extramural Research Programs in the Neurosciences and Neurological Disorders

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Carotid Revascularization Endarterectomy vs. Stent Trial	93.853	UMDNJ CU11-3191	1 R01 NS038384 01	RUTGERS, THE STATE UNIVERSITY NEW JERDEPARTMENT OF	OF \$0	\$58,783
Trajectories and modifiable risk factors of brain, gait, and cognitive decline in aging	93.853	AECM 311762	1R01AG062659-01A1	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$55,165
Targeting Endosomal Receptors for Treatment of Chronic Pain	93.853	NYU F1628-01	1R01DE029951-01	NEW YORK UNIVERSITY	\$0	\$185,224
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)	93.853	MAOJF COL-232483	1R01NS097876-01A1	Mayo Clinic Jacksonville	\$0	\$5,839
Long-term outcome in unruptured brain arteriovenous malformation patients	93.853	UCSF 10177sc	1R01NS099268-01A1	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$104,931
MRI Predictors of Disease and Disability Progression in African Americans With Multiple Sclerosis	93.853	ISMMS 0255-4191-4609	1R01NS10081-01A1	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$-1,406
The Effect of Lower Pressure over the Life Course on Late-life Cognition in Black	93.853	UMICHG 300465879	1R01NS102715-01	UNIVERSITY OF MICHIGAN	\$0	\$54,318
Novel regulation and function of the IncRNA Gomafu in human neurons	93.853	EMORYU A228115	1R01NS110110-01A1	EMORY UNIVERSITY	\$0	\$63,691
Understanding the fast and slow spatiotemporal dynamics of human seizures	93.853	BU 4500003407	1R01NS110669-01	BOSTON UNIVERSITY	\$0	\$154,423
Mitochondrial control of protein translation in Fragile X	93.853	YU GR107040 (CON-80001842)	1R01NS112706-01	YALE UNIVERSITY	\$0	\$178,994
Targeting Go and Grow in Glioblastoma	93.853	MAYO CJ COL-272751/PO #6753053	1R01NS118513-01	Mayo Clinic Jacksonville	\$0	\$306,254
Directing fate, subtype identity and survival in human pluripotent-derived midbrain dopamine neurons	93.853	MSKCC C21868477	1R01NS1188067-01A1	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$31,528
Corticospinal neuron dysfunction and degeneration in ALS: testing the role of corticomotor connectivity in motor neuron disease.	93.853	WMBMRI 112005-01	1R01NS119508-01	WINIFRED MASTERSON BURKE ME RES INST	D \$0	\$72,489
Diffusion MRI Model Parameter Estimation to Study Brain Microstructure as it Relates to Cognitive Status in Mild Traumatic Brain Injury	93.853	NYU 21-A1-00-1006161	1R01NS119767-01A1	NEW YORK UNIVERSITY	\$0	\$37,110
Recovery Of StrokE - Longitudinal Assessment With Neuroimaging (ROSE LAWN) (Columbia SOW)	93.853	UCINCI 013382-00002	1R01NS120493-01	UNIVERSITY OF CINCINNATI	\$0	\$22,897
Control of the axon initial segment in epilepsy	93.853	62613057-192061	1R01NS121106-01	STANFORD UNIVERSITY	\$0	\$372,385
Mechanisms of Pain Associated with Trigeminal Nerve Injury	93.853	UPITT AWD00004493 (136640-1)	1R01NS122784-01	UNIVERSITY OF PITTSBURGH	\$0	\$60,402
Development of 3D-FAST Optical Interface for Rapid Volumetric Neural Sensing and Modulation	93.853	UCOL FY22.889.001	1R01NS123665-01	UNIVERSITY OF COLORADO	\$0	\$105,046
Changing the neuromodulation game: ultrasound fenestration of the blood brain barrier for noninvasive viral transfection of primate CNS neurons	93.853	NKI 154775	1R34NS122272-01	Nathan S. Kline Institute for Psychiatri Research	c \$0	\$23,200
Development of Mechanisms Underlying Human Motor Learning	93.853	KKINS CU20-2768	1R35NS122266-01	KENNEDY KRIEGER INSTITUTE	\$0	\$38,459
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta	93.853	MSSM 0255-E021-4609	1R56NS119438-01	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$78,970
Unpacking the Importance of the Structural Injuries of MTBI	93.853	NYU 20-A0-00-1004792	1R56NS119767-01	NEW YORK UNIVERSITY	\$0	\$8,408
Topiramate as a Disease Altering Therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN) (NN108) Study	93.853	MGH CU18-2043	1U01NS095388-01A1	MASSACHUSETTS GENERAL HOSPITAL	\$0	\$5,607
Sleep for Stroke Management and Recovery Trial (Sleep SMART) Stroke Trial	93.853	UCINCI 011337-135721	1U01NS099043-01A1	UNIVERSITY OF CINCINNATI	\$0	\$324

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
Clinical Study: Brain Oxygen Optimization in Severe TBI Phase -3 (BOOST-3) Trial CSPR # 002	93.853	UMICHG SUBK10409CSPR-002	1U01NS099046-01A1	UNIVERSITY OF MICHIGAN	\$0	\$4,050
High-Speed Volumetric imaging of neural activity throughout the livingbrain	93.853	UCB 00009591	1U01NS103489-01	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$6,263
High density - cellular resolution multielectrode arrays with spatially selective unidirectional and rotating fields for investigation of neuronal networks	93.853	UMINN N006207501	1U01NS103569-01	UNIVERSITY OF MINNESOTA	\$0	\$-4
Circuitry underlying response summation in mouse and primate: theory and experiment	93.853	SALK CU17-3850	1U01NS108683-01	SALK INSTITUTE FOR BIOLOGICA STUDIES	AL \$0	\$556,851
Optimization and dissemination of non-linear Acousto-Optic Lens microscopy for multiscale 3D two-photon imaging	93.853	UCL CU18-4210	1U01NS113273-01	UNIVERSITY COLLEGE LONDON	\$0	\$41,536
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3	93.853	NU 60054977 COL	1U01NS113851-01	NORTHWESTERN UNIVERSITY	\$0	\$211
Optimization, application and dissemination of high-speed hybrid multiphoton volumetric imaging technologies	93.853	RFU SUB00000144	1U01NS115530-01	ROCKEFELLER UNIVERSITY	\$0	\$255,096
Optimization of Clear Optically Matched Panoramic Access Channel Technique (COMPACT) for large-scale deep-brain neurophotonic interface	93.853	PU 11001101-015	1U01NS118302-01	PURDUE UNIVERSITY	\$0	\$37,034
Investigation and Treatment of Undiagnosed Neuroinflammatory Diseases	93.853	UCSF 13232sc	1U01NS120836-01	UNIVERSITY OF CALIFORNIA SAI FRANCISCO	N \$0	\$194,400
Towards a Complete Description of the Circuitry Underlying SharpWave-Mediated Memory Replay	93.853	SU CU17-0676	1U19NS104590-01	STANFORD UNIVERSITY	\$0	\$492,479
Community Outreach and Engagement	93.853	3-312-0216124-66140L	1U24NS105535-01	RESEARCH TRIANGLE INSTITUTI	E \$0	\$170,074
Synergistic Interaction of amyloid-beta and alpha-synuclein in Lewy body Dementia - Project 3	93.853	MAOJF COL-259090	1U54NS110435-01A1	Mayo Clinic Jacksonville	\$0	\$536,121
kHz-rate in Vivo Imaging of Neural Activity throughout the Living Brain	93.853	UCB 00009979	1UF1NS107696-01	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$204,894
Shedding light on brain circuits mediating navigation of the odor plume in a natural environment	93.853	UCOL FY21.237.001	1UF1NS116241-01	UNIVERSITY OF COLORADO	\$0	\$45,878
Risk Factors FOR Stroke and Cognitive Decline in a Tri-Ethnic Region	93.853	UMIAMI OS00000185	2R01NS029993-23A1	UNIVERSITY OF MIAMI	\$0	\$26,113
Vascular Determinants of Dementia and Cognitive Decline in a Tri-EthnicRegion	93.853	UMIAMI OS00000824	2R56NS029993-28A1	UNIVERSITY OF MIAMI	\$0	\$25,109
Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) II	93.853	SU 61865504-125439	2U01NS038455-16A1	STANFORD UNIVERSITY	\$0	\$31,001
Vascular contributions to cognitive impairment and dementia and Stroke in a Bi-racial National Sample	93.853	UAB 000513792-005	2U01NS041588-17	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$221,472
Growth and development of Striatal Cerebellum circuitry in subjects at risk for Huntington s Disease	93.853	UIO S01224-01	2U01NS055903-10	UNIVERSITY OF IOWA	\$0	\$346,846
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) Trial (Study)	93.853	MAOJF COU-224063-05/66631416	2U01NS080168-08	Mayo Clinic Jacksonville	\$0	\$23,990
The Inherited Neuropathy Consortium (INC) RDCRC - Overall	93.853	UOI S01111-02	2U54NS065712-12	UNIVERSITY OF IOWA	\$0	\$9,991
CReATe CAPTURE (Clinical Procedures To Support Research)	93.853	UMIAMI SPC-001819	2U54NS092091-06	UNIVERSITY OF MIAMI	\$0	\$18,857
Innate and Adaptive Immunity in Parkinson Disease - Clinical Research Core.	93.853	UAB 000519299-SP002-001	1 5P50NS108675-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$6,729
Engineering stem cell therapies to understand and overcome glioblastoma adaption	93.853	UNC-CH 5109024	5R01NS099368-04	UNIVERSITY OF NORTH CAROLIN CHAPEL HILL	NA AT \$0	\$857

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name Sub	recipients	Total Expenditures
ICH Recovery Grant	<u>Listing No.</u> 93.853	Identfication No UCINCI 011078-00017	5R01NS100417-02	UNIVERSITY OF CINCINNATI, COLLEGE OF MEDICINE	\$0	(Includes Subrecipients) \$32,989
Discovery and analysis of the C. elegans neuronal gene expression network (CENGEN)	93.853	YU GR101266 (CON-80003188)	5R01NS100547-05	YALE UNIVERSITY	\$0	\$164,382
Androgen Receptors and Sex Differences in the Biological Clock	93.853	ORHSUN 1012987 COLUMBIA	5R01NS102962-04	OREGON HEALTH SCIENCES UNIVERSITY	\$0	\$88,886
miR regulation of the neurovasculature function in health and disease	93.853	SCII 22199-208-490	5R01NS107344-03	SCINTILLON INSTITUTE	\$0	\$82,213
Astrocytes-mediated regulation of Wnt/b-catenin pathway in ischemicbrain repair	93.853	UPITT AWD000001584 (133896-1)	5R01NS110755-02	UNIVERSITY OF PITTSBURGH	\$0	\$18,878
Lab-to-Marketplace: Commercialization of a stretchable microelectrode array	93.853	BEEDINC 2R44NS086118-03A1-CU	5R44NS086118-04	BIOMED STRETCH. ELASTIC DEVICES, LLC	\$0	\$6,930
Carotid Revasculaization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) Trial (93.853	MAOJF COU-224063-03	5U01NS080168-07	Mayo Clinic Jacksonville	\$0	\$16,592
NSTN National Clinical Coordinating Center Administrative Agreement	93.853	UCINCI 011414-Adm-Marshall	5U01NS086872-08	UNIVERSITY OF CINCINNATI	\$0	\$97,694
Neurological Emergencies Treatment Trials (NETT)- ESETT	93.853	SUBK00004095-ESETT	5U01NS088034-04	UNIVERSITY OF MICHIGAN	\$0	\$25,000
Using Direct Brain Stimulation to Study Cognitive Electrophysiology	93.853	UPENN 577998	5U01NS113198-03	UNIVERSITY OF PENNSYLVANIA	\$0	\$95,140
Mapping Algorithmic State Space in the Human Brain	93.853	BCMH 7000001579	5U01NS121472-02	BAYLOR COLLEGE OF MEDICINE HOUSTON	\$0	\$271,269
DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery	93.853	MGH 235400	5U19NS115388-03	MASSACHUSETTS GENERAL HOSPITAL	\$0	\$29,772
Targeting Kif11 to Treat Glioblastoma Invasion and Proliferation	93.853	MAOJF COL-232390	7R01NS073610-06	Mayo Clinic Jacksonville	\$0	\$93,184
Clinical Pathological Study of Cognitive Impairment in Essential Tremor	93.853	UTSW GMO211107 PO0000002121A	7R01NS086736-07	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICALCENTER AT	\$0	\$201,951
Pathologomics - Essential Tremor in the Broader Context of Neurodegeneration	93.853	UTSW GMO210306 PO0000002284	7R01NS088257-07	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICALCENTER AT	\$0	\$194,121
Identification and molecular characterization of somatic mutations in MCD	93.853	UNCCH 5116795	7R01NS094596-05	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	\$0	\$37,813
Environmental Epidemiology of Essential Tremor	93.853	GMO210309 PO0000002288	7R01NS094607-06	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICALCENTER AT	\$0	\$115,644
Mechanisms of Regulation of Progenitor Proliferation and Transformation	93.853	RFCUNY 42012-00-12	7R01NSO52738	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$40,739
Deep brain photoacoustic tomography at single-neuron resolution using arrays of photonic emitters and high-frequency ultrasound transducers	93.853	CALTECH 67C-1097568/S389076	U01NS099717	CALIFORNIA INSTITUTE OF TECHNOLOGY	\$0	\$287,147
Wide Deployment of Massively Multiplexed Nanosystems for Brain Activity Mapping	93.853	CALTECH S389576	U01NS099726	CALIFORNIA INSTITUTE OF TECHNOLOGY	\$0	\$127,558
Dynamic Neural Mechanisms of Audiovisual Speech Perception	93.853	UPENN 582947	U01NS113339	UNIVERSITY OF PENNSYLVANIA	\$0	\$140,379
Project 2 - Neural Basis of Motor Pattern Loops	93.853	CIT 21B-1098370	U19NS104655	CALIFORNIA INSTITUTE OF TECHNOLOGY	\$38,953	\$429,467
Allows and Infectious Diseases Pagesyah				······································	\$38,953	\$7,876,637
Allergy and Infectious Diseases Research Strategies for Tuberculosis Control in Prisons	93.855	SU 61485127-124916	1R01Al13005801	STANFORD UNIVERSITY	\$0	\$16,953

R&D Cluster Federal Grantor / Pass-through Grantor Assistance Pass-through Contract Number Passthrough Name Award Subrecipients Total Expenditures

rederar Grantor / r ass-tirrodgri Grantor	Listing No.	Identfication No	Pass-inrough Contract Number	Passinough Name Su	brecipients	(Includes Subrecipients)
The Role of Casual Contact and Migration in XDR TB Transmission in South Africa: a Geospatlal, Genomic and Social Network study	93.855	EU T937299	1R01Al138646-01	EMORY UNIVERSITY	\$0	\$29,009
New tools for antimalarial target identification	93.855	UCT30846	1R01AI143521-01	UNIVERSITY OF CAPE TOWN	\$0	\$27,614
The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination	93.855	SCRIPPS CU21-2650	1R01Al167372-01A1	Scripps Research Institute	\$0	\$2,357
Emergence of bedaquiline and clofazimine resistance after interruption of drug-resistance TB therapy in high HIV prevalence setting	93.855	AECM 311663	1R01AL145679-01A1	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$16,207
Differentially culturable tubercle Bacteria: The missing link in TB Transmission	93.855	WHC D1811140-04	1R01AL147349-01	WITS HEALTH CONSORTIUM	\$0	\$281,952
Innovative contact tracing strategies for detecting TB in mobile rural and urban South African populations	93.855	2004483467	1R01AL147681-01	JOHNS HOPKINS UNIVERSITY	\$0	\$39,909
Defining the nuclear import pathways of HIV-1	93.855	213273-Columbia	1R01AL162694-01A1	LOYOLA UNIVERSITY CHICAGO	\$0	\$73,142
Automated Visual Evaluation for Cervical Cancer Screening in HIV positive Women	93.855	UCT00028959	1R01CA250011-01	UNIVERSITY OF CAPE TOWN	\$0	\$122,962
Novel predictors of survival among breast cancer patients with/without HIV in South Africa	93.855	WHC 2007170-01	1R01CA250012-01	WITS HEALTH CONSORTIUM	\$0	\$129,663
Parasite-specific proteasome inhibitors to combat mult-drug resistant malaria	93.855	SU 61424825-123798	1R21AI127581-01	STANFORD UNIVERSITY	\$0	\$168,031
CD73 for sepsis	93.855	PPI CU21-3785	1R41AI149789-01A1	PURINE PHARMACEUTICALS, INC.	\$0	\$67,543
Intravenous ivermectin for sepsis	93.855	PPI CU21-3784	1R41AI156935-01	PURINE PHARMACEUTICALS, INC.	\$0	\$67,499
Tissue-engineered lymph node stroma to study peripheral tolerance in autoimmune diabetes	93.855	UMIAMI OS00000474	1R56AI151217-01A1	UNIVERSITY OF MIAMI	\$0	\$80,933
IeDEA Asia-Pacific Research Collaboration	93.855	AMFAR 110279-71-ISTA	1U01AI069907	AMERICAN FOUNDATION FOR AIDS RESEARCH (AMFAR)	\$0	\$29,158
Hope in Action: A Clinical Trial of HIV-to-HIV Deceases Donor Kidney Transplantation	93.855	JHU 2003649381	1U01Al134591-01	JOHNS HOPKINS UNIVERSITY	\$0	\$12,251
Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab , (Study)	93.855	MGH 232560	1U01AI136816-01	MASSACHUSETTS GENERAL HOSPITAL	\$0	\$35,038
HOPE in Action: A clinical trial of HIV-to-HIV Liver Transplantation	93.855	JH 2004360332	1U01AI138897-01	JOHNS HOPKINS UNIVERSITY	\$0	\$10,188
Rapid Low-Cost Paper-based Radiation Biodosimetry that reveals individuals organ injuries	93.855	ASU B00000501	1U01AI148319-01	ARIZONA STATE UNIVERSITY	\$0	\$126,585
MHC & KIR Sequencing and Association Analyses in the iGeneTrain Studies Effort	93.855	UPENN 582580	1U01AI152960-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$20,696
Molecular Mechanisms of Adjuvant Triplet Combinations	93.855	UCHICA AWD101938 (SUB00000486)	1U01AI160418-01	UNIVERSITY OF CHICAGO	\$0	\$95,371
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease	93.855	IMGX CU18-2990	1U44AI134590-01A1	IMMUNOGENX	\$0	\$8,925
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)	93.855	UAB 000522211-029	1U54AI150225-01	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$11,163
INNER CITY ASTHMA CONSORTIUM (ICAC3): CORE	93.855	UWIS 0000000796	1UM1AI114271-01	UNIVERSITY OF WISCONSIN	\$0	\$91,294
Childhood Asthma in Urban Settings (CAUSE)- Leadership Center	93.855	UWM 0000001419	1UM1AI160040-01	UNIVERSITY OF WISCONSIN MADISO	N \$0	\$808,051

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name Su	<u>brecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Function of antimalarial drug resistance proteins	93.855	GU 411310	2R01AI056312-10A1	GEORGETOWN UNIVERSITY	\$0	\$66,927
Function of Antimalarial Drug Resistance Proteins	93.855	GWU 414700 GR 414915-CU	2R01AI056312-15	GEORGETOWN UNIVERSITY	\$0	\$37,231
Advanced Genotypic and Phenotypic Monitoring of Drug Resistant TB to Improve TB Treatment Outcomes	93.855	AECM 311952	2R01Al114900-07A1	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$108,403
Monochromatic 222 nm UV light: Development of safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission	93.855	EPINIHSUB19-01	2R42AI125006-2A1	EDEN PARK ILLUMINATION	\$0	\$77,790
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium	93.855	IU 8982 COL	2U01AI069911-16	INDIANA UNIVERSITY	\$0	\$34,489
Central Africa International Epidemiology Database to Evaluate AIDS (CA-leDEA)	93.855	AECM 31614BJ	2U01AI096299-07	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$-591
East Africa international Epidemiologic Database to Evaluate AIDS (leDEA) Regional Consortium	93.855	8073 COL	2U01Al09629911-11	INDIANA UNIVERSITY	\$0	\$34,833
Central African International Epidemiological Database to Evaluate AIDS	93.855	AECM 31121B	2U01Al096299-13	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$51,739
Amanitin-CD5 mAb conjugate to deplete host peripheral T cells and thymocytes and induce durable chimerism with tolerance in nonhuman primates	93.855	UWIS 0000001549	2U01AI102456-06	UNIVERSITY OF WISCONSIN MADISO	N \$0	\$238,022
Vaccine induced immunity in the young and aged	93.855	EMORYU A335572	2U19AI057266-16	EMORY UNIVERSITY	\$0	\$132,068
HVTN Research & Mentorship Program (RAMP)	93.855	FHCRC 0001075710	2UM1Al068614-15	FRED HUTCHINSON CANCER CENTER	₹ \$0	\$87,666
Immune Tolerance Network	93.855	BRI FY21ITN440	2UM1AI109565-08	BENAROYA RESEARCH INSTITUTE	\$0	\$42,146
Kwazulu-Natal Clinical Trials Unit (CTU)	93.855	CAPRISA UM1AI069469	2UM1I069469-15	CENTRE FOR THE AIDS PROGRAMME OFRESEARCH IN SOUTH AFRICA	\$0	\$251,979
HVTN Protocol Funding	93.855	FHCRC 0001062694	2UMAI068614-08	FRED HUTCHINSON CANCER CENTE	₹ \$0	\$26,471
Dynamics and Tuning of the MHC II Presented Peptidome	93.855	WCMC 203313	3R01Al37198-04S1	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL JUNINFRSITY	\$0	\$69,170
Molecular Regulation of B cells and T cells in Human SLE // Protocol	93.855	EMORYU A585613	3U19Al110483-08S4	EMORY UNIVERSITY	\$0	\$40,488
A randomized controlled study to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderma COVID-19 Vaccine	93.855	HCRC 0001064446	3UM1Al068614-15S1	FRED HUTCHINSON CANCER CENTER	₹ \$0	\$-17,653
ADAPT Out COVID: ACTIV-2/ACTG A5401	93.855	UCLA CRS 30329 CU 30606 A5401	3UM1Al068636-14S2	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$0	\$13,137
HPTN083 Protocol Funding - Implementation Costs Harlem CRS	93.855	PO17001995	5 UM1Al068619-11	FHI DEVELOPMENT 360 LLC	\$0	\$147,834
Antimicrobial Resistant E. Coli before and after California Senate Bill 27 (ARES): a natural experiment	93.855	KFDNI RNG113791-Columbia	5R01Al30066-04	Kaiser Foundation Research Institute- -Division of Research	\$0	\$34,236
Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow	93.855	OSSIUM OOS030382-CU	5R44AI129444-03	OSSIUM HEALTH, INC.	\$0	\$292,093
School Inner-City Asthma Intervention Study	93.855	CHB GENFD0001578885	5U01AI110397-02	CHILDREN'S HOSPITAL BOSTON	\$0	\$247,681
AMERICAN AND ASIAN CENTERS FOR ARBOVIRUS RESEARCH AND ENHANCED SURVEILLANCE (A2CARES)	93.855	UC 00010878	5U01Al151788-02	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$16,968
HPTN 083 Protocol Funding - Development Cost	93.855	FHID PO16002898	5UM1AI068619	FHI DEVELOPMENT 360 LLC	\$0	\$38,936

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name Sub	precipients	R&D Cluster Total Expenditures
r Cacital Grantol / Lass-till Cagit Grantol	Assistance Listing No.	Award <u>Identfication No</u>	rass-unough Contract Number	rassumough ivaine Sur	orecipients	Includes Subrecipients
HPTN083 Protocol Funding - Implementation Costs Bronx CRS	93.855	FHID PO17002294	5UM1AI068619-11	FHI DEVELOPMENT 360 LLC	\$0	\$56,777
International Maternal Pediatric Adolescent AIDS Clinical Trials Network	93.855	JHC 2004512905	5UM1AI068632-14	JOHNS HOPKINS UNIVERSITY	\$0	\$89,598
Immune Tolerance Network	93.855	BRI FY16ITN109	5UM1AI109565-02	BENAROYA RESEARCH INSTITUTE	\$0	\$12,000
Immune Tolerance Network Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy	93.855	FY22ITN326	5UM1AI109565-06	BENAROYA RESEARCH INSTITUTE	\$0	\$46,76
The molecular basis of the carbapenem resistance epidemic	93.855	HMH G10063-19028	7R01Al090155-10	HACKENSACK MERIDIAN HEALTH	\$0	\$26,433
ACTG Protocol Funding - Core Funding	93.855	UCLA CU18-2702	7UM1Al068636-13	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$0	\$140,064
Evaluating the Healthix Bottom Up Strategy in New York City Using an Implementation Science Framework	93.855	AECM 311888	P30Al124414-05	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$7,972
A dual-beta-lactam strategy for treating multi drug resistant M abscessus	93.855	HMH 19022	R01Al141805	HACKENSACK MERIDIAN HEALTH	\$0	\$83,58
Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis	93.855	MBX CU19-2734	R43AI150001-01A1	MICROBIOTIX INC	\$0	\$119,078
Composition and structure of antibody receptors at the surface of primary human cells during immune activation	93.855	UGA SUB00002365	U01AL148114	UNIVERSITY OF GEORGIA	\$0	\$193,823
HPTN 094 Integra	93.855	FHID PO21000092	UM1 Al068619	FHI DEVELOPMENT 360 LLC	\$0	\$573,686
HPTN 081/085 Protocol Funding - Implementation - Centralized Laboratory and Other Operational Support	93.855	FHID PO16003322	UM1 AIO68619	FHI DEVELOPMENT 360 LLC	\$0	\$204,470
HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre- Exposure Prophylaxis in HIVUninfected	93.855	FHI360 PO18001958	UM1Al068619	FHI DEVELOPMENT 360 LLC	\$54,956	\$1,430,96
				<u></u>	\$54,956	\$7,429,767
Biomedical Research and Research Training Efficient Statistical Learning Methods for Personalized Medicine Using Large Scale Biomedical Data.	93.859	UNC-CH 5110020	1R01GM124104-01A1	UNIVERSITY OF NORTH CAROLINA AT	Г \$0	\$52,920
Statistical Methods for Single-Cell Transcriptomics	93.859	UPENN 572782	1R01GM125301-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$19,830
The mechanism through which mRNA translation enhancer elements drive cap-independent translation	93.859	RFCUNY CM00002680-00	1R01GM128239-01A1	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$117,27
The role of collisions in rescuing stalled ribosomes in bacteria	93.859	JH 2005039040	1R01GM136960-01A1	JOHNS HOPKINS UNIVERSITY	\$0	\$28,71
Kyaterekera Project: A Combination Intervention Addressing Sexual Risk-Taking Behaviors Among Vulnerable Women in Uganda	93.859	WASHU WU-19-203-MOD-1	1R01MH116768-01A1	WASHINGTON UNIVERSITY	\$0	\$62,08
MAVEN: Developing Diverse Senior Scientists Leaders	93.859	FIMR AWD00001308-CU	1R25GM139082-01	FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH	\$0	\$24,88
Structure-Based Antagonism of HIV1 Envelope Function in Cell Entry	93.859	DREXEL 910001-Columbia	2P01GM056550-22	DREXEL UNIVERSITY	\$0	\$310,16
Modulation of KCNQ1 Channel Activity	93.859	UMIAMI OS00000504	2R01GM109762-05	UNIVERSITY OF MIAMI	\$0	\$224,26
Guanidinium Toxins as Molecular Probes for NaV Study	93.859	SU 62585450-119297	2R01GM117263-05	STANFORD UNIVERSITY	\$0	\$122,29
Center on Macromolecular Dynamics by NMR Spectroscopy	93.859	NYSBC G00915-01	5P41GM118302-02	NEW YORK STRUCTURAL BIOLOGY CENTER	\$0	\$95,170

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Pasethrough Namo Suhr	ocinionte	R&D Cluster Total Expenditures
FEBio - Finite Elements for Biomechanics and Biophysics	Listing No. 93.859	Award Identfication No UUTAH 10054274-Columbia	5R01GM083925-14	Passthrough Name Subr UNIVERSITY OF UTAH	ecipients \$0	(Includes Subrecipients) \$204,148
Methods for integrated analysis of multi-level omics data	93.859	MGH 235245	7R01GM127862-03	MASSACHUSETTS GENERAL HOSPITAL	\$0	\$41,303
				HOSPITAL	<u> </u>	
Child Health and Human Development Extramural Research					\$0	\$1,303,046
Developmental Mechanisms of Trachea-Esophageal Birth Defects,project 1	93.865	CHMCO 140554	1P01HD093363-01	CINCINNATTI CHILDREN'S MEDICAL CENTER	\$0	\$288,056
Pediatric HIV/AIDS Cohort Study (PHACS): 2020	93.865	HARVARD 117267-0108-5115581	1P01HD103113-01	HARVARD UNIVERSITY	\$0	\$8,077
Medical Optimization & Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)	93.865	UNC 5106225	1R01HD086139-01A1	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	\$0	\$-16,820
Impact of Combined Use of Depot Medroxyprogesterone Acetate Contraception and Tenofovir PreExposure Prophylaxis on Bone Health (Depo-PrEP)	93.865	UWSC9850	1R01HD089843-01A1	UNIVERSITY OF WASHINGTONSEATTLE WASHINGTON	\$0	\$15,822
WeCare	93.865	AAP CU18-0762	1R01HD090191-01	AMERICAN ACADEMY OF PEDIATRICS	\$0	\$19,062
FANMI: A community-based cohort model for HIV adolescent care in Haiti	93.865	204412	1R01HD091935-01A1	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL	\$0	\$6,430
Using Smart Phones to Understand the Link between Social and Geographical Context and HIV Risk Behavior Among MSM	93.865	YU GR101489 (CON-80001024	1R01HD092185-01	YALE UNIVERSITY	\$0	\$11,496
Socioeconomic Disparities in Cognitive & Neural Development in the First 3 Years	93.865	TC 512158-01	1R01HD093707-01	TEACHERS COLLEGE COLUMBIA UNIVERSITY	\$0	\$17,597
Place matters - Adaptable Solutions to Violence at the Community Level	93.865	TUL-HSC-557611-20/21	1R01HD095609-01	TULANE UNIVERSITY	\$0	\$45,627
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)	93.865	GHU CU18-3693	1R01HD096559-01A1	GLOBAL HEALTH UGANDA	\$0	\$63,417
The NICU Antibiotics and Outcomes (NANO) Trial	93.865	UPITT AWD00001006 (133613-2)	1R01HD097578-01A1	UNIVERSITY OF PITTSBURGH	\$0	\$25,876
Childhood Pulmonary and Related Outcomes after Perinatal Exposure to Adjunctive Azithromycin Prophylaxis for Cesarean Delivery (C/SOAP Follow-Up Study II)	93.865	UAB 000523794-SC003	1R01HD098132-01	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$6,443
Community violence and disparities in maternal and infant health: effects and mechanisms	93.865	UC 00010352	1R01HD098138-01A1	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$40,929
Women s HIV Cohort Study: HIV infection and treatment among women of reproductive age	93.865	UM SPC-001401	1R01HD101352-01	UNIVERSITY OF MIAMI	\$0	\$26,411
Neuro-behavioral Disorders after Appendectomy in Childhood	93.865	GRT-00000289	1R01HD101415-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$92,280
PRagMatic Pediatric Trial of Balanced versus NOrmaL Saline FIUid in Sepsis (PRoMPT BOLUS)	93.865	CHOP GRT-00000762	1R01HD101528-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	\$0	\$40,859
Racial Disparities in Preterm Births and Fetal Loss	93.865	UCI 2021-1546	1R01HD103736-01A1	UNIVERSITY OF CALIFORNIA, IRVINE	\$0	\$33,435
The Genomic Architecture of Pregnancy Loss	93.865	MGH 239748	1R01HD105266-01	MASSACHUSETTS GENERAL HOSPITAL	\$0	\$65,770
Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy loss	93.865	YU CON-8000531 (GR115508)	1R01HD105267-01	YALE UNIVERSITY	\$0	\$6,920
Using EV-microRNAs to identify a non-invasive biomarker of uterine fibroid outcomes	93.865	GWU 19-M30	1R21HD096248-01A1	GEORGE WASHINGTON UNIVERSITY	\$0	\$53,655
The Role of Hypothalamic Pituitary-Adrenal Axis Dysregulation in Preterm Birth	93.865	HARVARD 117342-5115037	1R21HD102822-01	HARVARD UNIVERSITY	\$0	\$25,478

Federal Grantor / Pass-through Grantor Pass-through Contract Number Assistance Award Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) 93.865 The Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) UPITT AWD00002130 1U19AG068054-01 UNIVERSITY OF PITTSBURGH \$0 \$1,155,371 (136595-3)PU SUB0000361 2R01HD036916-16A1 Fragile Families and the Transition to Adulthood 93.865 PRINCETON UNIVERSITY \$0 \$54.739 Predictive Informatics Monitoring in the Neonatal Intensive Care Unit 93.865 UV GB10607-PO#2230352 2R01HD072071-04A1 UNIVERSITY OF VIRGINIA \$212,931 93.865 UWIS 865K196 2R01HD072077-06 UNIVERSITY OF WISCONSIN MADISON \$290.766 A multi-modality, multi-scale approach to understanding parturition \$0 Suubi+Adherence-R2:Examining the longitudinal HIV treatment adherence among youth living with 93.865 WUSOM WU-21-267 2R01HD074949-07 Washington University School of \$0 \$37.340 HIV (YLHIV) transitioning into young adulthood Medicinein St. Louis UNIVERSITY OF NORTH CAROLINA AT Early life adversities and the emergence of risk and resilience: A longitudinal study of child 93.865 UNC 5117284 2R01HD075875-07A1 \$0 \$67,616 CHAPEL HILL Innovation across the spectrum of pediatric HIV care 93.865 MGH 235202 2R01HD079214-06A1 MASSACHUSETTS GENERAL \$0 \$23,200 HOSPITAL Reserve against Disability in Early Multiple Sclerosis (RADIEMS) Longitudinal Cohort Study 93.865 MSSM 0255-1472-4609 2R01HD082176-06A1 ICAHN SCHOOL OF MEDICINE AT \$19,614 MOUNT SINAI The Maternal Fetal Medicine Unit Network 93.865 GWU CU14-1338 2U10HD036801-16 GEORGE WASHINGTON UNIVERSITY \$28,534 \$299,868 MASSACHUSETTS GENERAL Gene Mutation and Rescue in Diaphragmatic Hernia 93.865 MGH 230914 5P01HD068250-08 \$0 \$258,477 HOSPITAL Clinical Diagnostic Sequencing of Structural Variation 93.865 MGH 239749 5R01HD081256 MASSACHUSETTS GENERAL \$0 \$14,132 HOSPITAL UTSW GMO 160410 UNIVERSITY OF TEXAS \$13,585 Molecular mechanisms of infection-mediated cervical ripening 93.865 5R01HD086495-05 \$0 SOUTHWESTERN MEDICALCENTER AT UTSW GMO 170904 PO# UNIVERSITY OF TEXAS \$30,307 Mechanisms by which steroid hormones modulate cervical extracellular matrix structure and 93.865 5R01HD088481-05 \$0 function during pregnancy and provide therapeutic protection against preterm birth 00000939B SOUTHWESTERN MEDICALCENTER AT Innovative PK/PD Approaches to Optimize TBM Treatment in Children (PATCH Study) JOHNS HOPKINS UNIVERSITY 93.865 JHU 2002824937 R01HD074944-02 \$0 Protection Against Cognitive Decline in MS: Longitudinal Investigation of Reserve 93.865 MSSM 0255-1471-4609 R01HD082176 \$-494 ICAHN SCHOOL OF MEDICINE AT \$0 MOUNT SINAI MICHIGAN STATE UNIVERSITY Neurobiological Pathways Underlying Maladaptive Behaviors in Youth 93 865 MSU RC107642CU R01HD093334 \$56,379 U24HD036801 GEORGE WASHINGTON UNIVERSITY \$783,115 The Maternal Fetal Medicine Unit Network 93.865 GWU CU21-2046 \$230.847 \$259,381 \$4,193,765 Aging Research Roybal Center for Personalized Trials: Physical Activity Promotion to Foster Healthy Aging 93.866 AWD00001307-CU 1P30AG063786-01 FEINSTEIN INSTITUTE FOR MEDICAL \$0 \$62,083 RESEARCH Re-visiting Methods for MCI Diagnosis to Improve Biomarker and Trial Findings UCSD 73333288 (S9001382) 1R01AG049810-01A1 UNIVERSITY OF CALIFORNIA, SAN \$28,555 93.866 \$0 Novel Cognitive and Functional Measures for Alzheimer s Disease Prevention Trials 93.866 SRFMH 139964 1R01AG051346-01A1 RESEARCH FOUNDATION FOR \$0 \$339,098 MENTAL HYGIENEINC Cognitive Function, Alzheimer s Disease and Related Disorders in the HAALSI Cohort 93.866 HARVARD 116362-5111693 1R01AG054066-01A1 HARVARD UNIVERSITY \$0 \$115,137 Slow wave sleep (SWS) and the effect of African ancestry on amyloid burden, a longitudinal study 93.866 NYU 17-A1-00-007453-01 1R01AG056531-01A1 **NEW YORK UNIVERSITY** \$0 \$34,841 RUSH UNIVERSITY MEDICAL CENTER Identifying the molecular systems, networks, and key molecules that underlie cognitive resilience 93.866 RUMC 17021705-Sub02 1R01AG057911-01 \$0 \$65,856

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name S	Subrecipients .	Total Expenditures (Includes Subrecipients)
The Action for Health in Diabetes ADRD study (LookAHEAD-MIND)	93.866	WFUHS 162-55811085045103-10000	1R01AG058571-01	WAKE FOREST UNIVERSITY	\$0	\$24,496
Child Maltreatment and Risk for Mild Cognitive Impairment and Alzheimer s Disease	93.866	RFCUNY CM00001842-00	1R01AG05863-01A	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$173,274
Stress, Epigenetics, and Aging	93.866	EMORYU A008616	1R01AG058704-01	EMORY UNIVERSITY	\$0	\$93,368
Educational and Early Life Predictors of Mild Cognitive Impairment: New Evidence about Mediators and Moderators from High School & Beyond	93.866	UMINN H007058802	1R01AG058719-01A1	UNIVERSITY OF MINNESOTA	\$0	\$132,104
Subclinical Vascular Contributions to Alzheimer s Disease: The Multi Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD	93.866	WFUHS 551083	1R01AG058969-01	WAKE FOREST UNIVERSITY	\$0	\$567,084
Predicting post-transplant mortality and global functional health based on pre-transplant functional status in liver transplantation	93.866	UCSF 10865sc	1R01AG059183-01	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$54,998
Assessing the interactive effect of lifetime and old age cognitive engagement on cognitive decline and dementia: cognitive reserve versus use it or lose it	93.866	UMICHG SUBK00011643	1R01AG062447-01A1	UNIVERSITY OF MICHIGAN	\$0	\$34,469
Postoperative Delirium and Alzheimer s Disease Related Dementias	93.866	BWH 234365	1R01AG062509-01	BRIGHAM AND WOMEN'S HOSPITAL	_ \$0	\$213,652
UCD A20-0610-S002 The Neuropathologic Landscape of Alzheimer's Disease Hispanic decedents	93.866	UCD A20-0610-S002	1R01AG062517-01A1	UNIVERSITY OF CALIFORNIA, DAVIS	S \$0	\$45,796
Dissecting the genomic etiology of non-Mendelian early-onset Alzheimer disease and related phenotypes	93.866	UMIAMI SPC-001236	1R01AG064614-01	UNIVERSITY OF MIAMI	\$0	\$547,298
Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial	93.866	MAORO THE-277060-02	1R01AG065154-01A1	Mayo Clinic Rochester	\$0	\$517,550
Statistical method for neural mechanism mediating and moderating cognitive system in Alzheimer s disease and aging research.	93.866	RFMH 27412	1R01AG065278-01A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$94,887
Best Case/Worst Case: A Multisite Randomized Clinical Trial of Scenario Planning for Patients with End-Stage Kidney Disease	93.866	UWIS 0000000686	1R01AG065365-01	UNIVERSITY OF WISCONSIN	\$0	\$38,559
Spontaneous Speech and Health Disparities in Risk of Cognitive Decline: WHICAP Offspring Ancillary Study	93.866	KENT 403056-COL	1R01AG065432-01	KENT STATE UNIVERSITY	\$0	\$314,000
National Cohort Studies of Alzheimer s Disease, Related Dementias and Air Pollution	93.866	HARVARD 112576-5113206	1R01AG066793-01	HARVARD UNIVERSITY	\$0	\$22,500
Metabolic regulation of human DNA methylation clocks	93.866	RFMH 27496	1R01AG066828-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$15,657
24-hour activity cycles to optimize cognitive resilience to Alzheimer s disease in African Americans: the Jackson Heart Study	93.866	UAB SC002-Pal	1R01AG067513-01	UNIVERSITY OF ALABAMA AT BIRMINGHAM	\$0	\$122,975
Contributions of stress reactivity to risk of Alzheimer s disease and related dementias in a community-based cohort	93.866	NWU 60060219 CU	1R01AG067557-01A1	NORTHWESTERN UNIVERSITY	\$0	\$22,385
Chaperome networks in Alzheimer s Disease	93.866	MSKCC C22055357	1R01AG067598-01A1	MEMORIAL SLOAN-KETTERING CANCER CENTER	\$0	\$456,678
Social Convoys, Cognitive Reserve and Resilience, and Risk for Alzheimer s Disease and Related Dementias	93.866	RFMH 27627	1R01AG069041-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$202,130
Social Convoys, Cognitive Reserve and Resilience, and Risk for Alzheimer s Disease and Related Dementias	93.866	RFMH 27627	1R01AG06904101	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$48,87
Characterization of an 18F COX-2 PET ligand for in vivo brain imaging	93.866	RFMH 151573	1R01AG070042-01	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$66,453
Longitudinal Relationships Among Sleep, Cognition and Alzheimer s Disease Biomarkers: Discerning Causal Associations, Mediators, and Susceptibility	93.866	BWH 125298	1R01AG070867-01	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$182,760
Contribution of Longitudinal Neighborhood Determinants to Cognitive Health and Dementia Disparities within a Multi-Ethnic Cohort	93.866	DREXEL 900142	1R01AG072634-01	DREXEL UNIVERSITY	\$0	\$62,938

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
PP2A Dysregulation in the Pathogenesis of alphaSynucleinopathies	93.866	RUTGERS 0131	1R01NS101134-01	RUTGERS, THE STATE UNIVERS NEW JERDEPARTMENT OF	SITY OF \$0	\$17,767
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-Infected and Uninfected Women	93.866	AECM 311343	1R21AG059505-01	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$13,558
Nurses documentation of patient diagnoses, symptoms and interventions for home care patients with Alzheimer s Disease and related dementias: A natural language processing study	93.866	VNSNY 4627C	1R21AG065753-01A1	VISITING NURSE SERVICE OF NI YORK	EW \$0	\$19,600
Relationship between CNS Tau burden and perioperative neurocognitive disorder	93.866	UOP 580814	1R21AG067114-01	UNIVERSITY OF PENNSYLVANIA	\$0	\$95,089
Screening to Improve Survival in AL Amyloidosis	93.866	TMC 5019000-SERV	1R21AG070502-01	TUFTS MEDICAL CENTER, INC.	\$0	\$41,246
Development of a stress kinase inhibitor therapeutic candidate for Alzheimer's Disease and related dementia	93.866	NKT071388001	1R44 AG071388-01	NEUROKINE THERAPEUTICS	\$0	\$190,896
Cell type influence on exosome signaling and early pathologic signatures in Alzheimers disease	93.866	SCRIPPS 5-54377	1R56AG062618-01A1	Scripps Research Institute	\$0	\$110,587
Hippocampal circuit plasticity in human normal aging and Alzheimer s Disease	93.866	RFMH 27645	1R56AG063372-01A1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$101,055
The Origins of Alzheimer Disease in Individuals of African Ancestry	93.866	UMIAMI OS00000650	1R56AG072547-01	UNIVERSITY OF MIAMI	\$0	\$449,574
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experience	93.866	RUMC 09111306-sub3	1RF1AG036042-01	RUSH UNIVERSITY MEDICAL CE	NTER \$0	\$58,771
Genomic Characterization of Alzheimer s Disease Risk in the Puerto Rican population	93.866	UMIAMI 667606	1RF1AG054074-01	UNIVERSITY OF MIAMI	\$0	\$16,440
Genetic Epidemiology of EarlyOnset Alzheimer s disease in Caribbean Hispanics and nonHispanic Whites	93.866	UMIAMI SPC-000135	1RF1AG054080-01	UNIVERSITY OF MIAMI	\$0	\$-21,495
Healthy Heart, Healthy Brain? A pooled life-course cohort for dementia risk assessment	93.866	11276sc	1RF1AG054443-01	UNIVERSITY OF CALIFORNIA SA FRANCISCO	N \$0	\$178,175
Prevention of Alzheimer s disease in women: risks and benefits of hormone therapy	93.866	MAORO THE-234899-02	1RF1AG057547-01	Mayo Clinic Rochester	\$0	\$278,667
The Effect of Vascular Risk Factors on Risk of Alzheimer s Disease and Related Dementias after Stroke (STROKE COG)	93.866	UMICHG SUBK0001205	1RF1AG068410-01	UNIVERSITY OF MICHIGAN	\$0	\$34,817
Glucose homeostasis and the risk of Alzheimer s disease and Alzheimer s disease related dementias in the Multi-Ethnic Study of Atherosclerosis	93.866	WUBGSM 1092-45116-11000000260	1RF1AG070881-01A1	WAKE FOREST UNIVERSITY	\$0	\$59,531
Replication and Extension in African Americans of AD Sequencing	93.866	UMIAMI SPC-000756	1U01AG052410-01	UNIVERSITY OF MIAMI	\$0	\$48,519
Early Onset AD Consortium - the LEAD Study (LEADS)	93.866	IN-4683237-COL	1U01AG057195-01A1	INDIANA UNIVERSITY	\$0	\$50,736
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems	93.866	BU 4500004112	1U01AG058589-01A1	BOSTON UNIVERSITY	\$0	\$410,644
The Alzheimer Disease Sequence Analysis Collaborative	93.866	CWRU RES515785	1U01AG058654-01A1	CASE WESTERN RESERVE UNIVERSITY	\$0	\$158,227
Additional Sequencing Cohorts for the Alzheimer s Disease Sequencing Project	93.866	UMIAMI SPC-001303	1U01AG062943-01	UNIVERSITY OF MIAMI	\$0	\$105,839
Preclinical development of a novel small molecule inhibitor of Alzheimer s disease-related cognitive impairment	93.866	NWU 60056114 CU	1U01AG066722-01	NORTHWESTERN UNIVERSITY	\$0	\$466,045
Additional Sequencing for the Alzheimer s Disease Sequencing Project (ADSP)	93.866	UMIAMI OS00000156	1U01AG066767-1	UNIVERSITY OF MIAMI	\$0	\$92,813
Ultrascale Machine Learning to Empower Discovery in Alzheimer's Disease Biobanks	93.866	USC 137299535	1U01AG068057-01	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$281,975

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name Si	ubrecipients	Total Expenditures (Includes Subrecipients)
Integrative Pathways to Health & Illness	93.866	UWIS 000000779	1U19051426-01A1	UNIVERSITY OF WISCONSIN	\$0	\$4,847
The Long Life Family Study: Columbia University	93.866	WUSOM WU-22-0479	1U19AG063893-01	Washington University School of Medicinein St. Louis	\$0	\$1,520,445
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Clinical Core Fixed	93.866	MAORO CBL-263134-01	1U19AG063911-01	Mayo Clinic Rochester	\$0	\$86,113
Adult Changes in Thought (ACT) Research Program - Life Course Core (C)	93.866	KPWRI RNG211397-COLUMBIAU	1U19AG066567-01A1	KAISER PERMANENTE WASHINGTO RESEARCH IN-STITUTE	N \$0	\$104,261
Resistance to Alzheimer s Disease in Centenarians and their Offspring (RADCO)	93.866	BU CU20-3428	1U19AG073172-01	BOSTON UNIVERSITY	\$0	\$15,106
Alzheimer s Disease Sequencing Project Phenotype Harmonization Consortium	93.866	VANDER VUMC95856	1U24AG074855-01	VANDERBILT UNIVERSITY MEDICAL CENTER	\$0	\$10,161
The Microvascular Aging and Eicosanoids Women s Evaluation of Systemic aging Tenacity (MAE-WEST) Specialized Center of Research Excellence (SCORE) on Sex Differences	93.866	CSMCLA 1761036	1U54AG065141-01	CEDARS-SINAI MEDICAL CENTER	\$0	\$1,629
Improving Health Outcomes for an Aging Population	93.866	NBER 4135G.30.16.Columbia	2P01AG005842-30	National Bureau of Economic Research	\$0	\$72,389
DNA Repair, Mutations and Cellular Aging	93.866	AECM 31168B	2P01AG017242-24	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$62,360
What Does Health Insurance Do? Evidence from the Oregon Health	93.866	NBER 4126B.COLUMBIA	2R01AG034151-06A1	National Bureau of Economic Research	\$0	\$21,898
Pathogenesis of Postoperative Cognitive Dysfunction	93.866	MGH 235316	2R01AG041274-06A1	MASSACHUSETTS GENERAL HOSPITAL	\$0	\$287,732
Enhancing Retrospective Life History Data in the Health and Retirement Study	93.866	SUBK00010395	2R01AG051142-05	UNIVERSITY OF MICHIGAN	\$0	\$15,227
Dominantly Inherited Alzheimer Network	93.866	WASHU CU20-0606	2U19AG032438-08	WASHINGTON UNIVERSITY	\$0	\$14,035
Biomarkers of Cognitive Decline Among Normal Individuals: The Biocard Cohort	93.866	JHU 2004408143	2U19AG033655-11	JOHNS HOPKINS UNIVERSITY	\$0	\$41,666
Genome Center for Alzheimer s Disease (GCAD)- CORE C	93.866	UPENN 584632	2U54AG052427-06	UNIVERSITY OF PENNSYLVANIA	\$0	\$91,752
Novel Cognitive and Functional Measures for Alzheimer's Disease Prevention Trials: Sensitivity to Biomarkers	93.866	RFMH 27026	3R01AG051346-03S1	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$156,774
Novel Cognitive and Functional Measure for Alzheimer s Disease Prevention Trials	93.866	RFMH 27026	3R01AG051346-03S2	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$1,394
Improving the Usage and Impact of the Integrated Aging Studies Databank and Registry	93.866	WUBGSM 1016-33664-11000000333	3U24AG059624-04S1	WAKE FOREST UNIVERSITY	\$0	\$17,496
Exploring the Latent Class Structure of Inhibition in Aging	93.866	USC 127427367	4R00AG055684-03	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$23,781
Risk Factors, Pathology and Clinical Expressions of AD	93.866	RUMC L97092581-Sub07	5R01AG015819-18	RUSH UNIVERSITY MEDICAL CENTE	R \$0	\$128,742
Tau-Sliceosome Interactions in Alzheimer s Disease	93.866	BCMH 7000000572	5R01AG053960-05	BAYLOR COLLEGE OF MEDICINE HOUSTON	\$0	\$48,647
Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)	93.866	UCLA CU19-0515	5R01AG054366-03	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$0	\$53,934
Human tissue specific age-related gene expression changes, their genetic regulations and the link to human diseases	93.866	ISMMS 0255-4711-4609	5R01AG055501-03	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	\$0	\$112,033
Probing Heterogeneity of Alzheimer s Disease using iPSCs	93.866	BWH 119586	5R01AG055909-03	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$36,419

Federal Grantor / Pass-through Grantor	Assistance	August	Dage through Contract Number	Passthrough Name Sul	ara sini anta	Total Expanditures
recerai Grantor / Pass-tirrough Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passtnrough Name Sur	<u>orecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers: Inflammatory and Biological Aging Mechanism	93.866	UCLA 2000 G VK311	5R01AG056424-02	UNIVERSITY OF CALIFORNIA, LOS ANGELES	\$0	\$9,936
Combinatorial Actions of Genetic Variants and Gender Bias of Alzheimer sDisease	93.866	UCSD 131780734	5R01AG057706-03	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$9,506	\$770,751
Life Course Process of Alzheimer s Disease: Sex Difference and Biosocial Mechanisms	93.866	5113228	5R01AG057800-02	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	Г \$0	\$22,947
Resilience to Alzheimer s disease in humans with exceptional longevity	93.866	AECOM 311234	5R01AG057909-04	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$287,399
Elucidating the molecular drivers of impaired mobility and motor function in AD and related pathologies	93.866	RUMC 17092603-Sub02	5R01AG059732-02	RUSH UNIVERSITY MEDICAL CENTER	\$0	\$24,361
Defining the programmed proteome rejuvenation underlying gametogenesis	93.866	UCB 00010791	5R01AG071869-02	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$340,962
A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in the Subject	93.866	UCSD 92880900 (S9002311)	5U19AG010483-26	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$13,785
Genetic Variant-Based Drug Discovery Targeting Conserved Pathways of Aging	93.866	AECM 31169B	5U19AG056278-04	ALBERT EINSTEIN COLLEGE OF MEDICINEESHIVA UNIVERSITY	\$0	\$112,633
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer s Disease in the Framingham Cohorts	93.866	UTHSCSA 164208/163074	7R01AG054076-03	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	\$0	\$45,280
Functional connectivity network in default mode regions provides the underlying infrastructure for taskbased functional co-de/activation networks	93.866	WCMC 212545-1	7R01AG057962-03	WEILL (JOAN AND SANFORD I.) MEDICAL COLLEGE OF CORNELL	\$0	\$38,574
Differential vulnerability to tauopathy in Alzheimer's disease and Frontotemporal Lobe Dementia	93.866	UCL CU20-2502	7RF1AG063521-02	UNIVERSITY COLLEGE LONDON	\$0	\$60,258
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Clinical Core	93.866	MAORO COL-263134	IUI9AG063911-01	Mayo Clinic Rochester	\$0	\$202,683
The Four Repeat Tauopathy Neuroimaging Initiative	93.866	UCSF 10375sc	R01AG038791	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	\$0	\$1,240
Combinatorial regulation of the enhancer codes in senescence	93.866	UCSD 131072963 MP Invoice/P0 S	R01AG061521	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$36,780	\$92,542
Preferred Hospital-SNF Relationships and Variation in Information Sharing Practices: Impact on Care Transition for Persons with AD/ADRD	93.866	P008759353	R03AG072215	UNIVERSITY OF MINNESOTA	\$0	\$14,364
Impact of Financial Incentives on Setting of Care for Older Adults with Alzheimer s Disease and Related Dementias	93.866	RAND SCON-00000378	R21AG069787	RAND CORPORATION	\$0	\$20,005
Asian Cohort for Alzheimer s Disease (ACAD)	93.866	UOP 580820	R56A6069130	UNIVERSITY OF PENNSYLVANIA	\$0	\$332,493
Health and Retirement Study Yrs 29-34	93.866	UMICHG 3005916841	U01AG009740	UNIVERSITY OF MICHIGAN	\$0	\$41,799
Whole Genome Sequencing in Ethnically Diverse Cohorts for the ADSP Follow Up Study (FUS)	93.866	UMIAMI SPC-001254	U01AG057659	UNIVERSITY OF MIAMI	\$0	\$295,963
Health and Retirement Study Yrs 29- 34: Harmonized Cognitive Assessment Protocol (HCAP)	93.866	UMICHG 3004832623	U01AG058499	UNIVERSITY OF MICHIGAN	\$0	\$13,623
Alzheimer s Disease Neuroimaging Initiative 3 (ADNI3)	93.866	USC 79634713	U19AG02	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$3,135
Alzheimer s Clinical Trials Consortium (ACTC) (U24)	93.866	USC 105637272	U24AG057437	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$183,501
ARMADA: Advancing Reliable Measurement in Alzheimer s Disease and cognitive Aging	93.866	NWU 60048330CU	U2CAG057441	NORTHWESTERN UNIVERSITY	\$0	\$181,885
				······································	\$46,286	\$13,998,499

R&D Cluster

Vision Research

For year ended June 30, 2022

Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	Total Expenditures (Includes Subrecipients
HEY: Hispanic Study	93.867	UTEXAS 1R21EY029605-01(01)	1R21EY029605-01	UNIVERSITY OF TEXAS - RIO GRAI VALLEY	NDE \$0	\$1,552
Optical gearbox for high speed neural recording	93.867	PURDUNIV CU21-2737	1R21EY032382-01	PURDUE UNIVERSITY	\$0	\$63,023
Translational Research for Retinal Degeneration Therapies	93.867	UPENN 583307	2R01EY017549-15	UNIVERSITY OF PENNSYLVANIA	\$0	\$14,51°
Cell Death Pathways in Glaucomatous Neurodegeneration	93.867	ROCHSTR 417821G / UR FAO GR511	2R01EY018606-11A1	UNIVERSITY OF ROCHESTER	\$0	\$265,350
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa	93.867	MSU RC108391UC	R24EY027285	MICHIGAN STATE UNIVERSITY	\$0	\$117,800
Medical Library Assistance				<u>-</u>	\$0	\$462,236
BIGDATA: Causal Inference in Large-Scale Time Series	93.879	SIT 2102255-01	2R01LM011826-08	STEVENS INSTITUTE OF TECHNOLOGY	\$0	\$131,099
Mechanistic Machine Learning	93.879	UCD CU19-2358	7R01LM012734	UNIVERSITY OF COLORADO	\$0	\$22,014
International Research and Research Training				·····	\$0	\$153,113
Capacity development for HIV and mental health research in Asia (CHIMERA)	93.989	AMFAR 110278-70-ISTA	1D43TW011302-01	AMERICAN FOUNDATION FOR AID RESEARCH (AMFAR)	S \$0	\$8,35
Bangladesh Center for Global Environmental and Occupational Health	93.989	UCHICAGO FP056723-D	1U2RTW010122-01	UNIVERSITY OF CHICAGO	\$0	\$36
PALOP Mental Health Implementation Research Training	93.989	RFMH 27610	2D43TW009675-06	RESEARCH FOUNDATION FOR MENTAL HYGIENEINC	\$0	\$13,77
KNMU-SUNY HIV Research Training Program	93.989	RFSUNY 100-1132446-74921	5DA43TW010046-03	RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK	\$0	\$-4
					\$0	\$22,460
					505,585	73,427,89
Total Pass-through Programs					\$6,186,573	\$88,656,27
Total National Institute of Health					\$92,731,776	\$676,916,00
Grand Total: Department of Health & Human Services					\$95,039,105	\$698,049,465
National Science Foundation						
Direct Awards Covid 19 Related Funding:						
COVID-19-RAPID: Viral Structure-Function-Activity in the Engineered Wastewater Cycle	47.041	CBET-2026599			\$0	\$-18,575
COVID-19-Modeling Financial Catastrophe and COVID-19 Super Spreader Events	47.049	DMS-2106433			\$0	\$101,03

For year ended June 30, 2022

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number Pa	essthrough Name	Subrecipients	R&D Cluster Total Expenditures
COVID-19-2018-2023 Ship Operations -R/V Marcus G. Langseth	Listing No. 47.050	Identfication No OCE-1829304	<u>r ass arrough contract Humbor</u> re	assanough Name	\$18,822	(Includes Subrecipients) \$1,836,490
COVID-19-RAPID: Collaborative Research: The Internet under Widespread Shelter-in-Place: Resilience, Response, and Lessons for the Future	47.070	CNS-2028550			\$0	\$15,133
COVID-19-RAPID: Flexible, Efficient, and Available Bayesian Computation for Epidemic Models	47.074	DEB-2055251			\$0	\$133,164
COVID-19-RAPID: Science and Social Networks: COVID-19 in an Urban Epicenter	47.075	SES-2029336			\$0	\$4,797
COVID-19-CIC-E: COVID Information Commons Extension for Pandemic Recovery	47.083	OIA-2139391			\$0	\$393,065
					18,822	2,465,107
Computationally-scalable Black-box Tool for Bayesian Model Estimation	47.RD	49100421C0026			\$0	\$561,676
EFRI NewLAW: Novel Approaches to RF Non-Reciprocity in Semiconductor Systems	47.041	EFMA-1641100			\$565,189	\$5,605,705
MREFC: US ATLAS HL-LHC Upgrade Project	47.049	PHY-1948993			\$5,710,301	\$23,405,596
2018-2023 Ship Operations -R/V Marcus G. Langseth	47.050	OCE-1829304			\$3,056,447	\$32,531,899
RNC: Testbed: COSMOS Interconnecting Continents (COSMIC)	47.070	OAC-2029295			\$1,019,034	\$11,756,241

For year ended June 30, 2022

Fordered Country / Door through Country						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number P	assthrough Name S	ubrecipients	<u>Total Expenditures</u> (Includes Subrecipients
euroNex Theory Team: Columbia University Theoretical Neuroscience Center	47.074	DBI-1707398			\$740,990	\$6,195,37
sting the limits of deep neural network models of human vision with optimized stimuli	47.075	BCS-1948004			\$147,537	\$3,590,70
aduate Research Fellowship Program (GRFP)	47.076	DGE-2036197			\$0	\$6,436,83:
upporting Antarctic Research with Ongoing Operations and Development of the USAP-DC oject Catalog and Data Repository	47.078	OPP-1936530			\$0	\$1,634,46(
ollaborative Research: AccelNet: Clean Air Monitoring and Solutions Network (CAMS-Net)	47.079	OISE-2020677			\$0	\$224,76
F Convergence Accelerator Track D America s Water Risk: Water System Data Pooling for mate Vulnerability Assessment and Warning System	47.083	OIA-2040613			\$586,451	\$1,511,659
otal Direct Award Programs ass-through Awards ovid 19 Related Funding:				- - -	11,825,949 \$11,844,771	93,454,91 \$95,920,01
rgineering DVID-19-RAPID: Examining Greenspace Access Impacts on Well-being During the COVID-19 Indemic	47.041	BARNARD CU-2029301	CBET-2029301 B.	ARNARD COLLEGE	\$0	\$13,39
anueniiu				- - -	\$0 0	\$13,39 <u>2</u> 13,39
ational Science Foundation						
utron Imaging of Arecibo Observatory Cable Sockets for Forensic Quantification of Wire-Socket ilure Mechanism	47.RD	TMST CU21-2339	NSF CU21-2339 TI	HORNTON TOMASETTI	\$0	\$33,23
gineering				-	\$0	\$33,232
MREF: Collaborative Research: Design of surface functionality through surface composition and ucture	47.041	CMU 1122746-425274	CBET-1921946 C	ARNEGIE MELLON UNIVERSITY	\$0	\$56,156
Institute in Dynamic Systems	47.041	UWASH UWSC13224		NIVERSITY OF VASHINGTONSEATTLE WASHINGTO	\$0 ON	\$160,24

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name Subr	ecipients	<u>Total Expenditures</u> (Includes Subrecipients)
FMNet: NYC Future Manufacturing Collective	47.041	NYU F1545-01	CMMI-2036802	NEW YORK UNIVERSITY	\$0	\$26,119
LEAP-HI: Coordinated Advance in Reproductive Engineering for Health Research (CARE4HeR)	47.041	VPTISU 480759-19020	CMMI-2053851	VIRGINIA POLYTECHNIC INSTITUTE AND STATEUNIVERSITY	\$0	\$40,344
Nanosytems Engineering Research Center for Directed Multiscale Assembly of Cellular Metamaterials with Nanoscale Precision:CELL-MET	47.041	BU 4500004144	EEC-1647837	BOSTON UNIVERSITY	\$0	\$168,906
Mid-Infrared Topological Plasmon-Polaritons with 2D Materials	47.041	UMINN A006382202	EFMA-1741660	UNIVERSITY OF MINNESOTA	\$0	\$31,079
EFRI DCheM: Digital design of a network of distributed modular and agile manufacturing systems with optimal supply chain for personalized medical treatments	47.041	PURDUNIV 10001913-050	EFMA-2132142	PURDUE UNIVERSITY	\$0	\$11,736
Self-Powered Wireless Networking Technology for Monitoring Civil Infrastructure	47.041	VATECHI 445588-19020A	IIP-1738689	VIRGINIA TECHNICAL INSTITUTE	\$0	\$5,917
I-Corps Node (Track 2): New York City Regional Innovation Node (NYCRIN)	47.041	RFCUNY CM00000546-00	IIP-1740622	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$250,709
NSF I -Corps Hub: New York Region	47.041	RFCUNY CM00007239-00	IIP-2048498	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$41,781
STTR Phase II: CMOS Integrated Piezoelectric Vapor Sensors	47.041	LELANTOS CU21-1288	IIP-2126910	LELANTOS	\$0	\$67,465
				· · · · · · · · · · · · · · · · · · ·	\$0	\$860,447
Mathematical and Physical Sciences	47.040	DOOA 07474	OUE 0000044	DEC CORD FOR COURNOR	Φ0	#05.00
Unveiling Particle Energization in Astrophysical Plasmas	47.049	RCSA 27471	CHE-2039044	RES. CORP. FOR SCIENCE ADVANCEMENT	\$0	\$25,036
NSF Center for the Chemistry of Molecularly Optimized Networks	47.049	DUKEU 333-2768	CHE-2116298	DUKE UNIVERSITY	\$0	\$130,965
MRI Consortium: Development of Magneto-Ellipsometer for the MET Beamline of the National Synchotron Light Source (NSLS-II), Brookhaven National Laboratory	47.049	NJIT 996996	DMR-1828061	NEW JERSEY INSTITUTE OF TECHNOLOGY	\$0	\$152,796
Harnessing room-temperature quantum-dot-like states in 2D materials for nanoscale nonclassical light	47.049	MONTANA G108-21-W8416	DMR-2004437	MONTANA STATE UNIVERSITY	\$0	\$159,534
TRIPODS+X: VIS: Creating an Annual Data Science Forum	47.049	GIT AWD-102378-G1	DMS-1839340	GEORGIA INSTITUTE OF TECHNOLOGY	\$0	\$10,626
STC: Center for Integration of Modern Optoelectronic Materials on Demand	47.049	UWSC 12979	NSF-2019444	UNIVERSITY OF WASHINGTONSEATTLE WASHINGTON	\$0	\$24,858
U.S. ATLAS Operations: Discovery and Measurement at the Energy Frontier	47.049	RFSUNY 76749/1136652/2M&O	PHY-1624739	STATE UNIV. OF NEW YORK STONY BROOK	\$0	\$34,029
TeV Astrophysics with the VERITAS Gamma Ray Observatory	47.049	BARNARD CU-1806554	PHY-1806554	BARNARD COLLEGE	\$0	\$4,360
Wou-MMA: Understanding Cosmic Particle Accelerators with the VERITAS and CTA Gamma-Ray Observatories	47.049	BARNARD CU-2110497	PHY-2110497	BARNARD COLLEGE	\$0	\$110,30
WoU-MMA: Studying Extreme Particle Accelerators with VERITAS and CTA	47.049	UMARY 104695-Z3831201	PHY-2200857	UNIVERSITY OF MARYLAND	\$0	\$95,24
				<u></u>	\$0	\$747,749
Geosciences						
Creating better forecasting and predictive capabilities for coastal flooding due to storms	47.050	UCAR SUBAWD002256	AGS-1755088	UNIVERSITY CORPORATION FOR ATMOSPHERIC RESEARCH	\$0	\$9,09
Advancing Carbonyl Sulfide (OCS) as an Independent Atmospheric Tracer for Global Photosynthesis through Quantification of Microbial-Mediated Sources and Sinks in Soils	47.050	UA 587365	AGS-1933280	UNIVERSITY OF ARIZONA	\$0	\$25,55 ⁷
How do Energy Fluxes Link Precipitation Variability Across the Tropical Weather-Climate Continuum?	47.050	PU SUB0000556	AGS-2123327	PRINCETON UNIVERSITY	\$0	\$3,964

Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) COL SA16-35 Ocean Sciences for Rural Communities via Informal Science Education: Pop-Up/Drill Down 47.050 DRL-1515856 Consortium for Ocean Leadership \$0 \$26,799 LDEO Operation of Continuous GNSS Stations in Russia 47.050 IRIS SU-19-1001-01-LDEO EAR-1724509 Incorporated Research Institutions for \$0 \$21,281 Seismology CAREER: Long-term Controls on Short-term Patterns of Magmatism: Towards a Unified 47.050 OREGON 2009T0A EAR-1848554 UNIVERSITY OF OREGON \$16,288 Framework for Crustal Magma Transport 47.050 ICER-1824770 YALE UNIVERSITY \$128.317 CNH-L: Volcanism, Hydrology and Social Conflict: Lessons from Hellenistic and Roman-Era Egypt \$0 GR104087(CON-80001396) UNIVERSITY OF Collaborative Research: Global Ocean Repeat Hydrography Carbon & Tracer Measurements, 47.050 UWASH UWSC8202 OCE-1433922 \$0 \$14,122 2015-2020 WASHINGTONSEATTLE WASHINGTON UNIVERSITY OF CALIFORNIA, SAN Collaborative Research: Global Ocean Repeat Hydrography, Carbon, and Tracer Measurements, 47.050 UCSD 59692302 OCE-1437015 \$0 \$410,199 47.050 WHOI A101532 OCE-1638805 WOODS HOLE OCEANOGRAPHIC \$31,162 Designing a Modern, Scalable and Sustainable Infrastructure for the National Deep Submergence \$0 Facility (NDSF) INSTITUTION Worthington Deployment 47.050 WHOI REV-A101491 OCE-1806608 WOODS HOLE OCEANOGRAPHIC \$0 \$55,033 INSTITUTION Ocean Observatories Initiative Facility Board (OOIFB) Administrative Support Office 47.050 URI 0007471/0107122 OCE-1833654-009 UNIVERSITY OF RHODE ISLAND \$42,350 \$0 Collaborative Research: Ecology and Evolution of Microbial Interactions in a Changing Ocean UALASKA UAF 20-0084 UNIVERSITY OF ALASKA FAIRBANKS \$140 47.050 OCE-1937715 \$0 Center for Chemical Currencies of a Microbial Planet (C-CoMP) 47.050 WHOI A101559 OCE-2019589 WOODS HOLE OCEANOGRAPHIC \$0 \$15,674 INSTITUTION UNIVERSITY OF CALIFORNIA, SAN \$22,921 Collaborative Research: US GOSHIP 2021-2026 Repeat Hydrography, Carbon and Tracers 47.050 UCSD KR 704508 OCE-2023545 \$0 NORTHERN ARIZONA UNIVERSITY \$20,392 Imaging Small-scale Convection and Structure of the Mantle in the South Pacific: a US 47.050 NAU 1004583-01 OCE-2051265 \$0 Contribution to International Collaboration PacificArray Collaborative Research: Seismic Imaging of Volcano Construction, Underplating and Flexure NAU 1004591-01 NORTHERN ARIZONA UNIVERSITY 47.050 OCE-2051501 \$0 \$103,764 along the Hawaii-Emperor Seamount Chain NSFPLR-NERC The Future of the Thwaites Glacier and its Contribution to Sea-Level Rise 47.050 UCOL 1556529 OPP-1738913 UNIVERSITY OF COLORADO \$15.452 \$0 NSFPLR-NERC: Ground Geophysics Survey of Thwaites Glacier 47.050 PSU 5861-CU-NSF-8934 OPP-1738934 PENNSYLVANIA STATE UNIVERSITY \$33,557 NSF-NERC: Stability and Instability of Records of External Drivers and Resulting Past Behavior of 47.050 HOUSTN R-18-0061 OPP-1738942 UNIVERSITY OF HOUSTON \$0 \$14.567 Thwaites Glacier \$0 \$1,010,624 Computer and Information Science and Engineering MoISSI Seed Software Fellows 47.070 VPTISU 479590-19020 ACI-15647580 VIRGINIA POLYTECHNIC INSTITUTE \$0 \$28,161 AND STATEUNIVERSITY UNIVERSITY OF VIRGINIA SPX: Integrating Persistent Memory in the Cloud UV GA11375.PO#2236709 CCF-1822965 \$8,356 47.070 \$0 Computing Innovation Fellows 2020 Project 47.070 CRA CIF2020-CU-64 CCF-2030859 Computing Research Association \$129,430 PAWR Platform Full Proposal-COSMOS: Cloud-Enhanced Open Software-Defined 47.070 RUTGER 0425 CNS-1827923 RUTGERS, THE STATE UNIVERSITY OF \$12,435 \$60,449 Mobile-Wireless Testbed for City-Scale Deployment NEW JERDEPARTMENT OF BADIUI UCA . Mid-Scale RI-1 (M1:IP): FABRIC: Adaptive Programmable Research Infrastructure for Computer 47.070 UNC-CH 5115815 CNS-1935966 UNIVERSITY OF NORTH CAROLINA AT \$0 \$99,823 Science and Science Applications CHAPEL HILL UNIVERSITY OF CHICAGO CPS: Security and Privacy: Medium: Detecting and Controlling Unwanted Data Flows in the UCHICA AWD100678 47.070 CNS-1953740 \$0 \$24,937 Internet of Things (SUB00000205)

R&D Cluster

For year ended June 30, 2022

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name Subre	<u>cipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Computing Innovation Fellows 2021 Project	47.070	CRA 2021CIF-Columbia-34	CNS-2127309	Computing Research Association	\$0	\$59,493
A Framework for Data Intensive Discovery in Multimessenger Astrophysics	47.070	UWIS 203405434	OAC-1934752	UNIVERSITY OF WISCONSIN	\$0	\$63,255
Collaborative Research: Predictive Risk Investigation SysteM (PRISM) for Multi-layer Dynamic Interconnection Analysis	47.070	CU 90549-11302	OAC-1940276	CORNELL UNIVERSITY	\$0	\$49,004
Biological Sciences				······································	\$12,435	\$522,908
LTER: Luquillo LTER VI: Understanding Ecosystem Change in Northeastern Puerto Rico	47.074	UPR 2019-007	DEB-1831952	UNIVERSITY OF PUERTO RICO	\$0	\$47,496
CRCNS Research Project: Solving the Neural Code of Hydra	47.074	UWASH UWSC10704	EF-1822550	UNIVERSITY OF	\$0	\$43,725
<u></u>		<u> </u>		WASHINGTONSEATTLE WASHINGTON		
The rules of microbiota colonization of the mammalian gut	47.074	BWH 2025515	NSF2025515	BRIGHAM AND WOMEN'S HOSPITAL	\$0	\$424,671
Social, Behavioral, and Economic Sciences				······	\$0	\$515,892
Benchmarking Spatial Patterns of Glacier Change	47.075	SUNYBF R1182085	BCS-1853705	STATE UNIVERSITY OF NEW YORK AT BUFFALO	\$0	\$59,577
A Geospacial Analysis of Glacier Volume Change	47.075	UUTAH 10051082-COL	BCS-1853881	UNIVERSITY OF UTAH	\$0	\$20,819
The Impact of Disruptions to Migration on Land Use and Resilience in Agricultural Systems	47.075	UCOL 1562021	BCS-2149191	UNIVERSITY OF COLORADO	\$0	\$6,396
CAREER: Trust, Cooperation, and Collective Action in Diverse Communities	47.075	NYU F6637-01	SES-2101730	NEW YORK UNIVERSITY	\$0	\$10,706
Clean Growth and Comparative Advantage	47.075	YU CON-80003513 (GR115437)	SES-2117288	YALE UNIVERSITY	\$0	\$23,526
The Effects of the World War II Research Effort on Post-war U.S. Science, Technology and Innovation	47.075	DUKE 333-2681	SMA-1951470	DUKE UNIVERSITY	\$0	\$132,970
Education and Human Resources				· · · · · · · · · · · · · · · · · · ·	\$0	\$253,994
Fostering Computational Thinking Through Neural Engineering Activities in High School Biology Classes	47.076	UCONN 147661195	DLR-2101615	UNIVERSITY OF CONNECTICUT	\$0	\$36,442
Curriculum and Community Enterprise for Restoration of Keystone Species in New York Harbor	47.076	PACEU CD0005703	DRL-1759006	PACE UNIVERSITY	\$0	\$2,539
				· · · · · · · · · · · · · · · · · · ·	\$0	\$38,981
Polar Programs						
Continuing Operations Proposal: The United States Polar Rock Repository as a Research Tool for Understanding Antarctica s Geological Evolution	47.078	OSU SPC-1000005329/GR124610	OPP-1643713	OHIO STATE UNIVERSITY	\$0	\$14,245
Mapping Antarctic Subglacial Water in Three Dimensions with Novel Electromagnetic Techniques	47.078	UCSD 96644852	OPP-1643917	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$3,056
LTER Palmer, Antarctica (PAL): Land-Shelf-Ocean Connectivity, Ecosystem Resilience and Transformation in a Sea-Ice Influenced Pelagic Ecosystem	47.078	RUTGER 1352	OPP-2023425	RUTGERS, THE STATE UNIVERSITY OF NEW JERDEPARTMENT OF RADIOLOGY	\$0	\$4,012
				<u></u>	\$0	\$21,313
Office of International Science and Engineering PIRE: Climate Research Education in the Americas using Tree-Ring and Cave Sediment Examples (PIRE-CREATE)	47.079	SUNYA 18-28-79761	OISE-1743738	STATE UNIVERSITY OF NEW YORK AT ALBANY	\$0	\$305,795

For year ended June 30, 2022

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	R&D Cluster Total Expenditures
AccelNet:3D Concrete Printing Network (3DConnect) - An International Alliance for Concrete Additive Manufacturing	Listing No. 47.079	Identfication No ASUB00000615	OISE-2020095	ARIZONA STATE UNIVERSITY	\$0	(Includes Subrecipients
					\$0	\$316,96
Integrative Activities						
NSF Convergence Accelerator Workshop: Integrated Research on Societal Infrastructure Resilience to Stressing Events through Interdisciplinary and Transdisciplinary Convergence	47.083	USC SCON-00002728	OIA-2124634	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$4,99
PIRE: Dust Simulated Drawdown of Atmospheric CO2 as a Trigger for Northern Hemisphere Glaciation	47.083	ROCHSTR 416748	OISE-1545859	UNIVERSITY OF ROCHESTER	\$0	\$86,59
					\$0	\$91,58
					12,435	4,413,69
otal Pass-through Programs					\$12,435	\$4,427,08
Total National Science Foundation					\$11,857,206	\$100,347,10
National Aeronautics & Space Administration						
Direct Awards						
Covid 19 Related Funding:						
•						
COVID-19-Decision and Information System for the Coastal Waters of Oman (DISCO) - an integrative tool for Managing Coastal Resources under Changing Climate	43.001	NNX17AG66G			\$0	\$57,16
						57,16
Socioeconomic Data and Applications Distributed Active Archive Center (DAAC) for the EOS Data and Information Systems (EOSDIS)	43.RD	80GSFC18C0111			\$0	\$5,164,33
Interdisciplinary Research on Earth and Planetary Systems Modeling, the Impacts of Climate Change, and-the Habitability of Other Worlds	43.001	80NSSC20M0282			\$931,405	\$13,258,13
Physical and Biological Modulators of Space Radiation Carcinogenesis: Mechanistically-Based Model D	43.003	NNX16AR81A			\$0	\$61,47
Circulating miRNAs Provides Systemic Host Response to Microgravity: Utilizing GeneLab datasets o identify molecular targets for spaceflight studies	43.007	80NSSC19K1658			\$0	\$3
Dual Desalination/Concentrator Microfluidic Device for Amino Acid Sample Preparation for Search-For-Life Missions	43.012	80NSSC19K1180			\$0	\$71,44

For year ended June 30, 2022

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name S	ubrecipients 931,405	Total Expenditures (Includes Subrecipients) 18,555,430
Total Direct Award Programs				=	\$931,405	\$18,612,598
Pass-through Awards				_		
Covid 19 Related Funding:						
Science						
COVID-19-Ecological and Sociodemographic Determinants and Impacts of Urbanization and Restoration on Intertwined Urban-Wetland-Estuarine Systems	43.001	CCONY CM00001790-04	80NSSC17K0258	City College of New York	\$0	\$31,554
COVID-19-Modeling the Economic Impact of COVID-19 with EO-Based Technologies	43.001	IMAGE 20-94-05:03	80NSSC20K1810	ImageCat, Inc.	\$0	\$5,906
					\$0	\$37,460
				-	0	37,460
National Aeronautics & SpaceAdministration						
Geostationary Littoral Imaging and Monitoring Radiometer (GLIMR) Instrument	43.RD	UNH L0141	80LARC21DA002	UNIVERSITY OF NEW HAMPSHIRE	\$0	\$28,200
Bridging the Gap Between Galaxy and Star Formation with Star Clusters	43.RD	HST-HF2-51438.002-A	NAS5-26555	Space Telescope Science Institute	\$0	\$321,122
Operation, Densification, and Upgrade of Continuous GNSS Stations in Russia in the Framework of MOU between LDEO & JPL	43.RD	JPLCIT 1452786	NAS7-03001	JET PROPULSION LAB, CALIFORNIA INSTITUTEOF TECHNOLOGY	\$14,102	\$14,102
High Resolution Spectroscopy of the Spectral Feature in CCO J0821-4300	43.RD	SAO GO0-21055X	NAS8-03060	Smithsonian Astrophysical Observatory	, \$0	\$224,643
CYGNSS Estimates of Surface Heat Fluxes in Low-Latitude Extratropical Cyclones	43.RD	JPLCIT 1616842	NASA CU18-2642	JET PROPULSION LAB, CALIFORNIA INSTITUTEOF TECHNOLOGY	\$0	\$15,683
Weather Regime Tools for Subseasonal to Seasonal Forecasting of California Atmospheric Ridging Events	43.RD	JPLCIT 1649520	NASA CU19-2536	JET PROPULSION LAB, CALIFORNIA INSTITUTEOF TECHNOLOGY	\$0	\$67,130
Mapping the Baryonic Majority: Comprehensive Multi-Mission Analysis of the Circumgalactic Medium (CGM) and the Intergalactic Medium (IGM)	43.RD	JPLCIT 1663357	NASA CU20-3055	JET PROPULSION LAB, CALIFORNIA INSTITUTEOF TECHNOLOGY	\$0	\$25,843
Columbia University Participation in The Nuclear Spectroscopic Telescope Array (NuSTAR): Bringing the High Energy Universe Into Focus (Bridge Phase)	43.RD	CALTECH S376760	NNG08FD60C	CALIFORNIA INSTITUTE OF TECHNOLOGY	\$0	\$259,431
WFIRST Infrared Nearby Galaxy Survey	43.RD	UWASH UWSC9083	NNG16PJ28C	UNIVERSITY OF WASHINGTONSEATTLE WASHINGTON	\$0 ON	\$11,072
Science					\$14,102	\$967,226
TREX: Toolbox for Research and Exploration	43.001	PSINST 1523 Columbia Universit	80ARC017M00005	PLANETARY SCIENCE INSTITUTE	\$0	\$60,368
Ecological and Sociodemographic Determinants and Impacts of Urbanization and Restoration on Intertwined Urban-Wetland-Estuarine Systems	43.001	CCONY CM00001790-04	80NSSC17K0258	City College of New York	\$0	\$14,995
SLICE: Spectral Signs of Life in Ice	43.001	MONTANA G104-19-W7250	80NSSC18K0814	MONTANA STATE UNIVERSITY	\$0	\$26,772
Participation in the Effects of Density Fluctuations on Alfven Wave Turbulence in a Coronal Hole Program	43.001	SAO SV9-89006	80NSSC18K1207	Smithsonian Astrophysical Observatory	\$0	\$240
Europa STI - Exploring Communication Techniques and Strategies for Sending Signals Through the ICE (STI) for an Ice-Ocean Probe	43.001	JH 155891	80NSSC19K0613	JOHNS HOPKINS UNIVERSITY	\$0	\$174,057
Ag Out An Enhanced IMERG-based Agricultural Outlook System to Support Food Security and Agriculture in the Developing World	43.001	UCSB KK1981	80NSSC19K0686	UNIVERSITY OF CALIFORNIA, SANT BARBARA	A \$0	\$25,950

For year ended June 30, 2022

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name S	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Open Critical Infrastructure Exposure for Disaster Forecasting, Mitigation, and Response	43.001	IMAGE 19-94-03:03	80NSSC19K1112	ImageCat, Inc.	\$0	\$6,076
Nano-infrared identification of phosphorous in returned samples	43.001	UCSD 702975	80NSSC19K1210	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$241,267
Three-Dimensional Observational Estimates of Mesoscale Eddy Kinetic Energy in the Global Ocean: Understanding the Energetics of the Climate System	43.001	UWASH UWSC11553	80NSSC19K1252	UNIVERSITY OF WASHINGTONSEATTLE WASHINGT	\$0 ON	\$13,874
Exploring Ocean Worlds: Ocean System Science to Support the Search for Life	43.001	WHOI A101471	80NSSC19K1427	WOODS HOLE OCEANOGRAPHIC INSTITUTION	\$0	\$28,619
Using Earth Observations and Statistical Models to Enhance Drought, Food Security, and Agricultural Outlooks in Eastern and Southern Africa	43.001	UCSB KK2043	80NSSC20K0159	UNIVERSITY OF CALIFORNIA, SANT BARBARA	ΓA \$0	\$29,737
Inferring Ocean Transport from SWOT	43.001	NYU F1533-01	80NSSC20K1142	NEW YORK UNIVERSITY	\$0	\$42,778
Oxidizing Oases in the Paleoarchean Moodies Group, Barberton Greenstone Belt, South Africa	43.001	TAMU M2101726	80NSSC21K0443	TEXAS A&M UNIVERSITY	\$0	\$42,372
Advancing Remote Sensing of Microplastics on the Surface Ocean	43.001	UCONN 434859	80NSSC21K0515	UNIVERSITY OF CONNECTICUT	\$0	\$7,495
Technology for Sending Signals Through the Ice (STI Tech) on Ocean Worlds	43.001	JH 172059	80NSSC21K0995	JOHNS HOPKINS UNIVERSITY	\$0	\$103,607
Gas and Galaxies Across Cosmic Time with Enzo-E	43.001	STSCI 52577	80NSSC21K1053	Space Telescope Science Institute	\$0	\$19,079
High resolution imagery to train and validate deep learning models of inundation extent for multiple satellite sensors	43.001	ASU 639401	80NSSC21K1163	ARIZONA STATE UNIVERSITY	\$0	\$15,891
Investigating the roles of turbulences and reconnection in generating supra thermal seed populations for SEP events	43.001	PU SUB0000545	80NSSC21K1326	PRINCETON UNIVERSITY	\$0	\$31,399
Observational Estimates of Radiative Forcing by Greenhouse Gases in the Presence of Clouds	43.001	UMARY NASA0070-01	80NSSC21K1968	UNIVERSITY OF MARYLAND	\$0	\$11,224
Pangeo ML - Open Source Tools and Pipelines for Scalable Machine Learning Using NASA Earth Observation Data	43.001	CBP SUBAWD003	80NSSC21M0065	CARBONPLAN	\$0	\$83,067
Remote sensing of the ocean surface refractive index and oil spill detection for the PACE mission	43.001	TRI CU19-2545	NASA CU19-2545	TERRA RESEARCH INC	\$0	\$18,920
A Multi-Frequency Campaign to Probe Uranus Dynamics and Deep Atmospheric Structure	43.001	UCB 00009673	NNX16AK14G	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$24,673
Valuation of Applications Benefits Linked with Earth Science (VALUABLES) Consortium	43.001	REFF 1619	NNX17AD26A	RESOURCES FOR THE FUTURE	\$0	\$29,788
Fortunation .				················ <u>·</u>	\$0	\$1,052,248
Exploration pace radiation-induced persistent estrogenic response and risk of breast cancer development	43.003	GU 424468 GR413893-CU	80NSCC19K1649	GEORGETOWN UNIVERSITY	\$0	\$62,141
Space radiation and gastrointestinal cancer: A comprehensive strategy for risk assessment and model development	43.003	GU 410967 GR410946-CU-Project	NNX15AI21G	GEORGETOWN UNIVERSITY	\$0	\$65,680
miRNA Signature Detection and Countermeasures Against HZE Radiation Exposure for Tissue Degeneration	43.003	BCMH 7000000822	NNX16A069A	BAYLOR COLLEGE OF MEDICINE HOUSTON	\$0	\$20,972
Human Multi-tissue Platform to Study Effects of Space Radiation and Countermeasures/RAD0104	43.003	BCMH 7000001227	NNX16AO69A	BAYLOR COLLEGE OF MEDICINE HOUSTON	\$0	\$987,328
				· · · · · · · · · · · · · · · · · · ·	\$0	\$1,136,121
Office of Stem Engagement (OSTEM) NASA STEM Pathway Activities-Consortium for Education (NSPACE)	43.008	OKSU SPOCS-CU	80NSSC17M0021	OKLAHOMA STATE UNIVERSITY	\$0	\$15,583
NADA STEIN FAUNMAY ACUNIUS-CONSONIUM IOI EUUCAUOM (NOPACE)	43.000	ON30 3F0C3-CU	OUINGGC I / IVIUUZ I	ONLAHOIVIA STATE UNIVERSITY	ΦU	\$15,583

For year ended June 30, 2022

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	R&D Cluster Total Expenditures
New York Space Grant Consortium	Listing No. 43.008	Identfication No CU 90830-20366	80NSSC20M0096	CORNELL UNIVERSITY	\$0	(Includes Subrecipients) \$36,371
				· · · · · · · · · · · · · · · · · · ·	<u> </u>	<u></u>
					14,102	\$51,954 3,207,549
Total Pass-through Programs					\$14,102	\$3,245,009
Total National Aeronautics & Space Administration					\$945,507	\$21,857,607
Department of Energy						
Direct Awards						
MOU/BNL for Oleg Gang	81.RD	BNL CU16-2135			\$0	\$290,016
HIGH BETA TOKAMAK RESEARCH	81.049	DE-FG02-86ER53222			\$1,410,183	\$13,559,155
						ψ10,555,155
Harnessing Microbial Batteries for Efficient, Sustainable Water Treatment and Recycling in Rural Areas	81.086	DE-EE0009506			\$33,411	\$349,164
GIS-based Graphical User Interface Tool for Analysis of Solar Thermal Desalination Systems and	81.087	DE-EE0008401			\$0	\$84,532
High Potential Implementation Regions						
Next Generation Fiber-Encapsulated Nanoscale Hybrid Materials for Direct Air Capture with Selective Water Rejection	81.089	DE-FE0031963			\$135,604	\$409,052
PINE: Photonic Integrated Network Energy Efficient Datacenters	81.135	DE-AR0000843			\$1,104,258	\$4,337,603
					2,683,456	19,029,522
Total Direct Award Programs					\$2,683,456	\$19,029,522
Pass-through Awards						
Department of Energy						
Infrared Nano-Imaging of Metastable States	81.RD	LBNL 7431739	DE-AC02-05CH11231	LAWRENCE BERKELEY NATIONAL LABORATORY	- \$0	\$120,798

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name Su	<u>ibrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Deep Underground Neutrino Experiment (DUNE)	81.RD	FERMI 665837	DE-AC02-07CH11359	Fermi National Accelerator Laboratory	\$0	\$5,147
Hybrid Quantum/Classical Algorithms for Photochemistry and Nonadiabatic Dynamics	81.RD	SNAL No. 200586	DE-AC02-76SF00515	SLAC NATIONAL ACCELERATOR LABORATORY	\$0	\$184,224
Design of Carbide and Bimetallic Catalysts and Electrocatalysts	81.RD	BNL NO.233521	DE-AC02-98CH10886	Brookhaven National Laboratory	\$0	\$251,018
GO ORNL PROGRAM for Nikhil Rampal	81.RD	ORNL 4000160263	DE-AC05-00OR22725	OAK RIDGE NATIONAL LABORATORY	\$0	\$78,933
Emissions-MIP - An Emissions Sensitivity Evaluation	81.RD	PNNL 479284	DE-AC05-76RL01830	Pacific Northwest National Laboratory	\$0	\$37,734
Center for Thermal Energy Transport under Irradiation	81.RD	BEA No. 208385	DE-AC07-05ID14517	BATTELLE ENERGY ALLIANCE, LLC	\$0	\$309,878
Pathways to Achieving Pipe Parity for Solar Thermal Desalination of High Salinity Brines	81.RD	NREL SUB-2022-10085	DE-AC36-08GO28308	National Renewable Energy Laboratory	\$0	\$87,497
Secure Biosystems from Sequence to Cell to Populations	81.RD	NO. B640460	DE-AC52-07NA27344	Lawrence Livermore National Laborator	y \$0	\$423,229
AURORA: Autonomous and Resilient Operation of Energy Systems with Renewables	81.RD	SIEMENS 173-1	DE-EE0008768	SIEMENS CORPORATE RESEARCH, INCORPORATED	\$0	\$144,933
Climate Attribution through Enhanced Fingerprinting	81.RD	SANDIA 2331335	DE-NA0003525	SANDIA NATIONAL LABORATORIES	\$0	\$11,120
sPHENIX: digitizer readout system production	81.RD	BNL 382403	DE-SC0012704	Brookhaven National Laboratory	\$0	\$2,340,282
Flow Ordering and Hierarchical Bottleneck Identification for High Speed Data Networks	81.RD	RLABS CU20-0100	DE-SC0019523	RESERVOIR LABS	\$0	\$29,302
Dual Function Materials for Direct Air Capture of CO2	81.RD	SUSTEON S-038-1	DE-SC0020795	SUSTEON INC	\$0	\$117,648
Photonic Memory Controller Module (P-MCM)	81.RD	FРНОТО МСМ-Р2В	DOE CU18-0610	FREEDOM PHOTONICS	\$0	\$235,557
Establishing Approaches for Creating 3D Ordered Hierarchical Materials Through a Combination of DNA-Programmable Assembly at Nanoscale and Atomic Templating for Sub-NM Scale	81.RD	BNL 366419	DOE CU18-2347	Brookhaven National Laboratory	\$0	\$60,440
sPHENIX EMCAL Detector Upgrade at RHIC	81.RD	BNL 356535	DOE CU19-0001	Brookhaven National Laboratory	\$0	\$666
sPHENIX Minimum Bias Detector at RHIC	81.RD	BNL 354298	DOE CU19-0187	Brookhaven National Laboratory	\$0	\$414
Photonic-Storage Subsystem Input/Output (P-SSIO) Interface	81.RD	FPHOTO S7146-01	DOE CU19-0376	FREEDOM PHOTONICS	\$0	\$260,553
Joint Appointment Agreement FY22 for Prof. Kumar	81.RD	BNL 22441	DOE CU21-1284	Brookhaven National Laboratory	\$0	\$110,537
Synthesis of Nanoporous Membranes by Self-Assembly Using Spray Deposition	81.RD	BNL 401599	DOE CU21-2635	Brookhaven National Laboratory	\$0	\$41,358
Machine-Learned Design of Experiments for Optimal Model Calibration	81.RD	SANDIA 2306877	DOE CU21-3153	SANDIA NATIONAL LABORATORIES	\$0	\$61,140
Machine-Learned Anisotropic Constitutive Modeling for an Aluminum Alloy	81.RD	SANDIA 2340278	DOE CU21-4014	SANDIA NATIONAL LABORATORIES	\$0	\$19,636
Graduate Student Support Creating designated 3D structural matrices	81.RD	BNL 409302	DOE CU21-4062	Brookhaven National Laboratory	\$0	\$18,433
Tackling Solid-State Electrochemical Interfaces from Structure to Function Through High Performance Computing and Machine Learning	81.RD	BNL 414881	DOE CU22-1196	Brookhaven National Laboratory	\$0	\$1,583

Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	Total Expenditures (Includes Subrecipients
_			•	\$0	\$4,952,060
81.RD	BNL CU08-9027	DE-AC02-98CH10886	Brookhaven National Laboratory	\$0	\$108,203
			-	\$0	\$108,203
81.049	SP0027267-PROJ0011442	DE-SC0000989	NORTHWESTERN UNIVERSITY	\$0	\$180,886
81.049	UD 32826	DE-SC0001004	UNIVERSITY OF DELAWARE	\$0	\$118,08
81.049	RFSUNY 68856	DE-SC0012673			\$304,075
81.049	PSU 5933-CU-USDOE-8933	DE-SC0018933	PENNSYLVANIA STATE UNIVERSI	TY \$0	\$48,139
81.049	SUNYSB 82192/1148574/2	DE-SC0019212	STATE UNIV. OF NEW YORK STOR BROOK	NY \$0	\$179,04
81.049	CWRU RES513723	DE-SC0019409	CASE WESTERN RESERVE UNIVERSITY	\$0	\$139,47 ⁻
81.049	CU 86856-11154	DE-SC0019481	CORNELL UNIVERSITY	\$0	\$234,273
81.049	PSU S001043-DOE	DE-SC0021004	PENNSYLVANIA STATE UNIVERSI	TY \$0	\$72,549
81.049	RFCUNY CM00006743-00	DE-SC0022036	GRADUATE CENTER- CITY UNIVERSITY OF NEWYORK	\$0	\$58,310
81.049	CALTECH S534322	DE-SC0022088	CALIFORNIA INSTITUTE OF TECHNOLOGY	\$0	\$109,92
sk 81.049	PSU S002342-USDOE	DE-SC0022141	PENNSYLVANIA STATE UNIVERSI	TY \$0	\$72,840
81.049	CWRU RES516682	DE-SC0022214	CASE WESTERN RESERVE UNIVERSITY	\$0	\$11,020
			<u>-</u>	\$0	\$1,528,612
al 81.086	GMAUTO 4301260198	DE-EE0009204	GENERAL MOTORS	\$0	\$343,400
e 81.086	CU 137181-20864	DE-EE0009391	CORNELL UNIVERSITY	\$0	\$77,54°
81.086	OSRAMOS CU21-0426	DE-EE0009692	AMS-OSRAM USA INC.	\$0	\$114,69
			······································	\$0	\$535,635
81.087	UCI 2020-1298	DE-EE0008838	UNIVERSITY OF CALIFORNIA, IRV	INE \$0	\$217,842
				\$0	\$217,842
					\$143,433
	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	Listing No. Identification No 81.RD BNL CU08-9027 81.049 SP0027267-PROJ0011442 81.049 UD 32826 81.049 PSU 5933-CU-USDOE-8933 81.049 SUNYSB 82192/1148574/2 81.049 CWRU RES513723 81.049 CU 86856-11154 81.049 PSU S001043-DOE 81.049 RFCUNY CM00006743-00 81.049 CALTECH S534322 Sk 81.049 PSU S002342-USDOE 81.049 CWRU RES516682 81.049 CWRU RES516682 81.049 CWRU RES516682 81.049 CWRU RES516682	B1.049 SP0027267-PROJ0011442 DE-SC0000989 B1.049 UD 32826 DE-SC0001004 B1.049 RFSUNY 68856 DE-SC0012673 B1.049 PSU 5933-CU-USDOE-8933 DE-SC0018933 B1.049 SUNYSB 82192/1148574/2 DE-SC0019212 B1.049 CWRU RES513723 DE-SC0019409 B1.049 CU 86856-11154 DE-SC0019481 B1.049 PSU S001043-DOE DE-SC0022036 B1.049 RFCUNY CM00006743-00 DE-SC0022036 B1.049 CALTECH S534322 DE-SC0022088 B1.049 PSU S002342-USDOE DE-SC0022141 B1.049 CWRU RES516682 DE-SC0022214 B1.049 CWRU RES516682 DE-EE0009391 B1.086 GMAUTO 4301260198 DE-EE0009692 B1.087 UCI 2020-1298 DE-EE0008838	Listing No. Identification No	B1.049 SUNYSB 82192/1148574/2 DE-SC00019212 STATE UNIV. STORY ST

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	R&D Cluster Total Expenditures
Bench-Scale Development of a Novel Direct Air Capture Technology Using High-Capacity Structured Sorbents	<u>Listing No.</u> 81.089	Identfication No SUSTEON SUST000050	DE-FE0032118	SUSTEON INC	\$0	(Includes Subrecipients \$57,43
Collaborative Development Projects - Photonic Memory Controller Module (P-MCM)	81.089	PLCC CU18-0520	DOE CU18-0520	PLC CONNECTIONS	\$0	\$238,58
					\$0	\$439,457
Defense Nuclear Nonproliferation Research Consortium for Monitoring, Technology, and Verification (MTV)	81.113	UMICH SUBK00009795	DE-NA003920	UNIVERSITY OF MICHIGAN	\$0	\$249,21
					\$0	
Predictive Science Academic Alliance Program						
Center for Micromorphic Multiphysics Porous and Particulate Materials Simulations Within Exascale Computing Workflows	81.124	UCOL 1559906	DE-NA0003962	UNIVERSITY OF COLORADO	\$0	\$62,70
Advanced Research Projects Agency - Energy					\$0	\$62,700
Vinimally Orchestrated Storage Technology for Duration Addition to Electricity Storage	81.135	PRIMUS CU18-3145	DE-AR0000990	PRIMUS POWER	\$0	\$-203,93
An Iterative Approach for Solving the SCOPF Problem Applying LP, SOCP and NLP Subproblems	81.135	NWU 60052596 CU	DE-AR0001077	NORTHWESTERN UNIVERSITY	\$0	\$27,78
					\$0	\$-176,150
					0	7,917,57
Total Pass-through Programs						\$7,917,57
Total Department of Energy					\$2,683,456	\$26,947,09
Department of Defense						
Direct Awards Covid 19 Related Funding:						
COVID-19-COVID-19 Lung Injury, ARDS, and Thrombosis: Acute Disease and Long-Term Subphenotypes	12.420	W81XWH2110216			\$18,534	\$547,79
						
					18,534	547,79
BISC: Bioelectronic Interfacing to Sensory Cortex with massive, fully implanted, flexible wireless CMOS surface recording and stimulating arrays	12.RD	N66001-17-C-4002			\$1,864,576	\$4,024,43
Reengineering the Nervous System of a Cnidarian	12.300	N00014-20-1-2828			\$200,876	\$4,853,12

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
Development of Inhibitors of the Aging Process of Organophosphate Adducts of AChE	12.351	HDTRA1-16-1-0053			\$27,770	\$116,483
A novel bioengineering approach for generation of functional lungs in swine	12.420	W81XWH2010823			\$595,391	\$14,671,662
A Symbiotic Agent-Based Network Platform Linking Expert Knowledge and Machine Learning for Systemic Risk Mitigation	12.431	W911NF1910013			\$740,396	\$2,937,766
Physiologically-informed Just-in-time Agent Intervention Facilitates Trust-formation in Heterogeneous Teams	12.630	W911NF2120125			\$0	\$85,957
Ensembles of Molecules in Controlled Quantum States for Quantum Simulations, Ultracold Reactions, and Precision Metrology	12.800	FA9550-21-1-0069			\$1,415,473	\$2,756,194
TRAUMAS: Treatment and recovery augmented with electrical and ultrasound- mediated actuation and sensing	12.910	D20AC00004			\$2,834,554	\$7,999,351
Total Direct Award Programs Pass-through Awards					7,679,036 \$7,697,570	\$37,444,967 \$37,992,763
Covid 19 Related Funding:						
Department of the Army, Army Medical Research and Materiel Command COVID-19-Layer-by-Layer Multiple Antigen Nano-delivery Platform for SARSCoV-2 Vaccines	12.RD	LUNA 344103	W81XWH-21-C-0057	LUNA LABS USA LLC	\$0	\$279,724
					. <u></u>	\$279,724
					0	279,724
Department of Defense						
Columbia Entrepreneurship, Innovation, and Design Support for MD5 Staff	12.RD	CMI2 1904-01-012-01	47QTCA18D00DK	CIVIL-MILITARY INNOVATION INSTITUTE	\$0	\$17,192
Reverse Engineering Neocortical Intelligence	12.RD	BCM PO7000000428	D16PC0000	BAYLOR COLLEGE OF MEDICIN HOUSTON	≣ \$0	\$25,837
Deep Intermodal Video Analytics	12.RD	UMARY 92485-Z9618204	D17PC00345	UNIVERSITY OF MARYLAND	\$0	\$180,842
Engineered Living Materials	12.RD	ECODES CU16-2615	DARPA-BAA-16-50	ECOVATIVE DESIGN	\$0	\$584,210

The Trustees of Columbia University in the City of New York Schedule of Expenditures of Federal Awards For year ended June 30, 2022

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	Total Expenditures
	Listing No.	Identfication No	<u> </u>		<u> </u>	(Includes Subrecipients
Optimizing Micro Resonator s Based Sensor	12.RD	IMO PO#4441083200	DOD CU20-2364	ISRAELI MINISTRY OF DEFENSE	\$21,543	\$52,174
ong Term Potentiation Deficits after Repetitive Primary Blast	12.RD	SURVICE S17-095006	DOTC-17-01-INIT0086/OTA 2014-3	SURVICE ENGINEERING	\$0	\$-4
ong Term Potentiation Deficits after Repetitive Primary Blast	12.RD	SURVICE S21-095010	DOTC-19-04-INIT4280	SURVICE ENGINEERING	\$0	\$29,43
ligh Performance Computing (HPC) Network Topologies Utilizing Reconfigurable Photonics witches	12.RD	BAHI A10119/PROJECT AB10438	FA807518D0004	BOOZ ALLEN HAMILTON INC	\$0	\$148,03
2-13636 Project OWL Phase II SBIR	12.RD	OWL CU20-3530	FA864920P1017	PROJECT OWL LLC	\$0	\$34,35
Exploring Bile Acid Metabolizing Gut Bacteria as a Modulator of Human Performance	12.RD	S-168-4X5-001	FA8650-19- D-6109/FA8650-20-F-	UES INC	\$0	\$35,70
rogressive Damage Model Benchmarking for Ceramic Matrix Composite Components in Turbine ingine Applications	12.RD	ARTCOS 195208-19-05-C1	FA8650-19-C-5208	ARCTOS TECHNOLOGY SOLUTION	NS \$0	\$40,93
imultaneous Transmit and Receive Wideband Adaptive Reconfigurable ielf-Interference-canceller (STARWARS)	12.RD	BAESNSS 1106443	FA8650-21-C-7002	Bae Systems National Security SolutionsInc	\$0	\$213,839
suppression by Reflective Filtering using Wideband N-Way Circulators (SURFIN)	12.RD	RAYTHN 4202508979	FA8650-21-C-7008	RAYTHEON COMPANY	\$0	\$95,53.
nvestigating methods for estimating causally identifiable functionals	12.RD	CMU 22-00092-SUB-000	FA8702-15-D0002	CARNEGIE MELLON UNIVERSITY	\$0	\$100,58
hotonic IC (PIC) and Laser Source Development for Silicon Photonic Designs	12.RD	INTEL CW2070504	HR00111830002	INTEL CORPORATION	\$0	\$865,92
POCHS: Efficient Programmability of Cognitive Heterogeneous Systems	12.RD	IBM CW2912424	HR0011-18-C-0122	IBM THOMAS J WATSON RES. CTF	R. \$0	\$372,14
ROMAGER: Formal Reasoning OverMachine-code Assets, Given with Explicit Reticence	12.RD	GALOIS No. 2020-008	HR00111950076	GALOIS INC	\$0	\$106,48
ecure Handling of Isolated Executables without Leaking Data (SHIELD)	12.RD	PERSPECTA PO-0018620	HR0011-19-S0017	PERSPECTA LABS	\$0	\$158,06
PTICS	12.RD	PERSPECTA PO-0020017	HR0011119S0082	PERSPECTA LABS	\$0	\$557,16
Detection of novel attacks from unknown toolchain through embedding designs / reverse attack ector	12.RD	GEGR 401168808	HR00112090133	GE GLOBAL RESEARCHLOPMENT COMPANY	\$0	\$9,41
emantic Information Defender	12.RD	KITWARE K003088-00-S01	HR001120C0123	Kitware, Inc.	\$0	\$644,66
OCUS Automated Interpretation (POCUS AI)	12.RD	NETRIAS 20-001	HR00112190078	NETRIAS	\$0	\$62,07
ast Event-based Neuromorphic Camera and Electronics	12.RD	ASUB00000852	HR0011-21-C-0134	ARIZONA STATE UNIVERSITY	\$0	\$130,11
I-nitride flat optics device for broadband infrared to visible nonlinear conversion	12.RD	BBN 90224	HR0011-21-C-0244	BBN TECHNOLOGIES CORP.	\$0	\$134,28
NGEL: Assistant Navigating a Graphical Event Library	12.RD	KITWARE K003623-00-S02	HR001122C0007	Kitware, Inc.	\$0	\$87,69
SIS: Implantable bioluminescence interface for an all-optical neuroprosthesis to the visual cortex	12.RD	JBPL 295-B Phase III	N66001-17-C-4012	JOHN B. PIERCE LABORATORY	\$0	\$61,89
agnetic Optical and Acoustic Neural Access (MOANA) System	12.RD	RICEUNIV R1A26D	N6600119C4020	RICE UNIVERSITY	\$0	\$798,28
	12.RD	GIT AWD-000785-S1	N6600120C4002	GEORGIA INSTITUTE OF TECHNOLOGY	\$0	\$429,24

For year ended June 30, 2022

<u>ients</u> \$0	Total Expenditures (Includes Subrecipients
\$0	****
	\$436,822
\$0	\$99,642
\$0	\$3,86
\$0	\$2,88
\$0	\$19,63
\$0	\$155,17
\$0	\$42,430
\$0	\$75,000
\$0	\$27,91
1,543	\$6,839,492
••	\$500.00
\$0 	\$520,02
\$0	\$12,98
\$0	\$152,85
\$0	\$398,630
\$0	\$116,94
\$0	\$3,90
\$0	\$47,310
\$0	\$1,252,658
\$0	\$210,39
\$0	\$210,391
\$0	\$75,826
\$0	\$75,828
\$0	\$11,99
	\$0 \$0 \$0 \$0 \$0 \$0 \$0 \$0 \$0 \$0 \$0 \$0 \$0 \$

The Trustees of Columbia University in the City of New York Schedule of Expenditures of Federal Awards For year ended June 30, 2022

R&D Cluster Federal Grantor / Pass-through Grantor Assistance Award Pass-through Contract Number Passthrough Name Subrecipients Total Expenditures Listing No. Identfication No (Includes Subrecipients) Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus 12.420 RFMH 26965 W81XWH1810221 RESEARCH FOUNDATION FOR \$0 \$70,878 MENTAL HYGIENEINC W81XWH1820032 CORNELL UNIVERSITY \$63.035 Prostate Cancer Clinical Consortium Clinical Research Site: TargetedTherapies 12.420 WCMC 220154 \$0 HIV Immunoprophylaxis with bispecific antibody 12.420 HJFAMM 5795 W81XWH-18-2-0400 Jackson (Henry M.) Foundation for the \$125,009 Advancement of Military Medicine Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab WCMC 220755 W81XWH2010706 WEILL (JOAN AND SANFORD I.) \$49,715 12 420 \$0 MEDICAL COLLEGE OF CORNELL Determinants of Aneurysm Formation in Autosomal Dominant Polycystic Kidney Disease 12,420 UMARY F303852-1 W81XWH2010762 UNIVERSITY OF MARYLAND \$0 \$136,442 W81XWH2110762 Novel complex structural variants and epigenetic alterations link the genomes of prostate cancer 12.420 WCMC 210043 WEILL (JOAN AND SANFORD I.) \$0 \$13,893 MEDICAL COLLEGE OF CORNELL in African Americans with outcome disparity \$0 \$470,963 **Basic Scientific Research** 12.431 UNIVERSITY OF UTAH \$0 Bio-inspired Design of Adaptive Catalysis Center UUTAH10034220-S4 W911NF-14-1-0263 \$604,450 Fractional PDEs for Conservation Laws and Beyond: Theory, Numerics and Applications 12.431 BROWN 00000825 W911NF1510562 **BROWN UNIVERSITY** \$0 \$73,793 Multiscale Integration of Neural, Social, and Network Theory to Understand and Predict 12.431 UPENN 574211 W911NF1810244 UNIVERSITY OF PENNSYLVANIA \$0 \$121,691 Transitions from Illness to Wellness: A Proof of Concept with Mindfulness, Hypnosis and Alcohol Towards a Multi-Scale Theory on Coupled Human Mobility and Environmental Change 12.431 UFLRDA UFDSP00012221 W911NF1810267 UNIVERSITY OF FLORIDA \$0 \$230,931 Algorithms and Distribution-Free Models for Social and Information Networks 12.431 UCSCRUZ A19-0477-S001 W911NF1910294 UNIVERSITY OF CALIFORNIA SANTA \$172,797 CRU7 USC SCON-00002260 W911NF-21-1-0327 UNIVERSITY OF SOUTHERN 12.431 \$92.864 Anomalous Polar Textures in Quasi- 1D Chalcogenides and Heterostructures \$0 CALIFORNIA HARVARD 134396-5117991 W911NF2120147 HARVARD UNIVERSITY \$0 \$308.641 Multifunctional devices in precisely engineered van der Waals homojuctions 12.431 \$0 \$1,605,167 Basic, Applied, and Advanced Research in Science and Engineering Micro and Meso Signatures of Success in Human-Autonomy Teams 12.630 NU 504149-78051 W911NF1920135 NORTHEASTERN UNIVERSITY \$0 \$291,700 12.630 UDELAWARE 59130 W911NF2020080 UNIVERSITY OF DELAWARE \$0 \$22,499 Neural Network Models of Competency Status To Enhance Human-Agent Team Performance \$0 \$314,199 **Uniformed Services University Medical Research Projects** HU00011920008 Jackson (Henry M.) Foundation for the \$0 \$98,663 Investigating the transcriptional landscape of blast-related traumatic brain injury on the single cell USU 5741 level- a pilot study Advancement of Military Medicine \$0 \$98.663 Air Force Defense Research Sciences Program 12.800 FUT CU20-2357 FA864920C0235 FAR UV TECHNOLOGIES INC \$0 Krypton Disinfection Lighting \$41,781 Magnet-Free Non-Reciprocal Metamaterials Based on Spatio-Temporal Modulation 12.800 RFCUNY CM00001529-00 FA9550-18-1-0379 RESEARCH FOUNDATION OF CITY \$0 \$605,352 UNIVERSITY OF NEW YORK PU SUB0000339 PRINCETON UNIVERSITY (MURI) Theory, Implementations, and Applications of Mean Field Games: The Second Generation 12.800 FA9550-19-1-0291 \$0 \$39,394

Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name S	ubrecipients	Total Expenditures (Includes Subrecipients)
(MURI) Integrating Multiscale Modeling and Experiments to Develop a Meso-Informed Predictive Capability for Explosives Safety and Performance	12.800	UMISS C00064537-6	FA9550-19-1-0318	UNIVERSITY OF MISSOURI	\$0	\$164,372
Mechanistic Studies of Microdroplet Chemistry	12.800	SU 62742083-204669	FA9550-21-0170	STANFORD UNIVERSITY	\$0	\$115,720
(MURI-21) Molecular Systems Control in Networks of Communicating, Phase-Separated Droplets in Yeast	12.800	RFCUNY CM00005568-00	FA9550-21-1-0091	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	\$0	\$50,580
				<u> </u>	\$0	\$1,017,199
Research and Technology Development	12.910	LICED 422050222	D18AC00014	LININ/EDGITY OF CALIFORNIA CAN	\$0	\$132,778
Non-Equilibrium Order Parameter Optoelectronics for Quantum Information Processing	12.910	UCSD 122059822 (S9002421)	D16AC00014	UNIVERSITY OF CALIFORNIA, SAN DIEGO	\$0	\$132,776
DECADES: Deeply-Customized Accelerator-Oriented Data Supply Systems Synthesis	12.910	PU SUB0000254	FA8650-18-2-7862	PRINCETON UNIVERSITY	\$0	\$352,740
Smart Glass for Object Recognition	12.910	UWM 000000704	FA8650-20-01-7028	UNIVERSITY OF WISCONSIN MADIS	ON \$0	\$39,874
Electrogenic Regulation of Sleep Biomolecules for Circadian Cycle Adjustment	12.910	SU 62621899-192767	FA8650-21-2-7121	STANFORD UNIVERSITY	\$0	\$545,329
Generating Alternatives for Interpretation and Analysis (GAIA)	12.910	USC 98328001	FA8750-18-2-0014	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$556,153
CORAL: Combined Representations for Adept Learning	12.910	USC 124130701	FA8750-19-1-1000	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$116,778
Continual Learning Across Synapses, Circuits, and Brain Areas	12.910	BRI 7000000603	HR0011-18-2-0025	Baylor Research Institute	\$0	\$61,072
ZK Proofs Unbound: Next-Generation Pipelines for Real-world Applications	12.910	NYU F1400-1	HR00112020022	NEW YORK UNIVERSITY	\$0	\$127,376
TONIC: Trusted Online Content	12.910	UCB 00010808	HR00112020054	UNIVERSITY OF CALIFORNIA, BERKELEY	\$0	\$114,179
Efficient infrared-to-visible conversion with an upconverting nanoparticle microlaser	12.910	UNIVMEL TA106974-CU	HR00112220006	University of Melbourne	\$0	\$70,185
HEPIUS: Holistic electrical, ultrasonic, and physiological interventions unburdening those with spinal cord injury	12.910	JHU 2004888623	N6600012024075	JOHNS HOPKINS UNIVERSITY	\$0	\$595,140
Discovering Common Sense from Video, Images, Text and Knowledge Bases	12.910	USC 123870980	N660011924032	UNIVERSITY OF SOUTHERN CALIFORNIA	\$0	\$564,220
Synthesizing and Quantifying Novel Videos for Classifying, Detecting, and Tracking Activities	12.910	UMARY 85946-Z9448201	W911NF2020009	UNIVERSITY OF MARYLAND	\$0	\$179,878
					\$0	\$3,455,702
				=	21,543	15,340,262
Total Pass-through Programs				_	\$21,543	\$15,619,986
Total Department of Defense				_	\$7,719,113	\$53,612,749
Department of Commerce						
Direct Awards Covid 19 Related Funding:						
COVID-19-Understanding Methane Changes in Cities Affected by COVID-19 Shutdowns	11.431	NA21OAR4310235			\$0	\$51,236

For year ended June 30, 2022

Foderal Creater / Dage through Creater				5 " 11"	<u> </u>	R&D Cluster
	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
					0	51,236
eveloping Novel Methods to Measure Historic Wetland Accretion	11.420	NA20NOS4200140			\$0	\$53,007
Supporting Regional Implementation of Integrated Climate Resilience: Consortium for Climate Risk in the Urban Northeast (CCRUN) Phase II	11.431	NA20OAR4310147A			\$475,096	\$2,267,163
Maintenance and Development of the Subseasonal to Seasonal Prediction Project (S2S) Database and Tools in IRI Data Library	11.459	NA21OAR4590266			\$0	\$144,702
Development and Evaluation of New Statistical Calibration Methods for Multi-Model Ensemble Week 3-4 Probabilistic Forecasts	11.468	NA18NWS4680067			\$0	\$22,824
xperimentally-driven mapping of QoS-to-QoE for Mission-Critical Voice	11.609	70NANB19H003			\$43,846	\$596,901
					518,942	3,084,597
Fotal Direct Award Programs					\$518,942	\$3,135,833
Pass-through Awards						
lational Oceanic & AtmosphericAdministration/Department of Commerce						
High-resolution Shipboard Measurements of Phytoplankton Functional Types, Size Classes and Photosynthetic Competency in Support of SUOMI-VIIRS Ocean Color Observations	11.RD	GSTI SA18-CUNY01	ST-1330-17-CQ-0050	GLOBAL SCIENCE & TECHNOLOG	Y INC \$0	\$49,603
Climate and Atmospheric Research				_	\$0	\$49,603
Veddell Sea Moorings	11.431	UCAR SUBAWD001040	NA18OAR4310253B	UNIVERSITY CORPORATION FOR ATMOSPHERIC RESEARCH	\$0	\$4,809
ntegrating Seasonal and Sub-Seasonal Climate Information into Public Health Contexts: co-Producing Decision Support Applications in Puerto Rico and Dominica	11.431	UA 470206	NA18OAR4310338	UNIVERSITY OF ARIZONA	\$0	\$15,854
RSFO - CCRUN - Resilience of Small and Medium Businesses in Coastal Communities in the New York - New Jersey Metropolitan Region	11.431	UCAR SUBAWD002736	NA20OAR4310253C	UNIVERSITY CORPORATION FOR ATMOSPHERIC RESEARCH	\$12,859	\$45,551
lational Oceanic and Atmospheric Administration (NOAA) Cooperative Institutes					\$12,859	\$66,214
Surface Water pCO2 measurements from Ships	11.432	UMIAMI OS00000053	NA15OAR4320064	UNIVERSITY OF MIAMI	\$0	\$73,184

1 1 1 1 1 1 1 1 1 1	Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	R&D Cluster Total Expenditures
Machine and Af Quality Research Continuements to the RTE-RETINUED Residuals Code in Support of NOAA Operational Forecastial 11.459 AER P2519-001 NA21OARM590181 ATMOSPHERIC AND BRANKCHABENTAL 50 12.000 20.000	Ocean Exploration Cooperative Institute (OECI): Discovering the New America			NA19OAR4320072	OCEAN EXPLORATION TRUST	\$0	(Includes Subrecipients \$78,88
March Marc	NMME Phase-2: New Innovation in Seasonal Prediction Science	11.432	UMIAMI OS00000747	NA20OAR4320472	UNIVERSITY OF MIAMI	\$0	\$15,41
### ### ### ### ### ### ### ### ### ##						\$0	\$167,47
Total Pass Abrough Programs Facility Programs Programs Facility Programs Facility Programs Programs Facility Programs Programs	Weather and Air Quality Research						
12,800 302 10,800 10,8	Enhancements to the RTE+RRTMGP Radiation Code in Support of NOAA Operational Forecasts	11.459	AER P2516-001	NA21OAR4590161		NTAL \$0	\$19,64
State Separation of Presentation Of Mealth & Human Services Separation of Presentation Of Health & Human Services Separation of Presentation Of Health & Human Services Separation of Human Services Sep						\$0	\$19,64
Page						12,859	302,93
Page	Total Pass-through Programs					\$12.859	\$302.95
Department of Health & Human Services							
Pass through Awards	Total Department of Commerce					4331,001	Ψ5,436,77
Centers for Disease Control and Prevention/DHHS SARD NUDEP 8882988 CDC CU20-1087 NEW JERSEY DEPT. OF ENVIRON S0 S14.	Department of Health & Human Services						
Solidar Continued Ansenic Testing for Hunterdon Healthcare Patients Sol RD NJEP 8882968 CDC CU20-1087 NEW JERSEY DEPT. OF ENVIRON. Solidar S	Pass-through Awards						
PROTECTION Side	Centers for Disease Control and Prevention/DHHS						
Total Pass-through Programs S0 S14	Continued Arsenic Testing for Hunterdon Healthcare Patients	93.RD	NJDEP 8882968	CDC CU20-1087		1. \$0	\$14,45
Folial Pass-through Programs Folial Pass-through Programs Folial Department of Health & Human Services (Excluding NIH) Department of Education Direct Awards Columbia South Asia Institute: National Resource Centers 84.015 P015A180034 - 21 S158.216 \$631, Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134, Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88.293 \$251, \$246.509 \$1.018.						\$0	\$14,45
Total Department of Health & Human Services (Excluding NiH) Department of Education Direct Awards Columbia South Asia Institute: National Resource Centers 84.015 P015A180034 - 21 \$158.216 \$631. Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134. Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88.293 \$251. Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88.293 \$251.							14,45
Total Department of Health & Human Services (Excluding NiH) Department of Education Direct Awards Columbia South Asia Institute: National Resource Centers 84.015 P015A180034 - 21 \$158.216 \$631. Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134. Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88.293 \$251. Research	Total Dase through Drograms						\$14.45
Department of Education Direct Awards Columbia South Asia Institute: National Resource Centers 84.015 P015A180034 - 21 \$158,216 \$631. Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134. Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88,293 \$251. Research							\$14,45 \$14,45
Direct Awards Columbia South Asia Institute: National Resource Centers 84.015 P015A180034 - 21 \$158,216 \$631, Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134, Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education Research 84.305 R305D190048 - 21 \$88,293 \$251, Research 246,509 1,018,	Dopartical of House & Hamar Co. House (Excluding Hill)						
Columbia South Asia Institute: National Resource Centers 84.015 P015A180034 - 21 \$158,216 \$631, Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134, Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education Research 84.305 R305D190048 - 21 \$88.293 \$251, Research 246,509 1,018,	Department of Education						
Fullbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134, Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education Research 84.305 R305D190048 - 21 \$88,293 \$251, Research 246,509 1,018,	Direct Awards						
Fulbright-Hays Doctoral Dissertation Research Abroad 84.022 P022A210018-21 \$0 \$134, Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88,293 \$251, Research 246,509 1,018,	Columbia South Asia Institute: National Passures Contars	84 015	D015A180034 21			\$158 216	\$631.86
Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88,293 \$251, Research 246,509 1,018,	Columbia South Asia insulute. National Nesource Centers	04.013				ψ130,210	
Efficient and Flexible Tools for Complex Multilevel and Latent Variable Modeling in Education 84.305 R305D190048 - 21 \$88,293 \$251, Research 246,509 1,018,							
Research	Fulbright-Hays Doctoral Dissertation Research Abroad	84.022	P022A210018-21			\$0	\$134,61
246,509 1,018,							
246,509 1,018,		84.305	R305D190048 - 21			\$88,293	\$251,99
						246.509	1,018,46
							\$1,018,46

For year ended June 30, 2022

Direct Awards

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
otal Department of Education	Listing No.	<u>identification No</u>			\$246,509	\$1,018,469
epartment of Agriculture						
irect Awards						
Multi-Breadbasket Failures and Shocks to Food Systems: AgMIP Simulations	10.250	59-6000-0-0071			\$0	\$33,820
n Integrated Approach to a Zero-Energy Greenhouse Using Solar and Geothermal Energy	10.310	USDA 2021-67021-34201			\$0	\$42,340
uerto Rico Forest Disturbance and Regrowth Data Collection	10.684	USFS 19-DG-11132762-045			\$0	\$80,023
otal Direct Award Programs ass-through Awards					<u>0</u>	156,18 \$156,18
gricultural Research Basic and Applied Research tolecular characterization of innate immune responses during HIV-1 and Zika virus coinfection o	f 10.001	CRDF R-202104-67759	NIAID	CIVILIAN RESEARCH AND	\$0	\$9,91
acrophages				DEVELOPMENT FOUNDATION		\$9,914
otal Pass-through Programs otal Department of Agriculture					© \$0 \$0	9,912 \$9,914 \$166,097
Department of Homeland Security Direct Awards						
ddressing Gaps in Housing Disaster Recovery: A Training Program for the Whole Community	97.005	EMW-2017-CA-00043-S01			\$0	\$73,567
					0	73,567
otal Direct Award Programs otal Department of Homeland Security					\$0 \$0	\$73,56 \$73,56
Department of Interior						

For year ended June 30, 2022

Direct Awards

Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name S	<u>ubrecipients</u>	R&D Cluster Total Expenditures (Includes Subrecipients)
Enabling Enhanced Water Recovery and Minimized Concentrate for Desalination of San Joaquin Valley Irrigation Drainage	15.506	DIBR R21AC10032			\$0	\$145,458
Earthquake Simulators and Next Generation Hazard Models (UCERF4): Collaborative Research with Columbia University and USGS Golden	15.807	G21AP10345-00			\$0	\$114,845
Total Direct Award Programs Pass-through Awards				- = -	\$0	260,303 \$260,303
National and Regional Climate Adaptation Science Centers						
Host Cycle II of the Northeast Climate Adaption Science Center	15.820	UMASSAMH 22-015184-F-00	G19AC00091	UNIVERSITY OF MASSACHUSETTS AMHERST	\$0	\$37,950
					\$0	\$37,950
Total Pass-through Programs Total Department of Interior				-	\$0 \$0	37,950 \$37,950 \$298,253
Department of Justice				_		
Pass-through Awards						
Crime Victim Assistance						
SA COVID-19 Recovery Fund	16.575	NYSOPDV PDV01-T00018GG-1310000	DOJ CU21-2722	NEW YORK STATE OFFICE FOR THE PREVENTIONOF DOMESTIC VIOLEN		\$37,388
Second Chance Act Reentry Initiative				······ <u>··</u>	\$0	\$37,388
Learning Lab for Justice-Involved Emerging Adults in Massachusetts	16.812	UTEC CU20-2547	BJA 2017-11540	UTEC	\$0	\$21,877
Evaluation and Development Services in Support of DOJ-Funded Reentry Initiatives	16.812	UTEC CU21-3870	DOJ 2020-CY-BX-0019	UTEC	\$0	\$11,308
					\$0	\$33,185
				_ _	0	70,573
Total Pass-through Programs Total Department of Justice				_	\$0 \$0	\$70,573 \$70,573
Department of State				_	φυ	\$70,573

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	Total Expenditures
Correlation Detection and Location of Small Seismic Events in a Broad Region of Interest using data from a Rare Deployment	<u>Listing No.</u> 19.RD	Identfication No 19AQMM20P1944			\$0	(Includes Subrecipients \$122,21
Open Start Up Morocco 2	19.040	SMO55021CA3030			\$0	\$191,05
Supporting Chain of Command Analysis, Documentation, Preservation and Building Capacity of Civil Society to Pursue Justice and Accountability for Abuses Committed in Syria	19.345	SLMAQM20GR2491			\$391,586	\$526,24
					391,586	839,52
Total Direct Award Programs Pass-through Awards					\$391,586	\$839,52
International Programs to Support Democracy, Human Rights and Labor						
Developing Transitional Justice	19.345	NED 2020-08117	S-LMAQM-20-GR-2006	NATIONAL ENDOWMENT FOR DEMOCRACY	\$0	\$16,32
					\$0	\$16,32
					0	16,32
Total Pass-through Programs					\$0	\$16,32 \$855,84
Total Department of State Department of Transportation					\$391,586	
Pass-through Awards						
University Transportation Centers Program						
Center for Advanced Infrastructure and Transportation (CAIT) Regional UTC Consortium	20.701	RUTGER PO 966112/PID#824227	DOT 69A3551847102	RUTGERS, THE STATE UNIVERSIDENCE OF	SITY OF \$0	\$123,23
				BADIUI UGV	\$0	\$123,23
					0	123,23
Total Pass-through Programs					\$0	\$123,23
Total Department of Transportation Department of Veterans Affairs					<u>*0</u>	\$123,23
Direct Awards						
Neuroinflammatory and Epigenetic Mechanisms of Blood-Brain Barrier Compromise in Suicide	64.RD	JJPVA 36C24E18D0058			\$0	\$-1
					0	-1

For year ended June 30, 2022

ederal Grantor / Pass-through Grantor	Assistance	Award	Page through Contract Number	Pacethrough Namo	Subracipionts	R&D Cluster Total Expenditures
odoral Oranio / Lass-tillough Oranio	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	I otal Expenditures (Includes Subrecipients)
otal Direct Award Programs					\$0	\$-1
Department of Veterans Affairs					\$0	\$-1
ept. of HousingUrban Development						
irect Awards						
ban fungal exposure, sensitization and asthma among a low-income population	14.906	NYHHUOO42-18			\$222,761	\$341,401
					222,761	341,40
otal Direct Award Programs					\$222,761	\$341,40
ass-through Awards						
ead Technical Studies Grants						
etter Recognition of Exposure to Asthma Triggers in the Home Environment using Smartphones (REATHE-Smart)	14.902	OSU SPC-1000004622/GR122799	OHHHU0057-20	OHIO STATE UNIVERSITY	\$0	\$19,774
KEATHE-SMARI)		SPC-1000004622/GR122799				
						\$19,77 ———————————————————————————————————
stal Dage through Drawsons						
otal Pass-through Programs otal Dept. of HousingUrban Development					\$0 \$222,761	\$19,77 \$361,17
nvironmental Protection Agency					<u> </u>	
• •						
irect Awards						
utomated Model Reduction for Chemical Mechanisms	66.509	EPA 84001301			\$0	\$203,145
					0	203,145
otal Direct Award Programs					\$0	\$203,14
ass-through Awards						
nvironmental Protection Agency						
upport for EPA s Activities - Examining Sectoral Impacts of Climate Change and Linking observations and Projections	66.RD	ICFI 20SSSK0016	68HERH19D0029	ICF INTERNATIONAL	\$0 <u></u>	\$2 ⁴
ong Island Sound Program					\$0	\$24
Fifined Integration of Remote Sensing with Biological Parameters for Improved Management of S Water Quality/Long Island Sound Study 2018-2022	66.437	CCONY CM00005171-01	LI-96261317-0	City College of New York	\$0	\$48,496

Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients
Mainstream Deammonification with Biological Phosphorus Removal	66.509	WARF 5096	EPA 84008601-0	WATER RESEARCH FOUNDATION	\$0	\$16,58
Office of Research and Development Consolidated Research/Training/Fellowships				······································	\$0	\$16,58
Accounting for the Health Benefits of Air Pollution Regulations in China, 2008-2020	66.511	BU 4500003962	EPA CR-83998101	BOSTON UNIVERSITY	\$0	\$33,56
recounting for the regular Benefits of Air Foliation Regulations in Offina, 2000-2020	00.011	DO 4000000002	El A 0100000101	DOCTON CHIVERCHT	ΨΟ	ψ00,50
				•	\$0	\$33,56
					0	98,6
otal Pass-through Programs					\$0	\$98,6
otal Environmental Protection Agency					\$0	\$301,8
Japan US Friendship Commission						
Direct Awards						
2021-2022 Japan-U.S. Friendship Commission Prize for the Translation of Japanese Literature	90.300	JAPUS 21-13			\$0	\$10,94
						10,94
otal Direct Award Programs					<u></u>	\$10,9
Total Japan US Friendship Commission					\$0	\$10,9
Nat. Endowment for the ArtsHumanities						
Direct Awards						
An Integrated Online Archive for International History	45.149	PW-277555-21			\$0	\$121,40
						121,4
					0	
otal Direct Award Programs Total Nat. Endowment for the ArtsHumanities					<u>\$0</u>	\$121,4 ¹ \$121,4 ¹
						\$121,4
Other Agencies / Gov't						
Direct Awards						
Immunogens of high impact livestock pathogens	99.RD	KSU-1048			\$0	\$35,37
						35,3;
otal Direct Award Programs					<u> </u>	\$35,3

For year ended June 30, 2022

Federal Grantor / Pass-through Grantor	Assist	Δ	Door through Control No.	Decethrough No	.braainia+-	R&D Cluster
rederal Grantol / Pass-through Grantol	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name Si	<u>ubrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients
Pass-through Awards						
Small Business Development Centers						
The New York Small Business Development Center (NY SBDC)	59.037	SUNYRF 89275	SBA 1163898	RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK	\$0	\$35,222
					\$0	\$35,222
				_	0	35,22
otal Pass-through Programs				_	\$0	\$35,22
otal Other Agencies / Gov't				_	\$0	\$70,599
Social Secuirty Administration						
Pass-through Awards						
Social Security Administration/DHHS						
Early Intervention Mental Health Demonstration Study	96.RD	WESTAT 6464-S02	SS001660014	WESTAT	\$0	\$141,075
					\$0	\$141,075
				_	0	141,075
otal Pass-through Programs				=	\$0	\$141,07
otal Social Secuirty Administration				_	\$0	\$141,07
United States Agency for International Dvlpt.						
Direct Awards						
Nolkup: an app to access low arsenic water in Bangladesh	98.RD	7200AA21FA00010			\$0	\$7,024
				_	0	7,024
otal Direct Award Programs				=	\$0	\$7,02
Pass-through Awards				_		
I.S. Agency for International Development						
Strengthening Disaster and Climate Resilience in the Eastern and Southern Caribbean (SDCR) troject	98.RD	CIMH CU20-1330	AID CU20-1330	CARIBBEAN INST FOR METEOROLO & HYDROLO	GY \$0	\$38,648
ERVIR for USAID West Africa	98.RD	TETRARD 1865-Columbia-001	AID-OAA-I-13-00058	TETRA TECH ARD	\$0	\$6,538
JSAID Foreign Assistance for Programs Overseas					\$0	\$45,186
	98.001	CATHOLICRS CU 18-2493	7200AA18CA00051	CATHOLIC RELIEF SERVICES	\$86,562	\$340,089
Developing Acute Care and Emergency Referral Systems						

						R&D Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	Total Expenditures (Includes Subrecipients)
Preparing for Ring Opportunities through Market Introduction Support and Knowledge Exchange (PROMISE)	98.001	FHID PO20002930	AID-OAA-A-15-00045	FHI DEVELOPMENT 360 LLC	\$0	\$77,674
Simplification of Linkage to and Delivery of Antiretroviral Therapy in USAID-PEPFAR Supported Programs	98.001	WHC D1509970	AID-OAA-A-15-0069	WITS HEALTH CONSORTIUM	\$0	\$-141
Evaluating the implementation and effectiveness of an integrated psychosocial intervention to reduce psychological distress and intimate partner violence among forced migrants in Ecuador	98.001	FY20-A04-6024	AID-OAA-A-17-00002	HIAS	\$0	\$52,836
Clean Air Catalyst: A Global Partnership for Accelerating Clean Air Solutions	98.001	WRI G2264	USAID 7200AA20CA00014	WORLD RESOURCES INSTITUTE	\$0	\$81,607
					\$86,562	\$921,283
					86,562	966,469
Total Pass-through Programs					\$86,562	\$966,469
Total United States Agency for International Dvlpt.					\$86,562	\$973,493
Total: Research & Development Cluster					\$119,723,606	\$908,853,771

				Student F	inancial Aid Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
Student Financial Assistance Cluster					
Department of Health & Human Services	_				
Direct Awards					
Health Professionals	93.342			\$0	\$10,083,936
Nursing Students	93.364			\$0	\$1,172,132
Total Direct Award Programs Total: Department of Health & Human Services (Excluding NIH)				\$0 \$0 \$0	11,256,068 \$11,256,068 \$11,256,068
Department of Education Direct Awards					
Federal Perkins Loans	84.038			\$0	\$26,654,736
Total Direct Award Programs Total: Department of Education				\$0 \$0	26,654,736 \$26,654,736 \$26,654,736
Department of Education Direct Awards					
Supplemental Education Opportunity Grant 2021-2022	84.007	P007A212737		\$0	\$1,634,411
Federal Work Study 2021-2022	84.033	P033A212737		\$0	\$5,343,146
,					

				Student F	inancial Aid Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number Passthrough Name	<u>Subrecipients</u>	Total Expenditures (Includes Subrecipients)
Federal PELL Grant Program 2021-2022	84.063	P063P211840		\$0	\$10,685,852
Federal Direct Loan Program 2021/2022	84.268	P268K221840		\$0	\$322,104,830
				0	339,768,239
Total Direct Award Programs				\$0 \$0	\$339,768,239
Total: Department of Education				\$0	\$339,768,239
Total: Student Financial Assistance Cluster				<u> </u>	\$377,679,043

Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients
Global Aids						
Department of Health & Human Services						
Direct Awards						
Covid 19 Related Funding:						
COVID-19-Community-Based HIV Services for Key Populations and Adolescent Girls and Young Women	93.067	6NU2GGH001941-05-10			\$0	\$5,728,232
					0	5,728,232
Global AIDS	93.067	6NU2GGH002368-01-04			\$8,127,845	\$196,739,292
					8,127,845	196,739,292
Total Direct Award Programs					\$8,127,845	\$202,467,524
Pass-through Awards						
Global AIDS						
Key Populations Investment Fund Project	93.067	IRDO-1NU2GGH001963-ICA P	1NU2GGH001963	IMPACT RESEARCH AND DEVELOPMENTORGANIZATION	\$0	\$31,703
					\$0	\$31,703
					0	31,703
Total Pass-through Programs					\$0	\$31,703
Total Department of Health & Human Services (Excluding NIH)					\$8,127,845	\$202,499,227
Grand Total: Department of Health & Human Services					\$8,127,845	\$202,499,227
Total: Global Aids				<u> </u>	\$8,127,845	\$202,499,227

				Hig	her Education Eme	er Education Emergency Relief Fund			
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)			
Higher Education Emergency Relief Fund									
Department of Education									
Direct Awards Covid 19 Related Funding:									
COVID-19-Columbia University CARE Act Application	84.425E	P425E202142			\$0	\$22,392,119			
COVID-19-Columbia University HEERF II Application - Institutional Portion	84.425F	P425F205200			\$0	\$25,403,190			
					0	47,795,309			
Total Direct Award Programs					\$0 \$0	\$47,795,309			
Total Department of Education					<u>*0</u>	\$47,795,309			
Total: Higher Education Emergency Relief Fund					\$0	\$47,795,309			

Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	Subrecipients	<u>Total Expenditures</u> (Includes Subrecipients)
Highway Planning and Construction Cluster						
Department of Transportation						
Pass-through Awards						
Highway Planning and Construction						
September 11th Program for Regional Transportation Planning: Year 2020-2021 Academic Initiative	20.205	RFCUNY CM00005129	DOT CU20-3280	RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK	Y \$0	\$9,000
				· · · · · · · · · · · · · · · · · · ·	\$0	\$9,000
					0	9,000
Total Pass-through Programs					\$0	\$9,000
Total Department of Transportation					\$0	\$9,000
Total: Highway Planning and Construction Cluster				_	\$0	\$9,000

Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award Identfication No	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Highway Safety Cluster						<u> </u>
Department of Transportation						
Pass-through Awards						
National Priority Safety Programs						
Integrating Single and Polysubstance Impaired Driving Data into the Crash Outcome Data Evaluation System (CODES)	20.616	HRI 6582-01	DOT CU20-1445	Health Research Inc	\$0	\$90,356
					\$0	\$90,356
					0	90,356
Total Pass-through Programs					\$0	\$90,356
Total Department of Transportation					\$0	\$90,356
Total: Highway Safety Cluster					\$0	\$90,356

						TRIO Cluster
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	Subrecipients	Total Expenditures (Includes Subrecipients)
TRIO Cluster						
Department of Education						
Direct Awards						
Talent Search Program at Columbia University s Double Discovery Center	84.044	P044A210414			\$0	\$401,571
TRIO Upward Bound Program	84.047	P047A170670-21			\$0	\$839,750
					0	1,241,321
Total Direct Award Programs					\$0 \$0	\$1,241,321
Total Department of Education					\$0	\$1,241,321
Total: TRIO Cluster					\$0	\$1,241,321

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number Passthrough Name	Subrecipients	Other Programs Total Expenditures
	Listing No.	Identfication No	rass-unough contract Number rassunough Name	Subrecipients	(Includes Subrecipients
Other Programs					
Department of Health & Human Services					
Direct Awards Covid 19 Related Funding:					
COVID-19-CDC IPA Mobility Agreement	93 .U01	20IPA2014150		\$0	\$4,98
COVID-19-Strengthening Sustainability of Global Health Security Objectives in Sierra Leone	93.318	6NU2HGH000035-02-01		\$0	\$612,25
				0	617,24
lational Institute for Occupational Safety & Health/CDC/DHHS	93 .U02	20IPA2014150		\$0	\$29,16
lurse Anesthetist Traineeship	93.124	5A22HP33098-04-00		\$0	\$62,98
IIV-Related Training and Technical Assistance	93.145	5U1OHA29291-08-00		\$2,102,778	\$4,067,94
lealth Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's imergency Plan for AIDS Relief	93.266	6UH6HA30739-04-10		\$0	\$2,827,94
Complex Humanitarian Emergency and War-Related Injury Public Health Activities	93.269	6U01GH001644-05-03		\$0	\$41,09
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, systems, Capacity and Security	93.318	6NU2HGH000048-02-05		\$0	\$3,627,73
Grants for Primary Care Training and Enhancement	93.884	4T0BHP29302- 05- 01		\$0	\$3,12

For year ended June 30, 2022

Direct Awards

Federal Grantor / Pass-through Grantor	Assistance	Award	Pass-through Contract Number	Passthrough Name	Subrecipients	Other Programs Total Expenditures
	Listing No.	Identfication No	r ass through contract (variable)	<u>r assumough Namo</u>	<u>Subrecipients</u>	(Includes Subrecipient
Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants	93.924	1T22HA45125 01 00			\$0	\$251,58
					2,102,778	10,911,5
otal Direct Award Programs					\$2,102,778	<u>\$11,528,8</u>
Pass-through Awards Covid 19 Related Funding:						
Protecting and Improving Health Globally: Building and Strengthening Public Health Impa	ct. Systems. Capa	city and Security				
COVID-19-COVID-19 Vaccine Introduction in Sierra Leone	93.318	TFGH CU21-1349	NU51IP000873	TASK FORCE FOR GLOBAL HEALT	н \$0	\$159,24
				· · · · · · · · · · · · · · · · · · ·	\$0	\$159,2 ⁴
				•	0	159,24
				•		
HV Prevention Activities Non-Governmental Organization Based						
ASCLM/Alliance CDC PS21-2102	93.939	ASCNYC CU22-0732	1NU62PS924688-01-00	AIDS SERVICE CENTER OF LOWER MANHATTANINC	R \$0	\$76,8
Comprehensive High-Impact HIV Prevention Prog	93.939	NYPH CU22-1358	1NU62PS924702-01-00	PRESBYTERIAN HOSPITAL IN THE CITY OF NEWYORK	\$0	\$93,2
Comprehensive High-Impact HIV Prevention Projects for Community- Based Organizations	93.939	ASCNYC CU161123	U65PS004743	AIDS SERVICE CENTER OF LOWER MANHATTANINC	₹ \$0	\$18,79
				· · · · · · · · · · · · · · · · · · ·	\$0	\$188,89
				•	0	188,8
Total Pass-through Programs				•	\$0	\$348,1
Total Department of Health & Human Services (Excluding NIH)					\$2,102,778	\$11,876,9
National Institute of Health						
Pass-through Awards						
National Institute on Drug Abuse/NIH/DHHS						
TeleBup Program	93 .U03	SAEM RE2020-0000000131	NIDA	SOCIETY FOR ACADEMIC EMERGE MEDICINE	ENCY \$0	\$11,4
				<u>-</u>	\$0	\$11,41
					0	11,4
Total Pass-through Programs					\$0	\$11,4
Total National Institute of Health					\$0	\$11,4
Grand Total: Department of Health & Human Services					\$2,102,778	\$11,888,37
National Aeronautics & Space Administration						

						Other Programs
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (<u>Includes Subrecipients</u>)
NASA Johnson Space Center- Intergovernmental Personnel Agreement (IPA)	43 .U01	IPA-AH-19-060			\$0	\$165,230
Variable Stiffness Compliant Mechanisms for Deployable, Reconfigurable Structures	43.012	80NSSC20K0587			\$0	\$66,482
Total Direct Award Programs Pass-through Awards					<u> </u>	231,712 \$231,712
National Aeronautics & SpaceAdministration						
Assistance in the Organization of the 2021 Salinity Science Conference	43 .U02	JPLCIT 1661438	NASA CU20-4421	JET PROPULSION LAB, CALIFO INSTITUTEOF TECHNOLOGY	RNIA \$0	\$115,862
					\$0	\$115,862
Total Pass-through Programs					<u>0</u> \$0	115,862
Total National Aeronautics & Space Administration					\$0	\$347,574
Department of Defense						
Direct Awards						
Hacking for Defense at Columbia University	12.300	N00014-19-1-2002			\$0	\$1,552
					0	1,552
Total Direct Award Programs					\$0	\$1,552
Total Department of Defense					\$0	\$1,552
Department of Education						
Direct Awards						
FLAS: Middle East Institute, Columbia University, Title VI Proposal	84.015	P015B180080-21			\$6,614	\$1,285,311
					6,614	1,285,311
Total Direct Award Programs					\$6,614	\$1,285,311

						Other Programs
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	Total Expenditures (Includes Subrecipients)
Total Department of Education	Listing No.	identification NO			\$6,614	\$1,285,311
Department of Homeland Security						
Direct Awards						
Training Solutions: Transitioning Disaster Survivors from Temporary to Permanent Housing	97.005	EMW-2018-CA-00068-S01			\$0	\$1,837,015
					0	1,837,015
Total Direct Award Programs					\$0 \$0	\$1,837,015 \$1,837,015
Total Department of Homeland Security Department of Justice						\$1,637,015
Direct Awards						
ReNew Court Pilot	16 .U01	USDCNJ CU19-2776			\$0	\$80,150
					0	80,150
Total Direct Award Programs Total Department of Justice					<u> </u>	\$80,150 \$80,150
Department of State						
Direct Awards						
FY-18 - Ngwang Choephel Fellowship Program: Tibet	19.012	S-ECAGD-18-GR-0004			\$0	\$267,958
Support the Regional Framework Agreements (RFA) on Air Pollution in Africa with afocus on East Africa	t 19.017	SLMAQM20CA2347			\$927	\$103,136
To Implement Renovation of Badinan Gate Project Which Restore Damaged Historic Aspects of the Gate to its Original State	19.021	SIZ-100-19-GR0031			\$131,710	\$312,813
					132,637	683,907
Total Direct Award Programs					\$132,637	\$683,907

For year ended June 30, 2022

						Other Programs
Federal Grantor / Pass-through Grantor	Assistance <u>Listing No.</u>	Award <u>Identfication No</u>	Pass-through Contract Num	nber Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
Total Department of State	<u>Listing No.</u>	<u>identification No</u>			\$132,637	\$683,90
Department of Veterans Affairs						
Direct Awards						
Post exertion malaise in GWI Brain autonomic and behavioral interactions	64 .U01	36C24E19D0034			\$0	\$229,466
					0	229,466
Total Direct Award Programs Pass-through Awards					\$0	\$229,466
Department of Veterans Affairs						
Dynamic Regulation of Erythropoietin Gene Expression in Mammals - IPAs	64 .U02	JJPVA CU20-0737	DVAMC IPA	JAMES J PETERS VA MEDICAL CENTER	\$0	\$8,743
					\$0	\$8,743 8,743
Total Pass-through Programs					\$0	\$8,743
Total Department of Veterans Affairs					<u>\$0</u>	\$238,209
Nat. Endowment for the ArtsHumanities						
Direct Awards						
Promotion of the Arts Grants to Organizations and Individuals	45.024	NEA 1887916-31-22			\$0	\$15,000
						15,000
Total Direct Award Programs						\$15,000
Total Nat. Endowment for the ArtsHumanities					\$0	\$15,000
Other Agencies / Gov't						
Pass-through Awards Covid 19 Related Funding:						
Small Business Development Centers	50.007	OLINIVEE 00040	ODA OU00 0004	DECEMBOLI FOLINDATION OF T	IE #0	\$400.40F
COVID-19-The Small Business Development Centers Cares	59.037	SUNYRF 88013	SBA CU20-2061	RESEARCH FOUNDATION OF TH STATE UNIVERSITY OF NEW YO		\$129,125
					\$0	\$129,125
					0	129,125
Total Pass-through Programs					\$0	\$129,125
Total Other Agencies / Gov't					<u>\$0</u>	\$129,125

						Other Programs
Federal Grantor / Pass-through Grantor	Assistance Listing No.	Award <u>Identfication No</u>	Pass-through Contract Number	Passthrough Name	<u>Subrecipients</u>	<u>Total Expenditures</u> (Includes Subrecipients)
United States Agency for International Dvlpt.						
Direct Awards						
Malaria Diagnosis and Treatment Activity	98.001	72066318CA00005			\$0	\$3,347,168
					0	3,347,168
Total Direct Award Programs					\$0	\$3,347,168
Pass-through Awards						
U.S. Agency for International Development						
Egyptian Economic Governance for Development Project II	98 .U01	DAI 1004369-21S-35968-00	AID 7200AA18D00008/72026320F	DAI :	\$0	\$226,167
USAID Foreign Assistance for Programs Overseas					\$0	\$226,167
Meeting Targets and Maintaining Epidemic Control	98.001	JHPIEGO 19-SBA-149	7200AA19CA00003	JOHNS HOPKINS PROG FOR EDUCA. INGYN/OB	NTRN'L \$201,092	\$6,725,073
One Health Workforce - Next Generation (OHW-NG)	98.001	UCD A20-1412-S007	7200AA19CA00018	UNIVERSITY OF CALIFORNIA,	DAVIS \$0	\$613,964
					\$201,092	\$7,339,037
					201,092	7,565,204
Total Pass-through Programs					\$201,092	\$7,565,204
Total United States Agency for International Dvlpt.					\$201,092	\$10,912,372
Provider Relief Fund						
Direct Awards						
COVID-19 CARES Act General and Administrative (G&A) Benefit Expenses, Healthcare Related Expenses & Possible Lost Revenue Reimbursements	93.498	General and Administrative (G&A) Expenses			\$0	\$83,792,525
					0	83,792,525
Total Direct Award Programs					\$0	\$83,792,525
Total Provider Relief Fund					\$0	<u>\$83,792,525</u>
Total: Other Programs					\$2,443,121	\$111,211,117
Total Federal Award Expenditures:					\$130,294,572	\$1,649,379,144

The Trustees of Columbia University in the City of New York Notes to Summary Schedule of Expenditures of Federal Awards Year ended June 30, 2022

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") has been prepared in accordance with OMB Uniform Guidance. The purpose of the Schedule is to present a summary of those activities of the University for the year ended June 30, 2022, which have been financed by the U.S. Government ("Federal awards"). For purposes of the Schedule, Federal awards include all Federal assistance entered into directly between the University and the Federal government and also between the University and other primary recipients of Federal government funds (pass-through), recorded on the accrual basis of accounting. Negative amounts listed on the Schedule represent adjustments, in the normal course of business, to amounts included on the prior year's Schedule. The project number on the Schedule represents the number assigned by the direct or originating sponsor, and when not available an alphanumeric number is assigned by the University to manage sponsored project spending. The passthrough contract number on the Schedule represents the number assigned by the pass-through entity to the applicable program. Federal award Assistance number and pass-through numbers are provided when available.

2. Facility and Administrative Costs

The University elects not to use the 10% de minimis rate allowed under the Uniform Guidance. The University and the Federal government currently operate under a provisional agreement that provides for facilities and administrative ("F&A") cost rates under federal grants and contracts as of July 1, 2021 This agreement will remain in place until such time a new agreement is reached. The following are F&A provisional cost rates established bythe University:

	Rate
All campuses, excluding Lamont-Doherty Earth Observatory	
On-campus	62.5%
Off-campus	26.0%
Off-campus modified	28.5%
Lamont-Doherty Earth Observatory	54.50/
On-campus	54.5%
Off-campus	26.0%
Off-campus modified	28.5%
Other sponsored activity	
On-campus	31.0%
Off-campus	26.0%

3. Guaranteed Student Loan Programs

With respect to the Federal Direct Lending Program (Federal Assistance Listing #84.268), the University is only responsible for the performance of certain administrative duties; therefore, the transactions and the balances of loans outstanding related to this program are not included in the University's consolidated financial statements. The schedule includes the amounts loaned to students during the year ended June 30, 2022. It is not practical to estimate the outstanding balance of loans under this program.

The Trustees of Columbia University in the City of New York Notes to Summary Schedule of Expenditures of Federal Awards Year ended June 30, 2022

4. Student Loan Programs

The University is responsible for the oversight and management of the U.S. Department of Education's Federal Title IV Program which includes Federal Perkins Loan Programs (Federal Assistance Listing #84.038), as well as Health Resources and Services Administration (HRSA) Title VII and Title VIII loan programs funded by the Department of Health and Human Services:

(Amounts in thousands)

Federal Agency	Loan Program	Federal Assistance	Outstanding Principal			
	_	Listing Number	Balance at June 30, 2022			
Education	Perkins Loan	84.038	\$ 21,802			
DHHS	Health Professionals	93.342	8,578			
DHHS	Nursing Students	93.364	1,052			
	•		\$ 31,432			

The federally approved administrative cost allowed under the Title IV program for Federal Work study, Federal Perkins and Federal SEOG for the fiscal year ending June 30, 2022 was \$368 thousand. This expense was charged to the Federal Work Study Program. The administrative cost allowance is determined as a percentage of the total program expenditures. The formula permits administrative cost charges at 4.5% of the first \$5.5 million expended and 3% on expenditures over \$5.5 million.

5. CARES Act Funding

The Schedule includes grant activity related to the DHHS Coronavirus Aid Relief and Economic Security ("CARES") Act Assistance Listing Number 93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 2 and 3 funds received between July 1, 2020 and June 30, 2021 and expended by June 30, 2022 as reported to HRSA via the PRF Reporting Portal. In addition, the University received other COVID-19 related funding, identified on separate lines in the Schedule by Federal Assistance Listing number with "COVID-19" as a prefix added to the program name in the specific cluster where they reside.

The Trustees of Columbia University in the City of New York Schedule of Financial Responsibility Data For the Years Ended June 30, 2022 and 2021 (in thousands of dollars, unless otherwise noted)

Location in financial statements or related notes	Financial element	GAAP financial statement line item or disclosure		Amount used as	
Primary Reserve Ratio: Expendable Net Assets				_	
Statement of financial position Statement of financial position	Net assets without donor restrictions Net assets with donor restrictions	\$	8,303,326 10,129,905	\$	8,303,326 10,129,905
Note 23, Financial Responsibility Standards	Unsecured related party receivable		9,397		9,397
Note 23, Financial Responsibility Standards	Total property, plant, and equipment, net		6,077,595		-,
Note 23, Financial Responsibility Standards	Property, plant and equipment, net - pre-implementation				4,732,022
Note 23, Financial Responsibility Standards	Property, plant and equipment, net - post-implementation with outstanding debt for original purchase				23,968
Note 23, Financial Responsibility Standards	Property, plant and equipment, net - post-implementation without outstanding debt for original purchase				1,154,765
Note 23, Financial Responsibility Standards	Construction in progress				166,840
Statement of financial position	Total lease right-of-use assets		280,807		· ·
N/A	Lease right-of-use assets, pre-implementation		,		-
Statement of financial position	Lease right-of-use assets, post-implementation				280,807
N/A	Intangible assets		_		-
Statement of financial position	Post-employment and pension liabilities				
1	(Accrued employee benefit liabilities)		451,827		451,827
Note 23, Financial Responsibility Standards	Total long-term debt		1,758,918		,
Note 23, Financial Responsibility Standards	Long-term debt - for long-term purposes		-,,,,		
 -,	pre-implementation				1,586,760
Note 23, Financial Responsibility Standards	Long-term debt - for long-term purposes post-implementation				172,158
N/A	Line of Credit for Construction in progress				
Statement of financial position	Total liability related to lease right-of-use assets		290,718		
N/A	Liability related to lease right-of-use assets -		2,0,,10		
	pre-implementation				_
Statement of financial position	Liability related to lease right-of-use assets -				
	post-implementation				290,718
Note 23, Financial Responsibility Standards	Annuities and life income funds with donor restrictions		72,694		72,694
Note 23, Financial Responsibility Standards	Term endowments with donor restrictions		4,706,345		4,706,345
Note 23, Financial Responsibility Standards	Net assets with donor restrictions: restricted in		1,700,515		1,700,515
	perpetuity		4,567,845		4,567,845
Primary Reserve Ratio: Expenses and Losses Note 23, Financial Responsibility Standards	Total expenses and losses without donor restrictions	\$	5,508,794	\$	5,508,794
Equity Ratio: Modified Net Assets	And the second second		0.000.007		0.000.006
Statement of financial position	Net assets without donor restrictions	\$	8,303,326	\$	8,303,326
Statement of financial position	Net assets with donor restrictions		10,129,905		10,129,905
N/A Note 23, Financial Responsibility Standards	Intangible assets Unsecured related party receivable		9,397		9,397
	Chisecured related party receivable		7,371		7,377
Equity Ratio: Modified Assets	T . 1	s	22 221 005	Ф.	22 221 005
Statement of financial position N/A	Total assets Lease right-of-use assets, pre-implementation	2	23,231,005	\$	23,231,005
N/A N/A	Intangible assets				-
Note 23, Financial Responsibility Standards	Unsecured related party receivable		9,397		9,397
Net Income Ratio					
Statement of activities	Change in net assets without donor restrictions	\$	47,847	\$	47,847
Note 23, Financial Responsibility Standards	Total revenues and gains without donor restrictions				5,855,249
See accompanying independent auditors' report.					



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To The Trustees of Columbia University in the City of New York

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of The Trustees of Columbia University in the City of New York and its subsidiaries (the "University"), which comprise the consolidated balance sheet as of June 30, 2022, and the related consolidated statements of activities and of cash flows for the year then ended, and the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated October 12, 2022, except for footnote 23 with respect to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is March 28, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the University's internal control over financial reporting ("internal control") as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

New York, New York

Pricewoterhouse Coopers LAP

October 12, 2022, except for footnote 23 with respect to the consolidated financial statements and the opinion on the schedule of financial responsibility data, as to which the date is March 28, 2023.



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To The Trustees of Columbia University in the City of New York

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited The Trustees of Columbia University in the City of New York and its subsidiaries' (the "University") compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2022. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.



In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the University's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

Pricewoterhouse Coopers LAP

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

New York, New York

March 28, 2023

The Trustees of Columbia University in the City of New York Summary of Independent Auditors' Results Year Ended June 30, 2022

Section I - Summary of Independent Auditors' Results

Financial Statements

Unmodified Type of report of independent auditors issued: Internal control over financial reporting: _____Yes <u>X</u>No Material weakness (es) identified? Significant deficiencies(s) identified that are not Yes X None reported considered to be material weaknesses? Noncompliance material to financial statements noted? _____Yes <u>X</u>No **Federal Awards** Internal Control over major programs: _____Yes <u>X</u> No Material weakness (es) identified? Significant deficiencies(s) identified that are not considered Yes X None reported to be material weaknesses Type of independent auditors' report issued on compliance for major programs: Unmodified Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? _____ Yes ___<u>X</u> No Identification of major programs: Federal Assistance Listing Number(s) Name of Federal Program or Cluster Various Research & Development Cluster 93.266 ICAP2 93.498 COVID-19 CARES Act: Provider Relief Fund 84.425E, 84.425F COVID-19 CARES Act: Higher Education **Emergency Relief Fund** Dollar threshold used to distinguish between Type A and Type B programs: \$4,948,137 Auditee qualified as low-risk auditee? X Yes No

The Trustees of Columbia University in the City of New York Schedule of Findings and Questioned Costs Year Ended June 30, 2022

Section II—Financial Statement Findings

As a result of our audit, no instances of noncompliance related to the financial statements that are required to be reported in accordance with *Government Auditing Standards* were identified.

Section III—Federal Award Findings and Questioned Costs

No federal award findings and questioned costs were reported as a result of our audit.

The Trustees of Columbia University in the City of New York Summary Schedule of Prior Audit Findings Year Ended June 30, 2022

There were no prior year audit findings that require an update in this report.